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1 Introduction 
Right at this moment as we are reading these words, light is being absorbed by the retinal layer 
inside our eyes and converted by the photoreceptors on the surface of sensory cells into signals, 
which are rapidly processed by the brain to induce visual perception. Cell-surface receptors are 
protein structures anchored in the lipid bilayer of the cellular membranes. These machineries 
can recognize a wide array of stimuli from the surrounding environment like sound waves, 
temperature, pressure, chemicals from small molecules to peptides and even macromolecules 
like proteins. Upon binding to an activator, the receptor will initiate a chain of reactions, and 
thereby transmit external signals to a variety of intracellular sites. The final destination of 
intracellular signaling is usually the nucleus, where the activation of transcription factors turns 
on new gene expression and cell division can be induced, helping cells to respond to changes 
in the extracellular space and to communicate between each other so that biological processes 
of the whole organism can be regulated. 
Based on membrane topology, a transmembrane receptor can be classified by how many times 
its peptide chain passes the lipid bilayer. Receptors that cross the cell membrane seven times 
are called seven-transmembrane receptors or 7-TM receptors. The common core structure of 7-
TM receptors is composed of an extracellular N-terminus, followed by a bundle of seven α-
helices embedded in the cell membrane connected by three extracellular and three intracellular 
loops, and finally an intracellular C-terminus (Figure 1.1).1 
 
Figure 1.1: Typical structure of 7-TM receptors with seven transmembrane-crossing domains 
composed of extracellular modules (red) and intracellular modules (blue) (edited from Stevens 
et al.).1 
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Many members of this receptor superfamily are able to couple with heterotrimeric guanine 
nucleotide-binding proteins (G protein), and by this means signals can be forwarded. For this 
reason, 7-TM receptors are also called G protein-coupled receptors. 
1.1 G protein-coupled receptors 
Rhodopsin, one of the photoreceptors which helped us reading thus far, has been studied 
intensively. It is a remarkably stable protein, highly enriched in the bovine retina, and can 
therefore be obtained in large quantities for research purposes. At the time when the structure 
of rhodopsin was elucidated,2 it was believed that the protein is supposed to be homologous to 
bacteriorhodopsin, 3  the light-sensitive proton pump from archaebacteria, because of the 
common seven transmembrane domains. Scientist at that time concluded that 7-TM core 
structure has to be a unique feature of all light-sensitive proteins. In fact, rhodopsin is able to 
link with G proteins, but bacteriorhodopsin does not. Only after the β2-adrenergic receptor had 
been cloned, researchers acknowledged that seven membrane spans are indeed a signature 
feature of G protein-coupled receptors (abbr. GPCRs).4 One could say that all GPCRs are 7-
TM receptors but not vice versa. 
For a long time, it was difficult to study the structure–function relationships of GPCRs due to 
their low expression levels in native tissue as well as their inadequate thermo- and detergent-
stability. Bovine rhodopsin, with the advantages discussed above, was the first GPCR, of which 
a three-dimensional structure from the inactive, 11-cis-retinal bound conformation with a 
relative low resolution of 2.8 Å was obtained (Figure 1.2 A).5  Until 2008, as the crystal 
structures of opsin in both ligand-free and G protein-interacting conformations were revealed,6,7 
rhodopsin had served as the only model to study GPCRs. Advances in crystallography as well 
as in protein engineering have led to acquisition of further GPCR structures including β18- and 
β29-receptors, dopamine D3-receptor10, histamine H1-receptor11, muscarinic M212- and M313-
receptors, etc. Recently, the active, agonist-bound as well as the inactive, antagonist-bound 
crystal structures of the human A2A adenosine receptor (A2AAR) have been illustrated (Figure 
1.2 B and C).14   
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Figure 1.2: The first GPCR crystal structure: rhodopsin (A)5 and a structural comparison 
between an agonist-bound conformation (A2AAR/UK-432097 complex, orange) and an 
antagonist-bound conformation (A2AAR/ZM241385 complex, yellow) of the human A2A 
adenosine receptor (B: side view of helices I-IV and C: side view of helices V-VIII).14 
An important consequence of revealing the GPCR crystal structures is the insight into the 
mechanism of activation through the conformational changes of the receptors from inactive to 
active state. In the resting state, the GPCR is coupled to its inactive G protein, which is 
composed of an α-, β- and γ-subunit. In this state, guanosine diphosphate (GDP) binds to the 
Gα-subunit (Figure 1.3, Stage 1). The activation of a GPCR by an agonistic ligand leads to a 
conformational change in the receptor which catalyzes the release of GDP from the Gα-subunit 
to promote the binding of guanosine triphosphate (GTP) (Figure 1.3, Stage 2). The Gα- and Gβγ-
subunits dissociate subsequently from each other and independently interact with several 
downstream effector proteins, such as adenylyl cyclase, phospholipase C and ion channels 
(Figure 1.3, Stage 3). With its own intrinsic GTPase activity, the Gα-subunit can hydrolyze the 
attached GTP to GDP allowing it to re-associate with the Gβγ-subunit (Figure 1.3, Stage 4). 
During this stage the presence of a protein structural domain named regulator of G protein 
signaling (RGS) can drastically increase the rate of GTP hydrolysis via GTPase activation. The 
G protein heterotrimer now couples again to the receptor and the resting state (Stage 1) is 
restored.15 
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Figure 1.3: Activation cycle of a G protein-coupled receptor.15 
According to the primary signal transduction pathway of the Gα-subunits, the Gα proteins can 
be divided into four groups. The Gs subfamily stimulates adenylyl cyclase thus facilitating the 
synthesis of cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP), 
while the Gi/o subfamily inhibits this enzyme resulting in a decrease of intracellular cAMP 
concentration. The second messenger cAMP acts as an activator of protein kinase A in the 
cytosol, which triggers further cellular effects through phosphorylation of other proteins. Gq/11-
coupled receptors interact with phospholipase C that cleaves phosphatidylinositol-4,5-
bisphosphate (PIP2) into two second messengers: inositol-1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). The binding of IP3 to its receptor induces the release of calcium from 
the endoplasmic reticulum into the cytoplasm, whereas DAG activates protein kinase C. The 
effectors of the G12/13 pathway are Rho GTPases, whose function is to control the actin 
structures of the cytoskeleton.16,17 Independently of heterotrimeric G proteins, agonist-occupied 
GPCRs are also able to recruit ß-arrestins from the cytoplasm after being phosphorylated by 
GPCR kinases (GRKs). The GPCR/β-arrestin complexes can subsequently affect the activity 
of mitogen-activated protein kinases (MAPKs), which regulate several cellular processes 
including proliferation, differentiation and apoptosis.18 
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The diversity of G protein-coupled receptors is enormous. With almost 800 members identified 
in human19, they represent the largest class of membrane proteins capable of mediating most 
cellular responses as well as being responsible for vision, olfaction and taste. Based on sequence 
and structural similarity they are classified into six families, A-F.20 Class A includes around 
700 rhodopsin-like receptors representing the largest family; class B encloses 15 secretin 
receptor family members; class C consists of 15 metabotropic glutamate receptors. The classes 
D and E represent pheromone and cAMP receptors of fungi and slime molds. Finally, 24 
frizzled receptors comprise class F. More recently, an alternative classification (GRAFS) was 
suggested21, in which GPCRs are clustered into five families: Glutamate, Rhodopsin, Adhesion, 
Frizzled/Taste2 and Secretin. The largest family of rhodopsin-like receptors is divided further 
into four branches α, β, γ, δ according to phylogenetic similarity. Besides about 460 olfactory 
receptors, the rhodopsin family also contains most of the important GPCRs for pharmacology 
and drug development, for example opioid, purinergic, cannabinoid, muscarinic acetylcholine 
and several monoamine-activated receptors like adrenergic, histamine, dopamine, serotonin 
receptors etc. However, not all native transmitters for GPCRs have been found yet, there are 
still nearly 100 orphan receptors, for which the natural primary messengers remain 
undiscovered.22  
1.2 Cannabinoid receptors 
The plant Cannabis sativa has been used since ancient times for medicine, recreation, religious 
ceremonies as well as the source of hemp fiber, seed oils and livestock feed. Throughout history, 
the flowers and resin of cannabis have been prepared to treat an array of illnesses from 
menstrual disorders, gout, rheumatism, constipation, nausea and vomiting to fever, 
inflammation, pain, glaucoma, insomnia, epilepsy and anxiety.23  
In 1964, Δ9-tetrahydrocannabinol (Δ9-THC or THC, 1, Figure 1.4), the main psychoactive 
ingredient in cannabis was successfully isolated and characterized. 24  And after almost 3 
decades, the first THC-stimulated receptor (aka. cannabinoid receptor 1 or CB1) was cloned as 
an orphan receptor from a rat brain cDNA library.25 Within a few years, the second subtype 
(CB2) of cannabinoid receptors was found in a human leukemic cell line.
26 During this period, 
anandamide (2, Figure 1.4)27 and 2-arachidonoylglycerol (2-AG, 3, Figure 1.4)28,29 were the 
first natural ligands of cannabinoid receptors, the so-called endocannabinoids, to be identified. 
These lipids are synthesized on-demand from cell membrane arachidonic acid derivatives. 
Anandamide functions as a partial agonist at cannabinoid receptors with a higher preference for 
the CB1 than the CB2 subtype. The partial agonistic nature as well as the affinity for the CB1 
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receptor of anandamide is similar to that of THC. 2-AG, on the other hand, is a full agonist at 
cannabinoid receptors.30 Later on, some other anandamide analogs and N-acyldopamines have 
also been found to act on cannabinoid receptors.31 The discovery of THC along with many other 
cannabinoids produced by cannabis stimulated the synthesis of numerous analogs that included 
not only compounds structurally similar to phytocannabinoids but also analogs with different 
chemical structures, for example the potent CB agonist CP55,940 (4, Figure 1.4) and the CB1 
antagonist SR141716A (5, Figure 1.4).32 
 
Figure 1.4: Structures of some prominent cannabinoids. 
Cannabinoid receptor subtypes 1 and 2 are cell surface receptors possessing the typical seven 
transmembrane domains of GPCRs and belong to the branch α of class A (rhodopsin-like) 
GPCRs. Both receptors couple to Gi/o proteins and are able to inhibit adenylate cyclase thus 
activate MAP kinase.32 The CB1 receptor is the major cannabinoid receptor in the central 
nervous system (CNS), highly expressed in cerebral cortex and hippocampus, regions that are 
responsible for behavioral effects of cannabinoids. Lower levels of CB1 expression were also 
found in the peripheral nervous system as well as in many other tissues, such as bone marrow, 
heart, lung, prostate, testis, etc.33 In addition to the Gi/o pathway, CB1 receptors can also signal 
through Gs proteins leading to cAMP accumulation, which could be in association with a co-
expressed dopamine receptor.34 The CB2 receptor has 44 % amino acid identity with its CB1 
subtype. Predominant expression of CB2 has been detected in cells of the immune system, 
especially in peripheral blood cells including B lymphocytes, natural killer cells and monocytes. 
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By activating the CB2 receptors, immune cell migration and cytokine release can be regulated.
32 
There are evidences that some CB1 receptors are also expressed on non-neuronal cells, 
including immune cells33 and CB2 can be detected on some neurons, both central and peripheral 
ones.35 
Although compounds that act on cannabinoid receptors possess potential therapeutic benefits, 
their applications are currently limited mainly owing to psychoactive side-effects. Only a few 
pharmaceuticals are on the market, these are Nabilone, a structural analog of THC, and 
Dronabinol or synthetic THC, which were approved to treat chemotherapy-induced nausea and 
vomiting36 as well as to stimulate appetite in AIDS patients.37 The CB1 antagonist SR141716A 
(Rimonabant) had been approved as an antiobesity drug but was withdrawn later due to the 
serious depressive adverse effects leading to suicide. 38  Another cause for the moderate 
development of cannabinoid therapeutics is the fact that interactions of cannabinoids, both 
endogenous, phyto and synthetic, are not restricted to the CB1 and CB2 receptors, but also extend 
to other targets, for example, transient receptor potential cation channel vanilloid (TRPV) 
receptors,39 peroxisome proliferator-activated receptors (PPARs)40 and some orphan GPCRs 
like GPR18 and GPR55. As the main subjects of this thesis, GPR18 and GPR55 will be further 
described in the next chapters.  
1.3 G protein-coupled receptor 18 
Recently, an abnormal-cannabidiol-sensitive receptor has been identified as the orphan 
GPR18,41 which mediates mesenteric vasodilation42 in mice and microglial migration.43 The 
activating effects induced by anandamide and abnormal cannabidiol (abn-CBD, 7, Figure 1.5) 
on this receptor can also be mimicked by THC44 and blocked by SR141716A.42 It was also 
reported that N-arachidonylglycine (NAGly, 8, Figure 1.5), an endogenous metabolite of 
ananamide, stimulated Ca2+-influx and inihibited forskolin-induced cAMP production in 
GPR18-transfected Chinese hamster ovary (CHO) cells. The authors proposed that NAGly is 
an endogenous ligand of the Gαi/o protein-coupled receptor 18.
45 However, in a study examining 
the pharmacological interactions of different lipids with various GPCRs, NAGly did not 
activate GPR18. 46  A more recent study showed no inhibition of calcium release after 
application of NAGly on GPR18-expressing neurons.47  In our work-group, established ß-
arrestin assays of GPR18 could not confirm the above-mentioned proposal of NAGly being a 
GPR18 agonist.48 Latest investigations point to the existence of another endogenous GPR18 
activator: the polyunsaturated fatty acid metabolite Resolvin D2 (RvD2, 9, Figure 1.5), which 
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is mainly involved in inflammatory processes,49 but its confirmation as a GPR18 agonist is still 
awaited. 
 
Figure 1.5: Cannabidiol, a major phytocannabinoid and its synthetic analog abnormal 
cannabidiol (abn-CBD) as well as the proposed endogenous GPR18 ligands N-
arachidonoylglycine (NAGly) and Resolvin D2.  
Despite sharing several ligands with cannabinoid receptors, GPR18 belongs to a different 
branch (branch δ) of class A, rhodopsin-type receptor family and displays low sequence identity 
with CB1 and CB2 (13% and 8%, respectively).
32 The 331-amino acid GPCR is mainly 
expressed in organs of the immune system, such as spleen and thymus. Accordingly, it was 
suggested to be involved in the regulation of the immune system.45 Moderate GPR18 expression 
can be found in brain, testis, ovary, and lung.50 More recently, the receptor was also detected in 
metastatic melanomas 51  and human spermatozoa. 52  Moreover, GPR18 was proposed to 
participate in normal T cell homeostasis in the small intestine.53 
1.4 G protein-coupled receptor 55 
The orphan G protein-coupled receptor 55 (GPR55) had been proposed as a candidate for a new 
cannabinoid receptor subtype. However, studies of cannabinoids on GPR55 delivered mixed 
results. In particular, activation of this receptor by THC54, anandamide and CP55,94055 has 
been reported earlier, but a more recent study could not demonstrate activation of GPR55 by 
THC and anandamide in ß-arrestin assays using human embryonic kidney cell line (HEK293 
cells). In the same study, the cannabinoid receptor agonist CP55,940 has been found to 
1 Introduction 
9 
antagonize GPR55 and the CB1 antagonist SR141716A was able to activate the receptor.
56 In 
an effort to examine the effects of different phospholipids on GPR55, Oka et al. observed that 
a mixture of lysophosphatidylinositols (LPIs) derived from soybean was capable of inducing 
phosphorylation of MAPKs and transient increase of intracellular calcium level in GPR55-
expressing HEK293 cells.57 In a further study, a particular species of LPI, 2-arachidonoyl-sn-
glycero-3-phosphoinositol (2-AGPI, 10, Figure 1.6) found in rat brain has been shown to be 
more potent than soybean LPI.58  
 
Figure 1.6: Molecular structure of the proposed endogenous GPR55 activator: 1-LPI. 
Similar to GPR18, GPR55 is also a member of branch δ of the rhodopsin-like (class A) 
receptors, thus exhibits low sequence identity to both CB1 (13 %) and CB2 (14 %) subtypes. 
The orphan receptor has also been found to couple with Gq, G12, or G13 for signal transduction, 
which results in downstream activation of RhoA and phospholipase C (PLC).54, 59  High 
expression of GPR55 can be detected in some parts of the mammalian brain such as caudate 
putamen, frontal cortex, striatum, hypothalamus, as well as in glial cells and large dorsal root 
ganglia neurons. mRNA of this receptor is also expressed in different cell types including 
lymphocytes, endothelial cells, prostate and ovarian cells, as well as in several organs like 
spleen, stomach and intestine.59 A study has also determined a correlation of the GPR55/LPI 
system with the proliferation rate and aggressiveness of cancer cells.60 Moreover, GPR55 could 
play a role in cardiovascular functions, nociception, inflammation and bone metabolism.61 A 
very recent research report has discovered that GPR55 may be associated with obesity in 
humans.62  
1.5 Synthetic ligands for GPR18 and GPR55 
 Atypical cannabinoids 
Atypical cannabinoids are synthetic compounds derived from the natural cannabinoids in 
cannabis, for example, the above-mentioned abn-CBD. Both abn-CBD analogs: O-1602 (11) 
and O-1918 (12) do not bind with high affinity to either the cannabinoid CB1 or CB2 receptor 
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but exhibit totally different activities at GPR18 and GPR55. O-1602 is an agonist at both 
GPR1844 and GPR5555 while O-1918 exerts antagonistic activity at these receptors.63,64 
 
Figure 1.7: Molecular structures of two abn-CBD analogs: O-1602 and O-1918. 
 Coumarin derivatives 
Several compounds with a coumarin scaffold have been shown to be a novel class of GPR55 
antagonists. They exert from weak antagonistic properties to no activity at GPR18. Analysis of 
their structure-activity relationships indicates that the residue in position 7 of the coumarin 
scaffold is important for interaction with GPR55 and CB receptors. A long and bulky lipophilic 
residue at position 7 will lead to high inhibitory potencies of the compounds at GPR55. Thus, 
PSB-SB-487 (13) has been shown to be the most potent antagonist at GPR55 in this coumarin 
compound class possessing at the same time high affinities for the CB receptors. The absence 
of a substituent at position 7 led to an increased selectivity toward GPR55 and eradicated CB 
receptor binding but lowered the antagonistic activity of the coumarin derivative, e.g. PSB-SB-
489 (14).65 
 
Figure 1.8: Coumarin derivatives as potent (selective) antagonists of GPR55. 
 Bicyclic imidazole-4-one derivatives 
The imidazo[2,1-b]thiazin-3-one derivative 15 has been discovered as the most potent GPR18 
antagonist among all bicyclic imidazole-4-one derivatives showing weak binding affinity to CB 
receptors and no interaction with GPR55 receptors. In contrast, imidazo[2,1-b]thiazin-3-one 
derivatives bearing benzylidene residues without bulky substituents such as 16 have been 
shown to be better tolerated by GPR55 while exhibiting no affinity to CB as well as GPR18 
receptors.48 
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Fig. 1.5: Imidazo[2,1-b]thiazine derivatives as potent, selective antagonists of GPR18 and 
GPR55. 
 Magnolol derivatives 
Most of the synthetic compounds based on the natural product magnolol are highly selective 
CB receptor ligands showing no or moderate inhibition of GPR18 and GPR55. None of them 
were able to activate these orphan receptors. However, some small modifications such as the 
methylation of a phenolic hydroxyl group could increase inhibitory potency at GPR55. 
Compound 17 is the most potent GPR55 antagonist among the magnolol series, but it is even 
more potent at the CB receptors and thus not selective.66  
 
Fig. 1.6: A magnolol derivative which is a potent GPR55 antagonist, but also binds to CB 
receptors. 
  
1 Introduction 
12 
Summarized in Table 1.1 are the activities of some natural as well as synthetic ligands at GPR18 
and GPR55.  
Table 1.1: EC50/IC50 values of selected ligands for GPR18 and GPR55 determined in different 
assays. 
Compound hGPR18 hGPR55 
 Activity EC50 or IC50 (µM) Activity EC50 or IC50 (µM) 
1 Δ9-THC65 Agonist 4.61a Antagonist 14.2a 
10 1-LPI48 Antagonist >10a Agonist 1.00a 
11 O-160244,55 Agonist 0.065b Agonist 0.013c 
13 PSB-SB-48765 Antagonist 12.5a 
Antagonist 
(CB affinity) 
0.113a 
14 PSB-SB-48965 Antagonist >10a Antagonist 1.77a 
15 CID-
8546957165 
Antagonist 0.279a Antagonist >10a 
1648 Antagonist >10a Antagonist 3.15a 
1766 Antagonist >10a 
Antagonist  
(CB affinity) 
3.25a 
aEC50/IC50 values obtained from ß-arrestin recruitment assays. bEC50/IC50 values obtained from In-Cell Western 
assay to quantify MAPK phosphorylation. cEC50/IC50 values obtained from [35S]GTPγS binding assay. 
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2 Aims of the thesis 
With around 800 members, G protein-coupled receptors comprise the largest and most 
important family of transmembrane receptors.19 Signal transduction by GPCRs is involved in 
most physiological processes, from vision, smell and taste to neurological, cardiovascular, 
endocrine, and also reproductive functions, thus, making the GPCR superfamily a crucial target 
for therapeutic intervention. In fact, from all currently marketed drugs, more than 30 % are 
targeting GPCRs.67 Despite continuous progresses in GPCR research, there is still a large 
number of orphan receptors. Deorphanizing receptors by revealing their natural transmitters can 
lead to solve their (patho)physiological roles.  
Two orphan receptors are GPR18 and GPR55, which possibly have essential roles in the 
immune system, metabolism and cancer, and thus emerge as potential targets for new drugs. In 
this study, compounds of both natural and synthetic origin will be designed and subsequently 
evaluated in pharmacological assays at GPR18 and GPR55, and additionally for selectivity 
versus CB1 and CB2 receptors. The obtained data will provide information helping us to 
potentially discover the endogenous ligands of the receptors as well as to study structure-
activity relationships, which serve as a basis to develop more potent and selective agonists, 
antagonists and modulators as pharmacological tools for research studies on these receptors. 
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3 Results and discussion 
3.1 Synthesis of phenothiazine derivatives 
 Introduction 
The discovery of the heterocyclic drug phenothiazine dates back to 1876 when Heinrich Caro 
investigated aniline-based dyes and synthesized a pigment known as methylene blue.68 Initially 
it was used by Paul Ehrlich in his cell staining experiments. During these experiments he 
observed that methylene blue can also stain bacteria and parasites such as malaria. The 
compound was subsequently tested clinically and by the end of 19th century, methylene blue 
was being widely employed as the first synthetic drug for the treatment of malaria and later also 
livestock parasites. Further researches in the late 1940s led to the preparation of promethazine, 
which was the most powerful sedative at that time, and chlorpromazine, a low-potent but 
pioneer drug for the treatment of schizophrenia (Figure 3.1).  
 
Figure 3.1: The phenothiazine parent compound and its early developed drugs. 
Possessing a relative high lipophilicity, phenothiazine drugs can easily cross the blood-brain 
barrier and interact with a variety of receptors in the central nervous system including 
dopaminergic, serotonin, histamine, GABA, muscarinic and also α-adrenergic receptors. The 
effectiveness of phenothiazine-derived antipsychotics rely mainly on their ability to block the 
dopamine receptor subtype 2 (D2 receptor) in the mesolimbic pathway of the brain.
69 However 
binding of these agents at D2 receptors in other parts of the dopaminergic pathway as well as at 
different receptors cause mild to severe side effects like sedation, dry mouth, low blood 
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pressure, fast heart rate, weight gain and some drug-induced movement disorders, the so-called 
extrapyramidal symptoms. Phenothiazine antipsychotics with different types of side chains at 
the nitrogen atom usually have different potencies and side effect profiles. Aliphatic 
phenothiazines like chlorpromazine are weakly potent, and tend to have more anticholinergic 
than neurologic adverse effects, while piperazine-bearing analogs like perphenazine (22) and 
fluphenazine (23) are more potent but possess higher risk of extrapyramidal symptoms.70 
In our workgroup, more than 400 drugs of a proprietary collection were screened using the ß-
arrrestin assay at GPR18 to find new lead structures. As a result, chlorpromazine, perphenazine, 
fluphenazine, and fluphenazine sulfoxide (24) are the phenothiazine antipsychotics that 
appeared to be capable of inhibiting THC-induced GPR18 activation at low micromolar 
concentrations (Figure 3.2).  
 
Figure 3.2: Some phenothiazine antipsychotics that act as GPR18 antagonists. 
In the absence of the agonist THC, these drugs were even able to reduce the assay signal 
potentially indicating an inverse agonistic mode of action (Figure 3.3 A and B). In a later 
experiment, perphenazine in different concentrations was added to the activation of GPR18 by 
THC resulting in a suppression of the activation curves; the response was still increased but the 
maximal effect of THC could not be reached (Figure 3.3 C). This likely represents a non-
competitive inhibition, in which the antagonist does not bind to the same binding site of the 
agonist, but induces a conformational change of the receptor, so that the affinity of the agonist 
is decreased. 
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Figure 3.3: Effect of phenothiazine drugs at GPR18. (A) Inhibition curve of chlorpromazine 
in the presence of 10 µM THC (blue) and dose-response curve of chlorpromazine alone (red). 
(B): Inhibition curve of fluphenazine sulfoxide in the presence of 10 µM THC (green) and 
dose-response curve of fluphenazine sulfoxide alone (orange). (C) Activation curve of THC 
alone and in the presence of perphenazine in different concentrations. 
A comparison between the potencies of the mentioned phenothiazine drugs at GPR18 revealed 
that a chlorine substitution at position 2 of the heterocyclic core is more beneficial than a 
trifluoromethyl group. And furthermore an unoxidized thioether was clearly more preferred 
than a sulfoxide residue. The propylpiperazinylethanol substituent at position N-10 remains 
unchanged in all these drugs; it was probably optimized for the activity at dopamine receptors. 
But for the investigation of GPR18 and GPR55, this residue can be modified to obtain more 
potent and selective agonists and antagonists. Figure 3.3 illustrates 2-chlorophenothiazine (25) 
as the main scaffold for the synthesis of compounds described in the following section. 
A B 
C 
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Figure 3.4: The core structure 2-chlorophenothiazine. 
 Alkylation at the N-10 position of 2-chlorophenothiazine 
In most of the reactions, primary alkyl halides were used as versatile and readily available 
alkylating reagents. Since primary alkyl halides prefer an SN2 mechanism, the reaction rate 
depends heavily on the strength of the nucleophile. However, 2-chlorophenothiazine possesses 
a low basicity and thus a weak nucleophilicity due to delocalization of the nitrogen non-bonding 
electron pair into the aromatic ring. N-Alkylation of such amines usually requires a powerful 
but non-nucleophilic base to deprotonate the amino group whereupon a negatively charged 
nitrogen with increased electron density and nucleophilicity will be formed. The impact of 
solvents on the nucleophile is not negligible. Polar protic solvents like alcohols, acetic acid, 
water etc. are able to create a shell around the nucleophilic anion through hydrogen bonding 
making it less reactive. On the other hand, polar aprotic solvents such as N,N-
dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetone, acetonitrile, do not form 
hydrogen bonds with the bare nucleophile leaving it more reactive.  
Generally the alkylations of 2-chlorophenothiazine (25) using method 1 (Table 3.1) afforded 
moderate yields (32 - 52 %). In method 1, NaH was added as a single portion into a solution of 
2-chlorophenothiazine at 0 °C and stirred for 10 minutes prior to treatment with the alkyl halide. 
However, the reaction of 1-bromo-3-chloropropane and 2-chlorophenothiazine under this 
conditions did not deliver the desired product 42. Consequently, an alternative method 
described by Du et al.71(method 2) was attempted and the compound could be obtained at 54 
% yield. The key differences in the latter method are the reduction of solvent volume, a drastic 
increase of alkyl halide equivalent and an additional portion of NaH after a period of time. 
Consequently, method 2 was applied to a series of longer chain alkylations (compounds 30 – 
34) as well as for the preparation of 38 and 39 resulting in moderate to high yields. In cases of 
35 and 37, the combination of NaOH as a strong base and DMSO as s solvent also worked well.  
It is noteworthy that all those GPR18-inhibiting antipsychotics illustrated in Figure 3.2 have an 
aminopropyl residue at the N-10 position. Hence, some derivatives with a propyl linker (40 – 
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43) were synthesized to investigate the importance of the substitution attached to this linker for 
the interaction with our biological targets.  
Table 3.1: Methods for the synthesis of N-Alkylated phenothiazine derivatives and their 
isolated yields. 
 
Comp. R Method Yield (%)c 
26 methyl 1 50 
27 ethyl 1 52 
28 propyl 1 44 
29 isopropyl 1 38 
30 butyl 2 75 
31 pentyl 2 82 
32 hexyl 2 84 
33 heptyl 2 81 
34 octyl 2 87 
35 cyclohexylmethyl 3 32 
36 cyclohexylethyl 1a 34 
37 benzyl 3 50 
38 (3-methoxyphenyl)methyl 2 83 
39 (2-cyanophenyl)methyl 2 28 
40 3-phenylpropyl 1b 41 
41 3-aminopropyl 2 58 
42 3-chloropropyl 2 54 
43 3-hydroxypropyl 2 12 
44 indol-3-yl-ethyl 2 16 
a reaction conducted at 60 °C for 4 h. b reaction conducted at 60 °C for 24 h. c isolated yield. 
The most direct approach to prepare the indole-bearing derivative 44 would be an alkylation of 
2-chlorophenothiazine 25 with the already available 3-(2-bromoethyl)indole 45. The standard 
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strategy of employing NaH and DMF only gave a low yield of the main product along with 
several unknown impurities (Figure 3.5). A possible reason for this phenomenon could have 
been the presence of the unprotected indole NH-group, which can be deprotonated by NaH and 
subsequently undergo side reactions with one or more electrophiles in the reaction mixture. 
However, an attempted alkylation of 2-chlorophenothiazine with a Boc-protected 3-(2-
bromoethyl)indole was not successful. In another effort using potassium tert-butoxide (KOtBu) 
and tetrahydofuran (THF), the product 44 could not be detected in the reaction mixture. Hence 
the synthesis of 44 certainly requires optimization. 
 
Figure 3.5: Synthesis of the phenothiazine-indole hybrid via alkylation. 
There are a few cases where the yields were also low (43 and 39) probably due to the 
unprotected hydroxyl group or unexpected reduction of the cyano group by NaH. 
 Synthesis of 2-(1H-indol-3-yl)-1-(2-chloro-10H-phenothiazin-10-
yl)ethanone (46) 
In this part of the study, an amide derivative of 44 was prepared. This compound (46) has an 
additional carbonyl group at the first carbon of the ethyl linker. The synthesis starts with a 
temporary conversion of indole-3-acetic acid (47) to its acyl chloride. Thionyl chloride was the 
reagent of choice, superior to oxalyl chloride and phosphorus pentachloride because of its 
higher activity and easily removable gaseous by-products. The N-acylation between the 
resulting acyl chloride and 2-chlorophenothiazine was carried out twice under reflux conditions 
in two different solvents: toluene and o-xylene, which have relative high boiling points (110 
and 144 °C, respectively) (Figure 3.6). The latter was found to be better since toluene gave a 
lower yield (13 %). Perhaps this type of reaction needs a high temperature to accelerate the 
reaction. 
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Figure 3.6: Two-step synthesis of compound 46 via acyl chloride conversion and subsequent 
acylation. 
Due to the low yield in the direct synthesis of compound 44 via alkylation, an alternative route 
was probed, namely the amide group of compound 46 was left to react with three different 
reducing reagents: LiAlH4, NaBH4 and BH3-THF complex, which have been reported to 
successfully reduce similar compounds as our starting material. 72  However, several 
experiments with LiAlH4 always led to a cleavage of the amide bond giving 2-
chlorophenothiazine and some unknown byproducts. Meanwhile in the reaction with NaBH4 
only a minor peak with the mass of the product was detected by LC-MS. Unfortunately, the 
first application of BF3-THF did not deliver the desired product (Figure 3.7). 
 
Figure 3.7: Attempts to synthesize compound 44 via amide reduction of 44. 
 Synthesis of sulfonamide-linked phenothiazine analogs  
It is well-known that the basic amino group in dopamine forms a salt bridge with the highly 
conserved Asp-114 residue in the binding site of dopamine receptors. 73  This feature is 
responsible for the activity of antipsychotics at D2 receptors. It is possible to avoid this 
interaction just by abolishing the amino group. But if the presence of a hydrogen bond donor 
or acceptor is still required at this position, it is better to convert the amino group into a neutral 
polar substituent (sulfonamide, amide, urea etc.).  
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Figure 3.8: Multistep synthesis of sulfonamide-bearing phenothiazine derivatives  
The synthesis of sulfonamide-linked phenothiazine analogs followed a multistep approach 
reported by Kastrinsky et al. 74  beginning with the acylation of 2-chlorophenothiazine by 
chloroacetyl chloride and 3-bromoproprionyl chloride, respectively. After the conversion of the 
halides (48, 49) to the nitriles (50, 51) using sodium azide, and combined reduction to the amine 
precursors (52, 53) by BH3-THF complex. These precursors were finally derivatized with 4-
trifluoromethoxybenzenesulfonyl chloride to afford the products 54 and 55 (Figure 3.8). The 
obtained yields were sufficient and also comparable to those of literature. 
3.2 Pharmacological assays of phenothiazine derivatives 
 Introduction 
The antagonistic activity of some phenothiazine-derived drugs at GPR18 has just been 
discovered via ß-arrestin assays performed in our workgroup (see 3.1.1). The small ß-arrestin 
proteins are ubiquitously expressed and play an important role in the function of GPCRs. Upon 
activation, serine and threonine residues in the intracellular loops and the C-terminal tail of the 
agonist-bound receptor are phosphorylated by GPCR kinases (GRKs). These phosphorylated 
residues can be detected and bound by a ß-arrestin blocking recoupling of G protein subunits 
to the receptor/ß-arrestin complex, thus preventing further receptor stimulation.75 This process 
is called desensitization. 
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Figure 3.9: The principle of the PathHunter® ß-arrestin assay. 
Based on this mechanism of ß-arrestin, a modified β-galactosidase complementation assay, 
referred to as PathHunter® technology, has been developed by DiscoverX (Fremont, CA, U.S.). 
The assay makes use of a small enzyme donor fragment ProLink™ (PK), which is tethered to 
the C-terminus of the target GPCR. This tagged receptor is co-expressed in cells producing a 
fusion protein of a β-arrestin with the larger, N-terminal deletion mutant of β-galactosidase 
(called enzyme acceptor or EA). Upon recruitment of β-arrestin to the PK-tagged GPCR, the 
two enzyme fragments merge together resulting in the formation of an active β-galactosidase 
enzyme. The increase in enzyme activity can be quantified with the aid of chemiluminescent 
detection reagents (Figure 3.9).76 The ß-arrestin assay is not depending on G protein signaling 
and suitable for ligand screening and deorphanizing of GPCRs.  
In this study, ß-arrestin recruitment assays using Chinese hamster ovary (CHO) cells stably 
expressing the target receptors were performed by Dr. Clara Schoeder. Agonistic activities of 
test compounds were compared to the effect of the GPR18 agonist THC (EC50 4.61 µM) at 10 
µM or GPR55 agonist LPI (EC50 1 µM) at 1 μM. Whenever a compound shows an activation 
higher than 50 % (compared to the known agonist), full activation curves will be determined in 
order to calculate EC50 values.  For antagonistic activity, if a compound exerts an inhibition of 
agonist-induced receptor stimulation higher than 50 %, full concentration-inhibition curves will 
be determined in order to calculate IC50 values. Curves were obtained in three separate 
experiments, each in duplicates. 
 Structure-activity relationships of phenothiazine derivatives 
There are in total eighteen out of twenty five phenothiazine derivatives tested in ß-arrestin 
assays so far (Figure 3.10). None of them could activate the human GPR18 or GPR55 compared 
to the stimulation level of the known agonists. In the first set of compounds with different alkyl 
moieties substituted at the N-10 position. Derivatives carrying short alkyl side chain of up to 5 
carbons (26 – 31) were able to inhibit GPR55 activation at low micromolar concentrations (IC50 
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6.20 – 10.1 µM). In contrast, alkyl substituents with the length from 6 to 8 carbons (compounds 
32 - 34) were not tolerated. The binding pocket of GPR55 for the phenothiazine scaffold may 
not have enough depth for the binding of those compounds.  
Table 3.2: Results from ß-arrestin assays of phenothiazine analogs at GPR18 and GPR55. 
Comp. R hGPR18a hGPR55a 
  
EC50 ± SEM 
(µM) 
(% activation)b 
IC50 ± SEM 
(µM) 
(% inhibition)c 
EC50 ± SEM 
(µM) 
(% activation)d 
IC50  ± SEM 
(µM) 
(% inhibition)e 
26 methyl >10 (-12 ± 16) >10 (19 ± 9) >10 (7 ± 5) 10.1 ± 0.2 
27 ethyl >10 (12 ± 11) >10 (5 ± 15) >10 (-10 ± 13) 6.70 ± 2.08 
28 propyl >10 (25 ± 3) >10 (16 ± 12) >10 (-2 ± 8) 8.16 ± 1.57 
29 isopropyl >10 (39 ± 6) >10 (1 ± 9) >10 (6 ± 9) 6.27 ± 1.74 
30 butyl >10 (-19 ± 12) >10 (-36 ± 11) >10 (-15 ± 12) 7.22 ± 1.59 
31 pentyl >10 (-5 ± 12) >10 (-47 ± 10) >10 (9 ± 14) 6.20 ± 1.24 
32 hexyl >10 (-3 ± 11) >10 (16 ± 6) >10 (28 ± 8) >10 (28 ± 16) 
33 heptyl >10 (8 ± 6) >10 (22 ± 7) >10 (29 ± 9) >10 (39 ± 11) 
34 octyl >10 (26 ± 8) >10 (2 ± 10) >10 (17 ± 12) >10 (32 ± 16) 
35 cyclohexylmethyl >10 (17 ± 5) >10 (-18 ± 13) >10 (3 ± 11) 8.41 ± 0.73 
36 cyclohexylethyl >10 (36 ± 11) >10 (2 ± 10) >10 (15 ± 11) >10 (37 ± 14) 
37 benzyl >10 (18 ± 5) >10 (7 ± 5) >10 (30± 9) 7.28 ± 1.41 
38 (3-methoxyphenyl)methyl >10 (8 ± 3) >10 (31 ± 9) >10 (0 ± 6) (58 ± 5) 
39 (2-cyanophenyl)methyl >10 (14 ± 9) >10 (44 ± 15) >10 (-6 ± 7) (53 ± 23) 
40 3-phenylpropyl >10 (39 ±9) >10 (3 ± 16) >10 (3 ± 11) 5.29 ± 1.87 
41 3-aminopropyl >10 (-98 ± 15) 4.89 ± 0.96 >10 (3 ± 16) >10 (16 ± 14) 
43 3-hydroxypropyl n.d. n.d. >10 (-11 ± 11) (89 ± 16) 
46 2-(indol-3-yl)-1-ethanoyl n.d. n.d. >10 (-15 ± 10) 7.48 ± 0.48 
areceptors were expressed on CHO cells. b% activation in comparison to 10 µM THC induced luminescence signal. 
c% inhibition of 10 µM THC induced luminescence signal. d% inhibition of 1 µM LPI induced luminescence 
signal. e% activation in comparison to 1 µM LPI induced luminescence signal. All data with SEM resulted from 
three independent experiments, performed in duplicate. 
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In the series of compounds with cyclic substituents, compound 40 containing a phenyl ring 
separated by three carbons from the ring system was the most potent GPR55 antagonist 
possessing an IC50 value of 5.29 µM (Figure 3.10 B). By shortening the linker from three to 
one carbon, the potency was lowered to 7.28 µM as in the N-benzylated derivative 37. A 
comparable potency could also be obtained from a phenothiazine analog bearing an indole 
residue 46 (IC50 7.48 µM). Compounds linked with a substituted benzyl group (38 and 39) also 
exerted some inhibitory effects at GPR55, however more data are required to completely 
calculate the IC50 values. Through a comparison between the two related compounds 35 and 
36, it was shown that the extension of the linker at the cyclohexyl residue from one to two 
carbons clearly eliminated the antagonistic activity at GPR55. 
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Figure 3.10: Inhibition curves and potencies of the most potent GPR18- and GPR55 antagonists 
from the phenothiazine series. (A) 2-Chloro-10-(3-aminopropyl)-10H-phenothiazine (41). (B) 
2-Chloro-10-(3-phenylpropyl)-10H-phenothiazine (40). 
As the only phenothiazine derivative containing a primary amino group in this series, compound 
41 could inhibit THC-induced GPR18 activation with a moderate potency of 4.89 µM (Figure 
3.10 A). It actually serves as the common core structure of some antipsychotics including 
chlorpromazine, perphenazine, fluphenazine and fluphenazine sulfoxide. The basic nitrogen 
atom might play an important role in the activity of those compounds at GPR18. The amino 
group in 41 was later exchanged for a hydroxyl group forming 43, which in turn showed 
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GPR55-inhibiting properties in initial screening tests. However, an effect of 43 at GPR18 
cannot be excluded, since assay data for this compound at the receptor are still missing. 
3.3 Synthesis of N-acylamino acids 
 Introduction 
N-Acylamino acids comprise a class of lipids, in which amino acids are linked covalently to 
long-chain fatty acids by an amide bond (Figure 3.11). To date, about 70 naturally occurring 
members as well as several synthetic analogs of the N-acylamino acid family have been 
identified. 77  However, for most of these molecules, their biological functions remain 
undiscovered. 
 
Figure 3.11: General chemical structure of N-acylamino acids. 
N-Arachidonoylglycine (NAGly) was one of the first N-acylglycines to be identified in vivo in 
rat brain, spinal cord, small intestine, kidney and skin, at concentrations of approx. 50 - 140 
pmol/g of dry tissue weight.78 NAGly has been reported to be the physiological agonist of 
GPR18,45 although this discovery could not be validated by some research groups regardless of 
test system.46,47 A recent study concerning the presence of N-acylamino acids in rat brain has 
shown that conjugates of serine are the most abundant with 58.6 pmol/g wet brain for the 
palmitoyl derivative (56) and 35.2 pmol/g for the stearoyl analog (57).79  Furthermore, N-
palmitoylserine and N-arachidonoylserine (58) have been shown to exert neuroprotective 
effects in traumatic brain injury models. 80  Similar to fatty acyl serines, concentrations of 
palmitoyl (59) and stearoyl (60) glutamic acids also appeared to be high in rat brain (26.6 and 
36.5 pmol/g wet brain, respectively).79 These evidences, together with the fact that the 
eicosanoid lipids anandamide (2) and 2-arachidonoylglycerol (3) are natural transmitters of the 
endocannabinoid system, led us to assume that N-acylamino acids may serve as a new class of 
signaling molecules. 
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Figure 3.12: Some bioactive N-acylamino acids. 
The formation of an amide bond at the N-terminus of amino acids can be performed in many 
ways. The main requirement is the conversion of carboxyl groups in fatty acids into other 
activated derivatives such as acyl halides, acyl azides, anhydrides, esters, etc. which provide 
good leaving groups after the attack of the nucleophilic amino function. This conversion can be 
conducted prior to the amide bond formation or in situ in a one-pot reaction. In this study we 
employed several methods to prepare N-acylamino acids. 
 N-Acylation of amino acids using fatty acyl chlorides 
A method for preparation of N-acylamino acids from fatty acyl chlorides has been described 
earlier.81 This is a straightforward method since fatty acyl chlorides are readily available and 
inexpensive. The procedure required a single step, in which a solution of acyl chloride in THF 
was injected into the solution of the corresponding amino acid in aqueous NaOH. In contrast to 
the work-up protocol provided in the literature, a smaller amount of water was used to dilute 
the reaction mixture with the aim to decrease the amount of polar products dissolved in water 
and to thus increase the extraction yields.  
Some initial reactions were stirred for a maximal duration of 3 days and thin layer 
chromatography (TLC) of the reaction mixtures was performed frequently to check the progress 
of reaction. We could not reach completion of these reactions after 3 days but have found out 
that the most beneficial reaction duration was around 16 – 18 h (overnight stirring), since 
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durations of 2 or 3 days did not deliver any significant improvement in yields as shown by TLC 
analyses. In order to remove the remaining free fatty acids, the crude products were stirred in 
heptane for 30 min. In case of L-serine derivatives petroleum ether (bp. 40 – 60 °C) was used 
to avoid the formation of a gel-like structure.82 
Table 3.3: Results from the N-acylations of four amino acids, L-glutamic acid, L- and D-
tryptophan as well as L-serine, with different saturated fatty acyl chlorides. 
 
Amino acid R Config. (*)a Compound n Yield (%)b 
L-Glutamic acid 
(61) 
 
S 
65 0 (3) 
66 1 (9) 
67 2 18 
68 4 17 
69 6 29 
70 8 69 
71 10 62 
72 12 36 
59 14 37 
60 16 36 
L-Tryptophan 
(62) 
 
S 
73 0 82 
74 1 86 
75 2 32 
76 4 89 
77 6 87 
78 8 37 
79 10 73 
80 12 63 
81 14 67 
82 16 78 
D-Tryptophan 
(63) 
 
R 
83 8 19 
84 10 74 
85 12 63 
86 14 63 
87 16 76 
L-Serine 
(64)  
S 
88 8 27 
89 10 37 
90 12 53 
56 14 23 
57 16 53 
a absolute configuration of the Cα of the amino acids. b isolated yield. 
In general, reactions of tryptophan, regardless of its configuration, resulted in better yields than 
those of L-glutamic acid and L-serine probably because of the higher lipophilicity and thus 
better solubility of tryptophan in organic solvents. L-Glutamic acid derivatives with very short 
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acyl chain (acetyl 65, propionyl 66) are very polar and require individual optimization in 
extractive work-up. In some cases of tryptophan conjugates, the low yields are a result of loss 
during filtration. 
 Amide coupling of amino acids with free fatty acids 
In contrast to the shorter fatty acids (C4 – C18), whose acyl chlorides were employed in the 
previous chapter, arachidic (C20) and arachidonic acids (C20:4) were only available as free 
fatty acids. Besides the option to activate the carboxyl group separately prior to the addition of 
the amino acid reaction partner, one can conduct a one-pot amide formation using a coupling 
reagent. In the latter case, the carboxyl residues in amino acids must be protected at first in 
order to prevent their interference in the subsequent coupling reaction. However, the prominent 
advantage of this one-pot method lies in the possibility to avoid material loss during isolation 
of fatty acyl chlorides. On a basis of an already published method by Dinda et al.,83 we were 
able to synthesize several N-arachidoyl- and N-arachidonoylamino acids. In the first step, L-
glutamic acid, L- and D-tryptophan were temporary converted to their corresponding acid 
chloride forms using thionyl chloride (SOCl2). The chlorine was then replaced immediately by 
a methoxy group in the present of methanol acting as both reagent and solvent. A further 
neutralization step afforded the methyl esters 91 and 92 as oily compounds while methyl ester 
93 did not undergo neutralization, and thus remained as a hydrochloride salt for better handling 
and storage. Subsequently, the three methyl esters were subjected to a reaction with either 
arachidic or arachidonoic acid in the presence of N,N’-dicyclohexylcarbodiimide (DCC) and 1-
hydroxy-7-azabenzotriazole (HOAt) to form the acyl amino acid methyl esters 94 - 99. The 
application of hydrochloride salt 93 turned out to work fine when the solution of this compound 
was treated with a portion of N,N-diisopropylethylamine (DIPEA) before being added to the 
other reagents. Finally, the ester functional group was cleaved under basic conditions giving 
the sodium salts of the N-acylamino acids, which were converted into the free lipoamino acids 
100 – 105 upon neutralization with HCl (Figure 3.13).  
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Figure 3.13: Preparation of N-acylamino acids from free fatty acids. 
DCC is one of the classic coupling reagents, which is being widely used in peptide synthesis. 
The mechanism of DCC is illustrated in Figure 3.14 starting with a reaction of this coupling 
reagent with a carboxylic acid to form an ester O-acylisourea while the additive HOAt 
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suppresses the formation of the N-acylurea by-product and transfers the acyl group to the amino 
group to produce the desired amide and DCU, which is insoluble in most organic solvent and 
can be easily removed by filtration. 
 
Figure 3.14: Mechanism of the amide coupling reaction with DCC and HOAt. 
 Esterification of N-acyl-L-tryptophan derivatives 
The methyl esters 94 – 99 mentioned in the previous chapter were initially prepared as 
precursors for the synthesis of the free N-acylamino acid final products 100 – 105. They were 
also tested in ß-arrestin assays at GPR18 and GPR55 to examine whether the carboxylic group 
is essential for the compounds’ activities. Later on, as it was confirmed that our biological 
targets also tolerated the ester moiety, some active N-acyl-L-tryptophan derivatives were 
selected to undergo esterification with different alcohols including ethanol, propanol, etc. 
Quantitative yields were obtained when thionyl chloride had been added dropwise to an 
alcoholic solution of N-acyl-L-tryptophan at 0 °C before the reaction mixture was warmed to 
room temperature and stirred overnight (Figure 3.15).   
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Figure 3.15: Esterified derivatives of N-acyl-L-tryptophans with different alcohols. 
 Racemization of N-acylamino acids 
It is well known that amino acids can undergo racemization under basic condition.84 The proton 
bound to the Cα atom can be abstracted by a base (e.g. hydroxide anion) resulting in a planar 
enolate intermediate. In a subsequent protonation, a hydrogen atom can be attached to both 
sides of the planar intermediate yielding both, L- and D-isomers (Figure 3.16). After a certain 
time, the reaction reaches an equilibrium and the mixture of the two isomers will become 
racemic. 
 
Figure 3.16: Mechanism of amino acid racemization in basic condition. 
In order to examine, whether some reaction conditions involved 2N NaOH in this study could 
induce racemization, some N-acylamino acids were reprepared in a higher scale and their 
optical rotations were measured so that the specific rotations could be calculated using the 
equation 1.  
[α]λ
T  =  
α(obs)
l ×  c
 
Equation 1: The specific rotation [α]λ
T is calculated from the observed optical rotation α(obs) 
in degrees, l being the path length in decimeters, and c the concentration in g/mL, T is the 
temperature at which the measurement was taken (in degrees Celsius), and λ is the wavelength 
in nanometers. 
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By testing the solubility of N-dodecanoylamino acids in organic solvents, acetone was found to 
be able to dissolve large amounts of N-dodecanoylated glutamic acid (71) and tryptophan (79, 
84) derivatives. In case of the serine analog 89, methanol was used. Compound 79 synthesized 
from L-tryptophan gave a positive rotation while 84 originated from the D-isomer showed equal 
and opposite rotation (Table 3.4). This led to the assumption that the two compounds are a pair 
of enantiomers and a racemization of tryptophan derivatives under the acylation conditions had 
not occurred. Results from the measurements of glutamic acid and serine derivatives also 
indicated non-racemic mixtures. 
Table 3.4: Observed optical rotations as well as specific rotations of the four amino acid educts 
and some N-acylamino acids at given temperatures using a sodium lamp (λ = 589 nm). The path 
length was 1 dm, the concentration was 0.1 g/mL. 
Comp. Solvent Temp. (°C) α(obs) (°) [𝜶]𝑫
𝑻  (°) 
L-Glutamic acid 0.5 N NaOH 25.2 -0.13 -1.3 
L-Tryptophan 0.5 N NaOH 23.9 +0.48 +4.8 
D-Tryptophan 0.5 N NaOH 24.7 -0.41 -4.1 
L-Serine 0.5 N NaOH 25.7 -0.42 -4.2 
71 acetone 20.0 -0.64 -6.4 
79 acetone 25.2 +1.44 +14.4 
84 acetone 21.3 -1.44 -14.4 
89 methanol 20.0 +0.69 +6.9 
 
3.4 Pharmacological assays of N-acylamino acids 
 ß-Arrestin assays at human GPR18 and GPR55 
For the investigation of N-acylamino acids, ß-arrrestin assays at human GPR18 and GPR55 
were performed by Dr. Clara Schoeder, Tabea Wiedenhöft and Andhika Mahardhika. In 
contrast to the assays of phenothiazine derivatives mentioned in 3.2.1, a novel GPR18 agonist 
was utilized instead of THC. PSB-KK-1415 is an indole-bearing compound, which was 
developed by our workgroup. It has an EC50 value of 19 nM at human GPR18.  
So far, the major part of the N-acyl-L-tryptophan segment as well as some compounds from the 
L-glutamic acid and D-tryptophan series were tested. L-Glutamic acid derivatives were 
completely inactive at both GPR18 and GPR55; and no agonistic activity at the two orphan 
receptors could be detected for all species.  
However, some GPR18-inhibiting activities of fatty N-acyl-L-tryptophans derivatives could be 
observed when the acyl side chain started to reach 12 carbons and was abolished at 20 carbons. 
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IC50 values of those compounds ranged from 6.32 µM (81, palmitoyl) to 9.08 µM (79, lauroyl). 
Interestingly the antagonistic effect was restored when L-tryptophan was coupled with 
arachidonic acid. The free acid form (103, IC50 9.05 µM) is as potent as N-lauroyl-L-tryptophan 
(79), while its methyl ester derivative (97) possessed a higher potency (IC50 5.27 µM, Figure 
3.17 A). Esterification at the carboxyl group of L-tryptophan seems to be beneficial in terms of 
antagonistic activity. Regarding the inactivity of the N-eicosanoyl-L-tryptophan derivatives 
(102 and 96), it can be assumed that there is not enough space inside the binding pocket of 
GPR18 for this linear straight-chain alkyl residue. In contrast, the unsaturated arachidonoyl side 
chain, although having the same number of carbons, is able to fold up and would fit into the 
binding pocket.    
Table 3.5: Results from ß-arrestin assays of N-acylamino acids at GPR18 and GPR55. 
Comp. 
Amino 
acid 
Fatty 
acid 
hGPR18a hGPR55a 
   
EC50 ± SEM 
(µM) 
(% activation)b 
IC50 ± SEM 
(µM) 
(% inhibition)c 
EC50 ± SEM 
(µM) 
(% activation)d 
IC50  ± SEM 
(µM) 
(% inhibition)e 
67 
L-Glu 
C4:0 >10 (8 ± 5) >10 (-3 ± 10) >10 (6 ± 6) >10 (0 ± 8) 
70 C10:0 >10 (0 ± 7) >10 (-12 ± 8) >10 (12 ± 10) >10 (-2 ± 19) 
71 C12:0 >10 (-11 ± 8) >10 (7 ± 7) >10 (24 ± 9) >10 (-27 ± 21) 
72 C14:0 >10 (16 ± 7) >10 (-6 ± 10) n.d. n.d. 
59 C16:0 >10 (32 ± 10) >10 (22 ± 5) n.d. n.d. 
60 C18:0 >10 (36 ± 9) >10 (26 ± 6) n.d. n.d. 
75 
L-Trp 
C4:0 >10 (6 ± 3) >10 (3 ± 10) n.d. n.d. 
76 C6:0 >10 (-11 ± 9) >10 (-10 ± 9) n.d. n.d. 
77 C8:0 >10 (12 ± 4) >10 (-3  ± 10) n.d. n.d. 
78 C10:0 >10 (1 ± 15) >10 (-4 ± 7) n.d. n.d. 
79 C12:0 >10 (-4 ± 10) 9.08 ± 1.04 n.d. n.d. 
80 C14:0 >10 (-2 ± 9) 6.51 ± 1.14 n.d. n.d. 
81 C16:0 >10 (-10 ± 7) 6.32 ± 1.71 n.d. n.d. 
82 C18:0 >10 (-2 ± 10) 7.48 ± 1.90 n.d. n.d. 
102 C20:0 >10 (-4 ± 4) >10 (36 ± 11) n.d. n.d. 
103 C20:4 >10 (-1 ± 5) 9.05 ± 1.09 n.d. n.d. 
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Table 3.5 continued   
Comp. 
Amino 
acid 
Fatty 
acid 
hGPR18a hGPR55a 
   
EC50 ± SEM 
(µM) 
(% activation)b 
IC50 ± SEM 
(µM) 
(% inhibition)c 
EC50 ± SEM 
(µM) 
(% activation)d 
IC50  ± SEM 
(µM) 
(% inhibition)e 
106 
L-Trp-OMe 
C14:0 >10 (-5 ± 2) 10.2 ± 1.12 >10 (26 ± 9) >10 (47 ± 9) 
107 C16:0 >10 (-7 ± 3) >10 (44 ± 7) >10 (6 ± 30) >10 (32 ± 15) 
108 C18:0 >10 (2 ± 4) >10 (17 ± 10) >10 (19 ± 12) >10 (-16 ± 8) 
96 C20:0 >10 (-5 ± 7) >10 (-5 ± 9) n.d. n.d. 
97 C20:4 >10 (-3 ± 9) 5.27 ± 2.65 n.d. n.d. 
109 
L-Trp-OEt 
C14:0 >10 (-14 ± 4) 10.5 ± 1.02 >10 (21 ± 16) >10 (41 ± 10) 
110 C16:0 >10 (2 ± 4) >10 (6 ± 4) >10 (24 ± 13) >10 (-10 ± 17) 
111 C18:0 >10 (-9 ± 5) >10 (21 ± 3) >10 (-11 ± 9) >10 (0 ± 14) 
104 
D-Trp 
C20:0 >10 (-3 ± 7) 9.02 ± 0.945 >10 (13 ± 11) >10 (-95 ± 28) 
105 C20:4 >10 (1 ± 17) 6.65 ± 1.07 >10 (4 ± 10) >10 (1 ± 9) 
98 
D-Trp-OMe 
C20:0 >10 (-4 ± 3) >10 (12 ± 5) >10 (-10 ± 11) >10 (-6 ± 14) 
99 C20:4 >10 (-31 ± 7) 6.94 ± 0.405 >10 (-9 ± 19) 3.67 ± 1.36 
aReceptors were expressed on CHO cells. b% activation in comparison to 0.1 µM PSB-KK-1415 induced 
luminescence signal. c% inhibition of 0.1 µM PSB-KK-1415 induced luminescence signal. d% inhibition of 1 µM 
LPI induced luminescence signal. e% activation in comparison to 1 µM LPI induced luminescence signal. All data 
with SEM resulted from three independent experiments, performed in duplicate. 
After an increase in the inhibitory effect was observed in an esterified derivative, more methyl 
and ethyl esters of N-acyl-L-tryptophan (106 – 114) were introduced. However, compounds of 
this category were almost inactive. The boundary species are the two derivatives having the 
myristoyl side chain (106 and 109), both exhibiting very similar GPR18-inhibiting behaviour 
(IC50 10.2 µM and 10.5 µM, respectively).  
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Figure 3.17: (A) N-Arachidonoyl-L-tryptophan methyl ester (97) and its D-isomer (99) showed 
comparable antagonistic activities at GPR18. (B) The D-isomer also acts as a GPR55 
antagonist. 
In the series of D-tryptophan derivatives, a different trend was observed. At first, a low activity 
(IC50 9.02 µM) was detected with N-eicosanoyl-D-tryptophan (104), unlike its inactive L 
enantiomer 102. Moreover, no increase in activity took place after a methyl esterification of N-
arachidonoyl-D-tryptophan since both free acid (105) and methyl ester (99) derivatives acted 
as GPR18 antagonists with similar potencies (IC50 6.65 µM and 6.94 µM, respectively). 
Additionally, the methyl ester 99 is one of the few tested N-acylamino acids, which could inhibit 
LPI-induced GPR55 activation (IC50 3.67 µM, Figure 3.17 B).  
 Radioligand binding assays 
Although the orphan GPR18 and GPR55 are structurally not related to the cannabinoid 
receptors CB1 and CB2, they are still able to interact with their natural and some synthetic 
ligands. In order to examine, whether the newly synthesized GPR18 and GPR55 antagonists 
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can bind to cannabinoid receptors, radioligand binding assays were performed. The binding 
affinity of a test compound for a receptor can be calculated indirectly by measuring its ability 
to compete with the binding of a known radioactive ligand to this receptor. The unlabeled test 
compound in increasing concentrations will compete with the radioligand in a fixed 
concentration and displace it from the binding site, leading to a decrease in the concentration 
of radioligand receptor complex and accordingly the measured radioactivity. The experiment is 
thus also known as competition binding assay. From the resulting data, the concentration of the 
unlabeled ligand that inhibits the binding of the radioactive ligand by 50 % (IC50 value) is 
obtained. The dissociation constant (Ki) of the unlabeled compound representing its affinity to 
the examined receptor can be calculated from the IC50 value using following Cheng-Prusoff 
equation. If the Ki value is low, the affinity of the unlabeled ligand for the receptor will be high. 
Ki =  
IC50
1 +
[L]
KD
 
Equation 2: Cheng-Prusoff equation. [L] is the concentration of the radioactive ligand used in 
the assay and KD is the affinity of the radioligand for the receptor. 
Radioligand binding assays of N-acylamino acids in this study were performed by Dr. Clara 
Schoeder and Andhika Mahardhika. The cannabinoid receptor agonist radioligand [3H](-)-cis-
3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol 
([3H]CP55,940) with KD values of 2.4 nM (at human CB1) and 0.7 nM (at human CB2), was 
used. 
Table 3.6: Results from competition binding assays of N-acylamino acids at human CB1 and 
CB2 receptors.  
Comp. 
Amino 
acid 
Fatty 
acid 
hCB1a hCB2a 
   
Ki (µM) 
(% inhibition of specific binding)b 
Ki (µM) 
(% inhibition of specific binding)b 
67 
L-Glu 
C4:0 >10 (7 ± 3) >10 (3 ± 7) 
70 C10:0 >10 (25 ± 11) >10 (15 ± 8) 
71 C12:0 >10 (32 ± 10) >10 (-1 ± 2) 
72 C14:0 >10 (14 ± 4) >10 (10 ± 5) 
59 C16:0 >10 (37 ± 10) >10 (25 ± 14) 
60 C18:0 >10 (28 ± 5) >10 (9 ± 3) 
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Table 3.6 continued   
Comp. 
Amino 
acid 
Fatty 
acid 
hCB1a hCB2a 
   
Ki (µM) 
(% inhibition of specific binding)b 
Ki (µM) 
(% inhibition of specific binding)b 
75 
L-Trp 
C4:0 >10 (18 ± 5) >10 (1 ± 2) 
76 C6:0 >10 (14 ± 10) >10 (-3 ± 2) 
77 C8:0 >10 (34 ± 11) >10 (26 ± 11) 
78 C10:0 >10 (2 ± 13) >10 (9 ± 3) 
79 C12:0 >10 (8 ± 3) >10 (12 ± 3) 
80 C14:0 >10 (18 ± 6) >10 (30 ± 5) 
81 C16:0 >10 (22 ± 3) >10 (13 ± 3) 
82 C18:0 >10 (16 ± 4) >10 (12 ± 4) 
102 C20:0 >10 (2 ± 9) >10 (-10 ± 6) 
103 C20:4 >10 (21 ± 8) >10 (33 ± 5) 
106 
L-Trp-OMe 
C14:0 >10 (45 ± 20) >10 (39 ± 13) 
107 C16:0 >10 (50 ± 11) >10 (41 ± 11) 
108 C18:0 >10 (-7 ± 8) >10 (9 ± 7) 
96 C20:0 >10 (30 ± 13) >10 (11 ± 4) 
97 C20:4 (52 ± 6) (78 ± 8) 
109 
L-Trp-OEt 
C14:0 1.70 ± 0.08 2.50 ± 0.05 
110 C16:0 0.27 ± 0.012 >10 (36 ± 13) 
111 C18:0 >10 (5 ± 11) >10 (5 ± 12) 
104 
D-Trp 
C20:0 >10 (9 ± 12) >10 (8 ± 7) 
105 C20:4 0.98 ± 0.31 >10 (31 ± 5) 
98 
D-Trp-OMe 
C20:0 >10 (-3 ± 14) >10 (-4 ± 3) 
99 C20:4 1.89 ± 0.52 2.01 ± 0.29 
aReceptors were expressed on CHO cells. b% inhibition of binding of 0.1 nM [3H]CP55,940. All data with SEM 
resulted from three independent experiments, performed in duplicate. 
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Binding of N-acyltryptophan to CB1 and CB2 receptors occurred mostly when an arachidonoyl 
residue was present (Table 3.6, compounds 97, 99). In case of 103, only CB1 binding was 
observed (Ki 980 nM). This finding can be expected since the endogenous ligand anandamide 
(2) of cannabinoid receptors also possesses this residue, which may contribute greatly to the 
binding of this ligand to its biological targets. Nonetheless, N-myristoyl-L-tryptophan ethyl 
ester (109) has been found to have affinity to both CB1 and CB2 subtypes. By extending the 
fatty acyl side chain of this type of compound to palmitoyl (110), binding became selective 
toward CB1 with a significant increase in affinity (Ki 207 nM), however, with a stearoyl residue 
(111), binding to cannabinoid receptors was completely eliminated. 
3.5 Enzymatic hydrolysis of bovine phosphatidylinositol 
Inspired by the study showing a considerable higher potency of 2-AGPI (10) as compare to 
soybean LPI, the intention of this experiment was to enzymatically prepare a mixture of 1-
lysophosphatidylinositols (1-LPIs) from commercially available bovine liver PI, which consists 
of PIs with different fatty acyl residues at the sn-2 position (mainly C18:1, C18:2, C20:3 and 
C20:4). Under appropriate conditions, phospholipase A1 will cleave the ester bond at sn-1 
position of PI giving 1-LPIs and a free fatty acid (Figure 3.18).  
 
Figure 3.18: Hydrolysis of PIs using phospholipase A1 
The reaction protocol has been partly adopted from Oka et al. 58 Since the Rhizopus delemar 
lipase used by Oka was not available for us, a phospholipase A1 from Thermomyces lanuginosus 
(10 kilo lipase unit per gram (KLU/g), purchased from Sigma) was used instead. In the first 
attempt, the amount of PLA1 was calculated so that the enzyme can hydrolyze 5 equivalents of 
substrate. After the termination of the reaction and liquid-liquid extraction as described in the 
literature, the methanol-water layer was poured into a solid-phase extraction (SPE) tube. 
Aminopropyl-modified silica sorbent was chosen due to its usefulness in the separation of free 
fatty acids produced during the hydrolysis reaction.85 The solvents in the sample were led to 
flow through the tube leaving compounds binding to the solid phase, which was then washed 
with a mixture of diethylether/acetic acid to elute all fatty acids (Fraction 2). Finally, the ionic 
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strength of the solid phase was reduced by adding methanol/ammonia, thus the stronger-
retained phospholipids can be eluted (Fraction 3, Figure 3.19). All 3 fractions were examined 
via LC-MS but could not find any lysophosphatidylinositol (molecular weights from 591 – 623 
were scanned). 
 
Figure 3.19: Purification of phospholipids employing aminopropyl SPE tube. 
In a more recent attempt to hydrolyze 5 mg of bovine PI using phospholipase A1 from 
Thermomyces lanuginosus, DMSO was added to the reaction mixture in order to increase the 
solubility of PI in acetate buffer. The reaction condition and purification protocol remained 
unchanged. The m/z values revealed in the LC-MS positive mode (Figure 3.20) of the third SPE 
fraction corresponded to few 1-LPI species varied in the unsaturated sn-2 acyl groups, namely 
linoleic acid (C18:2, 115), arachidonic acid (C20:4, or 2-AGPI, 10) and dihomo-γ-linoleic acid 
(C20:3, 116) (Table 3.7).  
Table 3.7: Structures and m/z values of possible 1-LPIs identified in LC-MS spectra. 
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1-LPI Acyl residue [M+H]+ [M+NH4]+ 
115 C18:2 597 - 
10 C20:4 621 638 
116 C20:3 623 640 
Moreover, the presence of these fatty acyl groups also complies with the fatty acid distribution 
in commercial bovine liver PI provided by Avanti Lipid. Besides [M+H]+ ions, [M+NH4]
+ 
adducts were also observed, probably due to the use of ammonia in SPE purification. In 
addition, there were some m/z values, which cannot be assigned to any compound yet. 
 
Figure 3.20: LC-MS spectra of the product from PI hydrolysis. 
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The addition of DMSO to the reaction medium has showed some positive effects on the 
phospholipase A1-catalyzed hydrolysis of PI, as a few 1-LPI species were detected in the final 
SPE fraction by LC-MS analysis. The PLA1 from Thermomyces lanuginosus, also known as 
Lecitase Ultra, has been reported to possess a single active site with both lipase and 
phospholipase activity, which can be enhanced by Ca2+ and Mg2+ ions.86 However the pH-
optimum for this enzyme is controversial, hitherto two values (8.586 and 5.087) have been 
proposed. Furthermore, a complete hydrolysis of phosphatidylcholine (PC) to L-α-
glycerylphosphorylcholine (L-α-GPC) catalyzed by Lecitase Ultra in n-hexane–water biphasic 
media has been described. 88  Hence, optimizations for both reaction condition as well as 
purification method are required. 
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4 Conclusions and outlook 
The orphan G protein-coupled receptors GPR18 and GPR55 interact with cannabinoids, 
although they are only distantly related to the classical cannabinoid receptors CB1 and CB2. 
There is preliminary evidence for the involvement of GPR18 and GPR55 in various 
pathophysiological processes, and both receptors may have potential as future drug targets. 
Potent and selective pharmacological tool compounds, agonists and antagonists, are urgently 
required for target validation studies. Moreover, it is of great interest to identify physiological 
agonists of both orphan receptors. Physiological lipids have been postulated to activate the 
receptors, N-arachidonoylglycine (NAGly) for GPR18, and 1-lysophosphatidylinositol (1-LPI) 
for GPR55, but these have not been unambigously confirmed so far.  
In the here presented study, synthetic and natural products including many new, not previously 
described compounds have been prepared and investigated as new ligands for these receptors.  
 
Phenothiazine derivatives 
Compounds of the first series were derived from the 2-chlorophenothiazine scaffold. This 
compound came into focus after the discovery of antagonistic activities of perphenazine and 
related antipsychotics at GPR18 observed in a screening approach of a library of approved 
drugs. At first, the basic propylamino group, a typical feature of these drugs, was replaced by 
several alkyl, cycloalkyl and aryl substituents via alkylation at the N-10 position of 2-
chlorophenothiazine. The purpose of these modifications was to develop GPR18 antagonists 
without inhibitory activity at dopamine or other neurotransmitter receptors.  
Appropriate conditions for preparing N-alkylated phenothiazine derivatives using NaH and 
DMF were investigated and optimized in this study. As a result, several alkyl- and aralkyl-
substituted 2-chlorophenothiazines could be obtained in high yields (75–87%). Interestingly, 
these compounds lost their effect at GPR18 but were active as inhibitors of GPR55. The most 
potent phenothiazine-derived GPR55 antagonist was the 3-phenylpropyl-substituted derivative 
40 displaying an IC50 value of 5.29 µM at GPR55 (see Fig. 4.1). Moreover, N-alkylated 
phenothiazine derivatives with side chains of up to five carbon atoms behaved as moderately 
potent antagonists at GPR55 (IC50 6.20 – 10.1 µM). However, by exchange of the benzene ring 
in 40 for a primary amino group, the selectivity was shifted towards GPR18. Indeed, compound 
41 was the only derivative in this series capable of inhibiting the activation of GPR18 (IC50 
4.89 µM) while being inactive at GPR55 (Figure 4.1). Therefore, it could be assumed that an 
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amino group was required for GPR18 antagonism. In future experiments, the amino group in 
41 could be further modified, e.g. replaced by other non-basic functional groups such as amide 
or urea functions to study the role of the propylamino moiety for GPR18 inhibition. Further 
modifications may also be carried out at the phenyl group of 40 to develop more potent GPR55 
antagonists. 
 
Figure 4.1: Novel phenothiazine-derived GPR18- and GPR55 antagonists. 
 
N-Acylamino acids 
Several different N-acylamino acids have been found in mammalian brains as well as the 
periphery, and a few have been shown to possess biological effects e.g., modulating pain, 
inflammation, and cardiovascular functions. Via acylation and amide coupling methods, 
various conjugates of amino acids and natural fatty acids were prepared. Among the four amino 
acids employed in the present study, tryptophan as a constituent of the prepared N-acylamino 
acids appeared to be an important moiety for inhibiting GPR18 activation. Particularly, amides 
of L-tryptophan and fatty acids with a side chain preferably between 12 and 18 carbon atoms 
antagonized GPR18 at low micromolar concentrations (IC50 6.32 – 9.08 µM).  
Furthermore, arachidonic acid also appeared to be a well-tolerated residue by GPR18 with the 
L-tryptophan methyl ester 97 being the most potent conjugate (IC50 5.27 µM). However, this 
compound also showed binding affinities to both CB receptor subtypes in competition binding 
assays. Hydrolysis of the ester group of 97 eliminated binding to CB1 and CB2, and slightly 
decreased the potency at GPR18 (103, IC50 9.05 µM). In case of D-tryptophan conjugates, the 
trend was different. Ester 99 possessed moderate inhibiting potencies at both GPR18 (IC50 6.94 
µM) and GPR55 (IC50 3.67 µM) as well as binding affinities to both cannabinoid receptors. 
After hydrolysis, the activity of the resulting compound 105 at GPR18 remained almost 
unchanged (IC50 6.65 µM) while the affinities towards GPR55 and CB2 receptor were abolished 
(Figure 4.2). Thus, it was assumed that the carboxyl group plays an important role in the 
selectivity of N-acyltryptophan derivatives at cannabinoid-like receptors. 
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Figure 4.2: Enantiomers of N-arachidonoyltryptophan and their inhibitory potencies at GPR18, 
GPR55, CB1 and CB2 receptors. 
Due to the preference of GPR18 for tryptophan as an amino acid residue in the N-acylamino 
acids, structural modifications at the indole ring system could be considered as a meaningful 
next step to identify more potent ligands.  
In conclusion, in the present study, phenothiazine and N-acylamino acids have been identified 
as novel classes of ligands for the orphan receptors GPR18 and GPR55. The results provided 
herein will serve as a basis for further development of more potent and selective antagonists, 
which will be useful as pharmacological tools for elucidating the pathophysiological roles of 
these two orphan GPCRs and to validate them as future drug targets. 
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5 Experimental 
5.1 Material for synthesis 
 Chemicals and solvents 
Commercially available chemicals for synthesis were purchased from following producers: 
Sigma-Aldrich (Steinheim), Alfa Aesar (Karlsruhe), Acros Organics (Geel, Belgium), VWR 
(Siegburg), Merck (Darmstadt), Fluorochem (Hadfield, England) or TCI (Eschborn) and used 
without further purification. Solvents were obtained from various commercial sources. 
Dichloromethane was distilled over calcium hydride and other solvents were used without 
further purification. 
 Instruments and equipment 
Thin layer chromatography (TLC) 
Analytical thin layer chromatography (TLC) was performed on silica-coated aluminum plates 
containing a fluorescent indicator (Merck silica gel 60 F254, Darmstadt, Germany). 
Column chromatography 
For column chromatography silica gel 60 (0.063-0.200 mm) from Merck (Darmstadt, Germany) 
was used. 
Lyophilization  
Lyophilization of compounds was performed with an Alpha 1-4 LSC freeze dryer (Martin 
Christ Gefriertrocknungsanlagen GmbH, Osterode, Germany). 
High performance liquid chromatography - mass spectrometry (HPLC-MS) 
Low-resolution mass spectra were obtained on an API 2000 mass spectrometer (electrospray 
ionization, Applied Biosystems, Darmstadt, Germany) coupled to an HPLC system (Agilent 
1100) using the following procedure: compounds were dissolved in methanol (1 mg/mL). A 10 
µL sample of this solution was injected into the HPLC system containing a Phenomenex Luna 
C18 column (50 mm x 2.00 mm, particle size 3 µm). It was chromatographed using a gradient 
of water:methanol (containing 2 mM ammonium acetate, if not stated otherwise) from 90:10 to 
0:100 within 30 min. The gradient was started after 10 min, the flow rate was 250 µL/min. UV 
absorption was detected using a diode array detector (from 190 to 900 nm) and purity was 
determined at 254 nm. 
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Nuclear magnetic resonance spectroscopy (NMR) 
1H-, 13C- and 31P-NMR spectra were recorded on a Bruker Avance 500 MHz or a Bruker Ascend 
600 MHz spectrometer. Spectra were recorded at room temperature in DMSO-d6, CDCl3, 
MeOD or D2O as indicated. Chemical shifts are given in parts per million (ppm) relative to the 
remaining protons of the deuterated solvents used as internal standard. Coupling constants are 
given in Hertz (Hz). Spin multiplicities are abbreviated as s (singlet), d (doublet), t (triplet), m 
(multiplet), br (broad). Alpha, beta and gamma carbons of amino acids are labelled as Cα, Cß 
and Cγ, respectively. 
Melting point apparatus 
For the determination of melting points a Büchi Melting Point apparatus B-560 was used, and 
melting points were not corrected. 
Optical rotation determination 
The observed optical rotation was determined using a Bellingham + Stanley polarimeter with a 
sodium lamp (λ = 589 nm). The cell has a length of 1 dm. The concentration was 1 g/10 mL 
solvent. 
5.2 Procedures for the synthesis of phenothiazine derivatives 
 General procedures for N-alkylation of 2-chlorophenothiazine 
5.2.1.1 Method 1 
 
2-Chlorophenothiazine (25, 200 mg, 0.86 mmol, 1 eq.) was dissolved in dimethylformamide 
(DMF, 20 mL). NaH (60% in mineral oil, 1 - 2 eq.) was added in small fractions to the reaction 
mixture at 0°C. After stirring for 10 min at 0°C, alkyl iodide or alkyl bromide (1.2 – 2.2 eq.) 
was added. The resulting solution was stirred at r. t. or 60 °C for 4 – 24 h, before being treated 
with water (40 mL). Dichloromethane (60 mL) was added to the solution and the organic phase 
was washed with a saturated solution of NaHCO3 (40 mL), followed by an aqueous solution 
composed of 2 g of LiCl in 40 mL of water, and finally 3 times with water (40 mL). The organic 
phase was then dried over MgSO4 and concentrated under reduced pressure. The crude product 
was purified by column chromatography on silica gel to afford the title compounds. 
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5.2.1.2 Method 2 
 
To a mixture of 2-chlorophenothiazine (25, 233 mg, 1.00 mmol) and alkyl bromide or alkyl 
iodide (3 - 5 eq.) in dimethylformamide (DMF, 5 mL), NaH (60% in mineral oil, 48 mg, 1.2 
mmol) was added in an ice-bath. The reaction mixture was stirred at r. t. for 1 h, and an 
additional portion of NaH (60% in mineral oil, 48 mg) was added upon cooling in an ice-bath. 
The reaction mixture was further stirred at the r. t. for 0.5 h before being treated with water (50 
mL) and extracted with dichloromethane (3 x 30 mL). The combined organic phase was washed 
with an aqueous solution composed of 2 g of LiCl in 40 mL of water, and finally with water (3 
x 50 mL). The organic phase was then dried over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by a column chromatography on silica gel and if 
necessary recrystallized to afford the title compounds. 
5.2.1.3 Method 3 
 
2-Chlorophenothiazine (25, 400 mg, 1.72 mmol, 1 eq.), NaOH (89 mg, 2.2 mmol, 1.3 eq.) and 
alkyl bromide (1.2 eq.) were dissolved in dimethyl sulfoxide (DMSO, 20 mL) and the mixture 
was stirred overnight at r. t. The reaction mixture was then poured into water and extracted with 
dichloromethane. The combined organic phase was dried over MgSO4 and concentrated under 
reduced pressure. The crude residue was purified by column chromatography on silica gel to 
afford the title compounds. 
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 Procedure for the synthesis of 2-(1H-indol-3-yl)-1-(2-chloro-10H-
phenothiazin-10-yl)ethanone (46) 
 
A solution of thionyl chloride (SOCl2, 160 µL, 2.2 mmol) in diethyl ether (Et2O, 5 mL) was 
added over a period of 5 min to a stirring suspension of indolyl-3-acetic acid (350 mg, 2.0 
mmol) in diethyl ether (10 mL, dried over MgSO4) at 0 °C. The reaction mixture was stirred at 
0 °C for 1.5 h followed by removal of the solvent under vacuum affording a dark brown solid. 
Then a solution of 2-chlorophenothiazine (233 mg, 1.0 mmol) in o-xylene (20 mL) was added 
and the reaction mixture was refluxed for 3 h. The crude mixture was concentrated under 
vacuum then purified by column chromatography on silica gel (petroleum ether (b.p. 40 – 60 
°C):ethyl acetate = 8:2) yielding a white solid. 
 General procedure for the acylation of 2-chlorophenothiazine 
 
A solution of 2-chlorophenothiazine (25, 4.00 g, 17.1 mmol) in toluene (20.0 mL) was treated 
with chloroacetyl chloride (1.43 mL, 18.0 mmol) or 3-bromopropionyl chloride (1.82 mL, 18.0 
mmol) and heated to 100 °C for 1 h. The mixture was cooled to r. t., concentrated under vacuum, 
taken up in a minimal amount of toluene and purified by column chromatography on silica gel 
(petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 8:2) to afford the title compounds. 
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 General procedure for the synthesis of azide derivatives 
 
A solution of a substituted alkyl halogenide (2.1 - 3.2 mmol) in DMF (10 mL) was treated with 
sodium azide (NaN3, 3 eq.) and stirred at r. t. for 20 h. The solution was diluted with 
dichloromethane (100 mL) and the organic layer was washed with water (2 x 100 mL), followed 
by a saturated aqueous NaCl solution (100 mL), dried over MgSO4 and concentrated under 
reduced pressure. The residue was taken up in a minimal amount of dichloromethane and 
purified by column chromatography on silica gel (petroleum ether (b.p. 40 – 60 °C):ethyl 
acetate = 9:1) to afford the title compounds. 
 General procedure for the reduction of azide derivatives to amines 
 
A solution of an azide derivative (4 – 6.3 mmol) in tetrahydrofuran (THF, 5 mL) was cooled to 
0 °C and treated with a borane-tetrahydrofuran complex solution (BH3-THF, 1 M in THF, 4 
eq.). The flask was sealed, heated to 70 °C for 5 h, and then cooled to 0 °C. The solution was 
treated slowly and dropwise with a solution of aqueous 1 M HCl (8 eq.), stirred for an additional 
0.5 h, and then heated to 70 °C for 1 h. The mixture was cooled to r. t., treated with aqueous 4 
M NaOH until pH > 8, and then extracted with ethyl acetate (3 x 70 mL). The combined extracts 
were washed with saturated aqueous NaCl solution (100 mL), dried over MgSO4, and 
concentrated under vacuum. The residue was dissolved in a minimal amount of 
dichloromethane and purified by column chromatography on silica gel (petroleum ether (b.p. 
40 – 60 °C):ethyl acetate = 8:2 to remove nonpolar impurities followed by 
dichloromethane:methanol:NH4OH : 17:2:1 to elute the product). The combined fractions of 
pure product were concentrated, dried azeotropically with toluene, and then suspended in 
diethyl ether (50 mL) and treated dropwise with a 4 N HCl-dioxane solution (1 mL). The solid 
that had precipitated was collected by filtration affording the title compounds. 
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 General procedure for sulfonamide formation 
 
A solution of a substituted alkyl ammonium chloride (1 mmol) in DMF (5 mL) was cooled to 
0 C, treated with triethylamine (TEA, 293 µL, 2.1 mmol), and 4-
trifluoromethoxybenzenesulfonyl chloride (187 µL, 1.1 mmol). The mixture was warmed to r. 
t. and stirred for 2 h. It was then poured into a saturated aqueous NaCl solution (50 mL), and 
extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with 
saturated aqueous NaCl solution (2 x 50 mL), dried over MgSO4, and concentrated under 
vacuum. The residue was dissolved in a minimal amount of dichloromethane, purified by 
column chromatography on silica gel (petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 8:2) 
and recrystallized from ethanol affording the title compounds. 
 Analytical data of synthesized compounds 
 
2-Chloro-10-methyl-10H-phenothiazine (26)89 
The compound was prepared from methyl iodide (1.2 eq.), NaH (1 eq.), 
at r.t., in 4 h according to procedure 5.2.1.1. Chromatographic 
purification: petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 95:5 as 
eluent. 
Appearance: white solid. Yield: 106 mg, 50 %. Melting point: 91 – 93 °C (lit. m.p. 81 – 83 
°C).1 Purity by HPLC-UV (254 nm)-ESI-MS: 98.6 %. 
1H-NMR (500 MHz, CDCl3) : 7.16 – 7.09 (m, 2H, Harom.), 7.01 (d, J = 8.1 Hz, 1H, Harom.), 
6.85 (m, 2H, Harom.), 6.81 – 6.72 (m, 2H, Harom.), 3.74 (s, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 146.6 (2 x Carom., Cquat.), 133.4 (Carom., Cquat.), 127.6 (Carom., 
CH), 127.4 (Carom., CH), 127.0 (Carom., CH), 123.0 (2 x Carom., Cquat.), 122.3 (2 x Carom., CH), 
114.5 (Carom., CH), 114.3 (Carom., CH), 35.2 (CH3). 
LC-ESI-MS (m/z): 248 [M+H]+. 
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2-Chloro-10-ethyl-10H-phenothiazine (27)90 
The compound was prepared from ethyl iodide (1.2 eq.), NaH (1 eq.), at 
r.t., in 5 h according to procedure 5.2.1.1. Chromatographic purification: 
petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 95:5 as eluent. 
Appearance: white solid. Yield: 118 mg, 52 %. Melting point: 130 – 
132 °C (lit. m.p. 120 °C).2 Purity by HPLC-UV (254 nm)-ESI-MS: 98.2 %. 
1H-NMR (500 MHz, CDCl3) : 7.16 – 7.05 (m, 2H, Harom.), 6.99 (d, J = 8.1 Hz, 1H, Harom.), 
6.93 – 6.75 (m, 4H, Harom.), 3.91 (s (br), 2H, CH2), 1.39 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 145.8 (2 x Carom., Cquat.), 133.2 (Carom., Cquat.), 127.6 (Carom., 
CH), 127.4 (2 x Carom., CH), 122.8 (2 x Carom., Cquat.), 122.3 (2 x Carom., CH), 115.5 (2 x Carom., 
CH), 42.0 (CH2), 12.8 (CH3). 
LC-ESI-MS (m/z): 262 [M+H]+. 
 
2-Chloro-10-propyl-10H-phenothiazine (28)74 
The compound was prepared from n-propyl iodide (1.2 eq.), NaH (1 eq.), 
at r.t., in 24 h according to procedure 5.2.1.1. Chromatographic 
purification: petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 95:5 as 
eluent. 
Appearance: pink-colored solid. Yield: 105 mg, 44 %. Melting point: 60 – 62 °C. Purity by 
HPLC-UV (254 nm)-ESI-MS: 98.7 %. 
1H-NMR (500 MHz, CDCl3) : 7.17 – 7.07 (m, 2H, Harom.), 7.00 (d, J = 8.1 Hz, 1H, Harom.), 
6.89 – 6.77 (m, 4H, Harom.), 3.78 (s (br), 2H, N-CH2), 1.80 (sext, J = 7.3 Hz, 2H, CH2CH3), 0.99 
(t, J = 7.4 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 146.5 (Carom., Cquat.), 144.5 (Carom., Cquat.), 133.1 (Carom., Cquat.), 
127.8 (Carom., CH), 127.4 (Carom., CH), 127.3 (Carom., CH), 124.7 (Carom., Cquat.), 123.4 (Carom., 
Cquat.), 122.8 (Carom., CH), 122.1 (Carom., CH), 115.7 (2 x Carom., CH), 49.2 (N-CH2), 20.0 
(CH2CH3), 11.3 (CH3). 
LC-ESI-MS (m/z): 276 [M+H]+. 
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2-Chloro-10-(1-methylethyl)-10H-phenothiazine (29) 
The compound was prepared from isopropyl iodide (2 eq.), NaH (2 eq.), 
at r.t., in 4 h according to procedure 5.2.1.1. Chromatographic 
purification: petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 95:5 as 
eluent. 
Appearance: off-white solid. Yield: 90 mg, 38 %. Melting point: 55 – 57 °C. Purity by 
HPLC-UV (254 nm)-ESI-MS: 97.6 %. 
1H-NMR (500 MHz, CDCl3) : 7.15 – 7.08 (m, 4H, Harom.), 7.00 (d, J = 8.2 Hz, 1H, Harom.), 
6.97 – 6.92 (m, 1H, Harom.), 6.89 (dd, J = 8.2, 2.1 Hz, 1H, Harom.), 4.25 (sept, 
J = 6.9 Hz, 1H, N-CH), 1.60 (d, J = 6.9 Hz, 6H, 2 x CH3). 
13C-NMR (125 MHz, CDCl3) : 145.9 (Carom., Cquat.), 143.9 (Carom., Cquat.), 132.8 (Carom., Cquat.), 
127.7 (Carom., CH), 127.4 (Carom., CH), 127.3 (Carom., CH), 126.5 (Carom., Cquat.), 125.5 (Carom., 
Cquat.), 123.4 (Carom., CH), 122.8 (Carom., CH), 118.7 (Carom., CH), 118.5 (Carom., CH),  54.0 (N-
CH), 22.0 (2 x CH3). 
LC-ESI-MS (m/z): 276 [M+H]+. 
 
2-Chloro-10-butyl-10H-phenothiazine (30)91 
The compound was prepared from iodobutane (5 eq.) according to 
procedure 5.2.1.2. Chromatographic purification: petroleum ether (b.p. 40 
– 60 °C):ethyl acetate = 95:5 as eluent.  
Appearance: colorless oil. Yield: 233 mg, 75 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 96.7 %. 
1H-NMR (600 MHz, CDCl3) : 7.15 – 7.07 (m, 2H, Harom.), 7.00 - 6.97 (m, 1H, Harom.), 6.92 – 
6.78 (m, 4H, Harom.), 3.80 (s, 2H, N-CH2), 1.74 (m, 2H, CH2), 1.42 (m, 2H, CH2), 0.92 (m, 3H, 
CH3). 
13C-NMR (125 MHz, CDCl3) : 146.6 (Carom., Cquat.), 144.6 (Carom., Cquat.), 133.2 (Carom., Cquat.), 
127.8 (Carom., CH), 127.5 (Carom., CH), 127.4 (Carom., CH), 124.7 (Carom., Cquat.), 123.5 (Carom., 
Cquat.), 122.8 (Carom., CH), 122.2 (Carom., CH), 115.7 (Carom., CH), 114.9 (Carom., CH), 47.1 (CH2), 
28.9 (CH2), 20.1 (CH2), 13.8 (CH3). 
LC-ESI-MS (m/z): 290 [M+H]+. 
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2-Chloro-10-pentyl-10H-phenothiazine (31)92 
The compound was prepared from 1-bromopentane (5 eq.) according to 
procedure 5.2.1.2. Chromatographic purification: petroleum ether (b.p. 
40 – 60 °C):ethyl acetate = 98:2 as eluent. 
Appearance: colorless oil. Yield: 265 mg, 82 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 97.9 %. 
1H-NMR (600 MHz, CDCl3) : 7.14 – 7.09 (m, 2H, Harom.), 6.99 (d, J = 8.2 Hz, 1H, Harom.), 
6.90 – 6.79 (m, 4H, Harom.), 3.80 (s, 2H, N-CH2), 1.77 (quintet, J = 7.3 Hz, 2H, CH2), 1.41 – 
1.29 (m, 4H, 2 x CH2), 0.88 (t, J = 7.2 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 146.5 (Carom., Cquat.), 144.5 (Carom., Cquat.), 133.1 (Carom., Cquat.), 
127.8 (Carom., CH), 127.4 (Carom., CH), 127.3 (Carom., CH), 124.7 (Carom., Cquat.), 123.4 (Carom., 
Cquat.), 122.8 (Carom., CH), 122.1 (Carom., CH), 115.7 (2 x Carom., CH), 47.4 (CH2), 29.1 (CH2), 
26.5 (CH2), 22.3 (CH2), 14.0 (CH3). 
LC-ESI-MS (m/z): 304 [M+H]+. 
 
2-Chloro-10-hexyl-10H-phenothiazine (32) 
The compound was prepared from 1-bromohexane (5 eq.) according to 
procedure 5.2.1.2. Chromatographic purification: petroleum ether (b.p. 
40 – 60 °C) as eluent. 
Appearance: colorless oil. Yield: 287 mg, 84 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 97.1 %. 
1H-NMR (600 MHz, CDCl3) : 7.14 – 7.09 (m, 2H, Harom.), 6.99 (d, J = 8.6 Hz, 1H, Harom.), 
6.94 – 6.79 (m, 4H, Harom.), 3.80 (s, 2H, N-CH2), 1.76 (quintet, J = 8.1 Hz, 2H, CH2), 1.41 (s, 
2H, CH2), 1.29 - 1.27 (m, 4H, 2 x CH2), 0.86 (t, J = 6.5 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 146.5 (Carom., Cquat.), 144.5 (Carom., Cquat.), 133.1 (Carom., Cquat.), 
127.8 (Carom., CH), 127.4 (Carom., CH), 127.3 (Carom., CH), 124.7 (Carom., Cquat.), 123.5 (Carom., 
Cquat.), 122.8 (Carom., CH), 122.2 (Carom., CH), 115.7 (2 x Carom., CH), 47.5 (CH2), 31.4 (CH2), 
26.8 (CH2), 26.6 (CH2), 22.6 (CH2), 13.9 (CH3). 
LC-ESI-MS (m/z): 318 [M+H]+. 
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2-Chloro-10-heptyl-10H-phenothiazine (33) 
The compound was prepared from 1-bromoheptane (5 eq.) according 
to procedure 5.2.1.2. Chromatographic purification: petroleum ether 
(b.p. 40 – 60 °C) as eluent. 
Appearance: light yellow oil. Yield: 288 mg, 81 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 97.4 %. 
1H-NMR (600 MHz, CDCl3) : 7.12 – 7.09 (m, 2H, Harom.), 6.99 (d, J = 8.1 Hz, 1H, Harom.), 
6.90 – 6.78 (m, 4H, Harom.), 3.80 (s, 2H, N-CH2), 1.76 (quintet, J = 7.6 Hz, 2H, CH2), 1.42 - 
1.37 (m, 2H, CH2), 1.32 - 1.21 (m, 6H, 3 x CH2), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 146.6 (Carom., Cquat.), 144.5 (Carom., Cquat.), 133.2 (Carom., Cquat.), 
127.8 (Carom., CH), 127.4 (Carom., CH), 127.3 (Carom., CH), 124.7 (Carom., Cquat.), 123.5 (Carom., 
Cquat.), 122.8 (Carom., CH), 122.2 (Carom., CH), 115.7 (2 x Carom., CH), 47.4 (CH2), 31.7 (CH2), 
28.8 (CH2), 26.8 (2 x CH2), 22.5 (CH2), 13.9 (CH3). 
LC-ESI-MS (m/z): 332 [M+H]+. 
 
2-Chloro-10-octyl-10H-phenothiazine (34) 
The compound was prepared from 1-bromooctane (5 eq.) 
according to procedure 5.2.1.2. Chromatographic purification: 
petroleum ether (b.p. 40 – 60 °C) as eluent. 
Appearance: light yellow oil. Yield: 322 mg, 87 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 98.2 %. 
1H-NMR (600 MHz, CDCl3) : 7.13 – 7.09 (m, 2H, Harom.), 6.99 (d, J = 8.0 Hz, 1H, Harom.), 
6.87 – 6.78 (m, 4H, Harom.), 3.84 (s, 2H, N-CH2), 1.76 (quintet, J = 7.3 Hz, 2H, CH2), 1.40 
(quintet, J = 7.1 Hz, 2H, CH2), 1.31 - 1.19 (m, 8H, 4 x CH2), 0.85 (t, J = 6.7 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 133.2 (Carom., Cquat.), 127.7 (Carom., CH), 127.4 (2 x Carom., CH), 
124.8 (Carom., Cquat.), 123.5 (Carom., Cquat.), 122.9 (Carom., CH), 122.3 (Carom., CH), 115.7 (2 x 
Carom., CH), 47.3 (CH2), 34.1 (CH2), 32.8 (CH2), 31.7 (CH2), 29.1 (CH2), 26.8 (CH2), 22.6 
(CH2), 14.1 (CH3), (2 x Cquat. signals not visible). 
LC-ESI-MS (m/z): 346 [M+H]+. 
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2-Chloro-10-(cyclohexylmethyl)-10H-phenothiazine (35) 
The compound was prepared from cyclohexylmethyl bromide (1.2 eq.) 
according to procedure 5.2.1.3. Chromatographic purification: petroleum 
ether (b.p. 40 – 60 °C) as eluent. 
Appearance: colorless oil. Yield: 180 mg, 32 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 95.8 %. 
1H-NMR (500 MHz, CDCl3) : 7.17 – 7.06 (m, 2H, Harom.), 7.02 (d, J = 8.1 Hz, 1H, Harom.), 
6.96 – 6.77 (m, 4H, Harom.), 3.65 (s (br), 2H, N-CH2), 1.93 – 1.78 (m, 3H, Hcyclohexyl),  1.72 – 
1.69 (m, 2H, Hcyclohexyl), 1.54 (s, 1H, Hcyclohexyl), 1.27 – 1.05 (m, 3H, Hcyclohexyl), 0.98 - 0.77 (m, 
2H, Hcyclohexyl). 
13C-NMR (125 MHz, CDCl3) : 147.1 (Carom., Cquat.), 144.9 (Carom., Cquat.), 133.1 (Carom., Cquat.), 
128.0 (Carom., CH), 127.6 (Carom., CH), 127.3 (Carom., CH), 125.4 (Carom., Cquat.), 124.1 (Carom., 
Cquat.), 122.8 (Carom., CH), 122.2 (Carom., CH), 116.1 (Carom., 2 x CH), 53.8 (N-CH2), 34.6 
(CHcyclohexyl), 30.9 (2 x CH2,cyclohexyl), 26.6 (2 x CH2,cyclohexyl), 25.7 (CH2,cyclohexyl). 
LC-ESI-MS (m/z): 330 [M+H]+. 
2-Chloro-10-(2-cyclohexylethyl)-10H-phenothiazine (36) 
The compound was prepared from 2-cyclohexylethyl bromide (1.2 eq.), 
NaH (1 eq.), at 60 °C, in 4 h according to procedure 5.2.1.1. 
Chromatographic purification: petroleum ether (b.p. 40 – 60 °C) as 
eluent. 
Appearance: colorless oil. Yield: 203 mg, 34 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 99.6 %. 
1H-NMR (500 MHz, CDCl3) : 7.17 – 7.07 (m, 2H, Harom.), 7.00 (d, J = 8.1 Hz, 1H, Harom.), 
6.91 – 6.73 (m, 4H, Harom.), 3.78 (s (br), 2H, N-CH2), 1.75 – 1.60 (m, 6H, N-CH2-CH2 and 
Hcyclohexyl),  1.46 – 1.37 (m, 1H, Hcyclohexyl), 1.28 – 1.09 (m, 4H, Hcyclohexyl), 1.00 - 0.92 (m, 2H, 
Hcyclohexyl). 
13C-NMR (125 MHz, CDCl3) : 146.9 (Carom., Cquat.), 144.8 (Carom., Cquat.), 133.1 (Carom., Cquat.), 
127.3 (Carom., 3 x CH), 125.7 (Carom., Cquat.), 124.7 (Carom., Cquat.), 122.7 (Carom., CH), 121.9 
(Carom., CH), 115.7 (Carom., 2 x CH), 53.4 (N-CH2), 45.3 (N-CH2-CH2), 35.8 (CHcyclohexyl), 33.2 
(2 x CH2,cyclohexyl), 26.4 (2 x CH2,cyclohexyl), 26.2 (CH2,cyclohexyl). 
LC-ESI-MS (m/z): 344 [M+H]+. 
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2-Chloro-10-(phenylmethyl)-10H-phenothiazine (37)93 
The compound was prepared from benzyl bromide (1.2 eq.) according to 
procedure 5.2.1.3. Chromatographic purification: petroleum ether (b.p. 
40 – 60 °C):ethyl acetate = 98:2 as eluent. 
Appearance: colorless oil. Yield: 279 mg, 50 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 98.2 %. 
1H-NMR (500 MHz, CDCl3) : 7.35 – 7.29 (m, 2H, Harom.), 7.29 – 7.23 (m, 3H, Harom.), 7.05 
(dd, J = 7.6, 1.5 Hz, 1H, Harom.), 6.98 – 6.92 (m, 2H, Harom.), 6.87 – 6.78 (m, 2H, Harom.), 6.62 
(d, J = 8.1 Hz, 1H, Harom.), 6.59 (d, J = 2.0 Hz, 1H, Harom.), 5.06 (s, 2H, CH2). 
13C-NMR (125 MHz, CDCl3) : 143.8 (Carom., Cquat.), 136.0 (Carom., Cquat.), 133.1 (Carom., 2 x 
Cquat.), 128.9 (Carom., 2 x CH), 127.4 (Carom., CH), 127.3 (Carom., 2 x CH), 126.9 (Carom., CH), 
126.5 (Carom., 2 x CH), 123.0 (Carom., Cquat.), 122.4 (Carom., Cquat.), 115.8 (Carom., 2 x CH), 115.6 
(Carom., 2 x CH), 52.7 (CH2). 
LC-ESI-MS (m/z): 324 [M+H]+. 
 
2-Chloro-10-[(3-methoxyphenyl)methyl]-10H-phenothiazine (38) 
The compound was prepared from 3-methoxybenzyl bromide (3 eq.) 
according to procedure 5.2.1.2. Chromatographic purification: 
petroleum ether (b.p. 40 – 60 °C):ethyl acetate = 98:2 as eluent.  
Appearance: colorless oil. Yield: 295 mg, 83 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 97.4 %. 
1H-NMR (600 MHz, CDCl3) : 7.23 (t, J = 7.9, 1H, Harom.), 7.05 (dd, J 
= 7.6, 1.5 Hz, 1H, Harom.), 6.96 – 6.94 (m, 2H, Harom.), 6.86 – 6.77 (m, 5H, Harom.), 6.63 (d, J = 
8.1, 1H, Harom.), 6.60 (d, J = 2.0, 1H, Harom.), 5.04 (s, 2H, CH2), 3.75 (s, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 160.1 (Carom., Cquat.), 145.7 (Carom., Cquat.), 143.7 (Carom., Cquat.), 
133.1 (Carom., Cquat.), 129.9 (Carom., CH), 127.4 (Carom., CH), 127.2 (Carom., CH), 126.8 (Carom., 
CH), 123.1 (Carom., CH), 122.5 (Carom., CH), 118.8 (Carom., CH),  115.8 (Carom., CH), 115.6 
(Carom., CH), 112.6 (Carom., CH), 112.1 (Carom., CH), 65.8 (CH2), 55.2 (OCH3), (3 x Cquat. signals 
not visible). 
LC-ESI-MS (m/z): 354 [M+H]+. 
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2-Chloro-10-[(2-cyanophenyl)methyl]-10H-phenothiazine (39) 
The compound was prepared from 2-(bromomethyl)benzonitrile (3 eq.) 
according to procedure 5.2.1.2. Chromatographic purification: petroleum 
ether (b.p. 40 – 60 °C):ethyl acetate = 95:5 as eluent.  
Appearance: pink-colored solid. Melting point: 88 – 90 °C. Yield: 98 
mg, 28 %.  Purity by HPLC-UV (254 nm)-ESI-MS: 94.2 %. 
1H-NMR (600 MHz, CDCl3) : 7.73 (dd, J = 7.7, 1.3 Hz, 1H, Harom.), 7.48 (td, J = 7.7, 7.6, 1.3 
Hz, 1H, Harom.), 7.41 (d, J = 7.9 Hz, 1H, Harom.), 7.36 (td, J = 7.6, 7.6, 1.2 Hz, 1H, Harom.), 7.10 
(dd, J = 7.6, 1.5 Hz, 1H, Harom.), 7.00 (td, J = 8.0, 7.9, 1.9 Hz, 2H, Harom.), 6.88 (m, 2H, Harom.), 
6.60 – 6.55 (m, 2H, Harom.), 5.23 (s, 2H, CH2). 
13C-NMR (125 MHz, CDCl3) : 145.4 (Carom., Cquat.), 143.3 (Carom., Cquat.), 140.0 (Carom., Cquat.), 
133.4 (Carom., CH), 133.3 (Carom., Cquat.), 133.2 (Carom., CH), 127.9 (Carom., CH), 127.8 (Carom., 
CH), 127.7 (Carom., CH), 127.5 (Carom., CH), 127.3 (Carom., CH), 123.9 (Carom., Cquat.), 123.5 
(Carom., CH), 122.9 (Carom., CH), 122.7 (Carom., Cquat.), 116.9 (Carom., Cquat.),  115.6 (Carom., CH), 
115.5 (Carom., CH), 110.9 (Carom., CN), 50.7 (CH2). 
LC-ESI-MS (m/z): 349 [M+H]+. 
2-Chloro-10-(3-phenylpropyl)-10H-phenothiazine (40) 
The compound was prepared from 3-phenylpropyl bromide (1.2 eq.), 
NaH (1 eq.), at 60 °C, in 24 h according to procedure 5.2.1.1. 
Chromatographic purification: petroleum ether (b.p. 40 – 60 °C):ethyl 
acetate = 95:5 as eluent. 
Appearance: pink-colored oil. Yield: 250 mg, 41 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 97.1 %. 
1H-NMR (500 MHz, CDCl3) : 7.28 – 7.21 (m, 2H, Harom.), 7.18 – 7.14 (m, 1H, Harom.), 7.14 – 
7.10 (m, 4H, Harom.), 7.02 (d, J = 8.1 Hz, 1H, Harom.), 6.91 – 6.73 (m, 4H, Harom.), 3.82 (s (br), 
2H, N-CH2), 2.73 (t, J = 7.5 Hz, 2H, CH2-C6H5),  2.16 – 2.06 (m, 1H, CH2-CH2-CH2). 
13C-NMR (125 MHz, CDCl3) : 146.5 (Carom., Cquat.), 144.6 (Carom., Cquat.), 141.1 (Carom., Cquat.), 
133.1 (Carom., Cquat.), 128.5 (Carom., 2 x CH), 128.4 (Carom., 2 x CH), 127.3 (Carom., 2 x CH), 125.9 
(Carom., 2 x CH), 122.9 (Carom., Cquat.), 122.3 (Carom., Cquat.), 115.9 (Carom., 2 x CH), 115.8 (Carom., 
2 x CH), 32.6 (3 x CH2,propyl). 
LC-ESI-MS (m/z): 352 [M+H]+. 
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2-Chloro-10-(3-aminopropyl)-10H-phenothiazine (41)94 
The compound was prepared from 3-bromopropylamine hydrobromide 
(5 eq.) according to procedure 5.2.1.2. Chromatographic purification: 
dichloromethane/methanol/aq. NH3: 90/9/1 as eluent. 
Appearance: dark green oil. Yield: 180 mg, 58 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 99.2 %. 
1H-NMR (600 MHz, CDCl3) : 7.16 – 7.10 (m, 2H, Harom.), 7.00 (d, J = 8.1 Hz, 1H, Harom.), 
6.91 (t, J = 7.5 Hz, 1H, Harom.), 6.89 – 6.84 (m, 3H, Harom.), 3.91 (t, J = 6.7 Hz, 2H, N-CH2), 
2.82 (t, J = 6.8 Hz, 2H, CH2), 1.91 (m, 4H, CH2, NH2). 
13C-NMR (125 MHz, CDCl3) : 146.5 (Carom., Cquat.), 144.5 (Carom., Cquat.), 133.2 (Carom., Cquat.), 
127.9 (Carom., CH), 127.6 (Carom., CH), 127.4 (Carom., CH), 125.1 (Carom., Cquat.), 123.8 (Carom., 
Cquat.), 122.9 (Carom., CH), 122.3 (Carom., CH), 115.9 (2 x Carom., CH), 44.9 (CH2), 39.5 (CH2), 
29.9 (CH2). 
LC-ESI-MS (m/z): 291 [M+H]+. 
 
2-Chloro-10-(3-chloropropyl)-10H-phenothiazine (42)95 
The compound was prepared from 1-bromo-3-chloropropane (5 eq.) 
according to procedure 5.2.1.2. Chromatographic purification: petroleum 
ether (b.p. 40 – 60 °C):ethyl acetate = 95:5 as eluent. 
Appearance: light yellow oil. Yield: 180 mg, 54 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 97.6 %. 
1H-NMR (500 MHz, DMSO-d6) : 7.23 (ddd, J = 8.2, 7.3, 1.6 Hz, 1H, Harom.), 7.19 – 7.15 (m, 
2H, Harom.), 7.12 (d, J = 2.1 Hz, 1H, Harom.), 7.09 (dd, J = 8.2, 1.1 Hz, 1H, Harom.), 7.03 – 6.95 
(m, 2H, Harom.), 4.04 (t, J = 6.7 Hz, 2H, CH2-Cl), 3.72 (t, J = 6.3 Hz, 2H, N-CH2), 2.10 (quint, 
2H, CH2-CH2-CH2). 
13C-NMR (125 MHz, DMSO-d6) : 146.3 (Carom., Cquat.), 143.9 (Carom., Cquat.), 132.7 (Carom., 
Cquat.), 128.3 (Carom., CH), 127.9 (Carom., CH), 127.5 (Carom., CH), 123.8 (Carom., Cquat.), 123.3 
(Carom., CH), 123.2 (Carom., Cquat.), 122.5 (Carom., CH), 116.5 (Carom., CH), 115.9 (Carom., CH), 
43.7 (CH2), 42.7 (CH2), 29.3 (CH2). 
LC-ESI-MS (m/z): 310 [M]+, 312 [M+2]+, 314 [M+4]+. 
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2-Chloro-10-(3-hydroxypropyl)-10H-phenothiazine (43)96 
The compound was prepared from 3-iodo-1-propanol (3 eq.) according 
to procedure 5.2.1.2. Chromatographic purification: petroleum ether (b.p. 
40 – 60 °C):ethyl acetate = 6:4 as eluent. Recrystallization: n-
hexane/ethyl acetate. 
Appearance: pink-colored solid. Melting point: 132 – 133 °C. (lit. m.p. 
118 - 119 °C).96 Yield: 36 mg, 12 %. Purity by HPLC-UV (254 nm)-
ESI-MS: 97.6 %. 
1H-NMR (500 MHz, DMSO-d6) : 7.20 (ddd, J = 8.2, 7.3, 1.6 Hz, 1H, Harom.), 7.14 – 7.12 (m, 
2H, Harom.), 7.07 (d, J = 2.1 Hz, 1H, Harom.), 7.05 (dd, J = 8.2, 1.2 Hz, 1H, Harom.), 6.98 – 6.94 
(m, 2H, Harom.), 4.55 (t, J = 5.0, 1H, OH), 3.93 (t, J = 7.1, 2H, N-CH2), 3.50 (td, J = 6.0, 6.0, 
4.9 Hz, 2H, CH2-OH), 1.86 – 1.77 (m, 2H, N-CH2-CH2). 
13C-NMR (125 MHz, DMSO-d6) : 146.4 (Carom., Cquat.), 144.1 (Carom., Cquat.), 132.6 (Carom., 
Cquat.), 128.1 (Carom., CH), 127.9 (Carom., CH), 127.3 (Carom., CH), 123.3 (Carom., Cquat.), 123.0 
(Carom., CH), 122.6 (Carom., Cquat.), 122.1 (Carom., CH), 116.3 (Carom., CH), 115.7 (Carom., CH), 
58.0 (CH2), 43.7 (CH2), 29.6 (CH2). 
LC-ESI-MS (m/z): 292 [M+H]+. 
 
2-Chloro-10-[2-(1H-indol-3-yl)ethyl]-10H-phenothiazine (44) 
The compound was prepared from 3-(2-bromoethyl)indole (3 eq.) according 
to procedure 5.2.1.2. Chromatographic purification: petroleum ether (b.p. 40 
– 60 °C):ethyl acetate = 9:1 – 8:2 as eluent.  
Appearance: off-white solid. Melting point: 142 – 144 °C. Yield: 75 mg, 
16 %. Purity by HPLC-UV (254 nm)-ESI-MS: 95.9 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.84 (s, 1H, NHindole), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.32 
(d, J = 8.0 Hz, 1H, Harom.), 7.27 – 7.21 (m, 2H, Harom.), 7.19 – 7.11 (m, 4H, Harom.), 7.06 (ddd, 
8.0, 6.9, 1.1 Hz, 1H, Harom.), 7.02 – 6.93 (m, 3H, Harom.), 4.15 (t, J = 7.0 Hz, 2H, CH2), 3.92 (t, 
J = 7.2 Hz, 2H, CH2). 
13C-NMR (150 MHz, DMSO-d6) : 146.4 (Carom., Cquat.), 144.0 (Carom., Cquat.), 136.2 (Carom., 
Cquat.), 132.6 (Carom., Cquat.), 128.2 (Carom., CH), 127.9 (Carom., CH), 127.4 (Carom., CH), 127.2 
(Carom., Cquat.), 123.5 (Carom., Cquat.), 123.2 (Carom., CH), 123.0 (Carom., CH), 122.8 (Carom., Cquat.), 
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122.2 (Carom., CH), 121.1 (Carom., CH), 118.5 (Carom., CH), 118.2 (Carom., CH), 116.4 (Carom., CH), 
115.9 (Carom., CH), 111.5 (Carom., CH), 111.3 (Carom., Cquat.), 47.7 (CH2), 22.5 (CH2). 
LC-ESI-MS (m/z): 377 [M+H]+. 
 
2-(1H-Indol-3-yl)-1-(2-chloro-10H-phenothiazin-10-yl)ethanone (46) 
The compound was prepared according to procedure 5.2.2.  
Appearance: white solid. Melting point: 210 - 212 °C. Yield: 224 mg, 
52 %.  Purity by HPLC-UV (254 nm)-ESI-MS: 95.6 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 7.79 (s, 1H, 
Harom.), 7.70 (d, J = 7.9 Hz, 1H, Harom.), 7.56 – 7.48 (m, 2H, Harom.), 7.42 
(td, J = 7.7, 1.4 Hz, 1H, Harom.), 7.38 – 7.25 (m, 4H, Harom.), 7.01 (t, 7.7 Hz, 1H, Harom.), 6.92 – 
6.86 (m, 2H, Harom.), 3.92 (s, 2H, CH2). 
13C-NMR (150 MHz, DMSO-d6) : 170.0 (C=O), 140.2 (Carom., Cquat.), 138.7 (Carom., Cquat.), 
136.4 (Carom., Cquat.), 132.5 (Carom., Cquat.), 131.9 (Carom., Cquat.), 131.8 (Carom., Cquat.), 129.4 
(Carom., CH), 128.4 (Carom., CH), 128.0 (Carom., CH), 127.9 (Carom., CH), 127.8 (Carom., CH), 127.7 
(Carom., CH), 127.4 (Carom., Cquat.), 127.3 (Carom., CH), 124.1 (Carom., CH), 121.4 (Carom., CH), 
118.8 (Carom., CH), 118.7 (Carom., CH), 111.7 (Carom., CH), 107.5 (Carom., Cquat.), 31.4 (CH2). 
LC-ESI-MS (m/z): 391 [M+H]+. 
 
2-Chloro-1-(2-chloro-10H-phenothiazin-10-yl)ethanone (48)74 
The compound was prepared from 2-chloroacetyl chloride (1.05 eq.) 
according to procedure 5.2.3.  
Appearance: white solid. Melting point: 119 – 120 °C (lit. m.p. 115 - 
118 °C).97 Yield: 3.94 g, 74 %. Purity by HPLC-UV (254 nm)-ESI-MS: 
95.3 %. 
1H-NMR (500 MHz, DMSO-d6) : 7.79 (s, 1H, Harom.), 7.68 (d, J = 7.7 Hz, 1H, Harom.), 7.61 – 
7.58 (m, 2H, Harom.), 7.45 – 7.40 (m, 2H, Harom.), 7.35 (td, J = 7.6, 1.4 Hz, 1H, Harom.), 4.53 (s, 
2H, CH2). 
13C-NMR (125 MHz, DMSO-d6) : 165.1 (C=O), 138.8 (Carom., Cquat.), 137.2 (Carom., Cquat.), 
132.1 (Carom., Cquat.), 131.8 (Carom., Cquat.), 131.5 (Carom., Cquat.), 129.3 (Carom., CH), 128.3 (Carom., 
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CH), 127.9 (Carom., CH), 127.8 (Carom., CH), 127.5 (Carom., CH), 127.0 (Carom., CH), 126.9 (Carom., 
CH), 42.8 (CH2). 
LC-ESI-MS (m/z): 310 [M+H]+. 
 
3-Bromo-1-(2-chloro-10H-phenothiazin-10-yl)propanone (49)98 
The compound was prepared from 3-bromopropionyl chloride (1.05 eq.) 
according to procedure 5.2.3 and used directly in the next step without 
further analysis and purification 
Appearance: white solid. Yield: 4.5 g, 55 %. LC-ESI-MS (m/z): 369 
[M+H]+. 
2-Azido-1-(2-chloro-10H-phenothiazin-10-yl)ethanone (50)74 
The compound was prepared from 48 (3.2 mmol) according to procedure 
5.2.4 and used directly in the next step without further analysis and 
purification.  
Appearance: white solid. Yield: 792 mg, 77 %. LC-ESI-MS (m/z): 317 
[M+H]+. 
 
3-Azido-1-(2-chloro-10H-phenothiazin-10-yl)propanone (51)  
The compound was prepared from 49 (2.1 mmol) according to procedure 
5.2.4. 
Appearance: white solid. Melting point: 102 – 103 °C. Yield: 526 mg, 
76 %. Purity by HPLC-UV (254 nm)-ESI-MS: 98.0 %. 
1H-NMR (600 MHz, CDCl3) : 7.55 (s, 1H, Harom.), 7.48 – 7.42 (m, 2H, 
Harom.), 7.36 – 7.31 (m, 2H, Harom.), 7.28 – 7.19 (m, 2H, Harom.), 3.67 – 3.50 (m, 2H, CH2), 2.73 
(s, 1H), 2.61 (s, 1H). 
13C-NMR (125 MHz, CDCl3) : 169.1 (C=O), 139.3 (Carom., Cquat.), 137.8 (Carom., Cquat.), 133.2 
(Carom., Cquat.), 132.9 (Carom., Cquat.), 131.6 (Carom., Cquat.), 128.6 (Carom., CH), 128.3 (Carom., CH), 
127.6 (Carom., CH), 127.4 (Carom., 2 x CH), 127.3 (Carom., CH), 127.1 (Carom., CH), 47.2 (CH2), 
33.9 (CH2). 
LC-ESI-MS (m/z): 331 [M+H]+. 
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2-(2-Chloro-10H-phenothiazin-10-yl)ethanamine hydrochloride (52)74 
The compound was prepared from 50 (6.3 mmol) according to procedure 
5.2.5. 
Appearance: white solid. Melting point: 283 – 284 °C. Yield: 1.45 g, 74 
%. Purity by HPLC-UV (254 nm)-ESI-MS: 99.0 %. 
1H-NMR (600 MHz, MeOD) : 7.31 (dd, J = 7.8, 1.5 Hz, 1H, Harom.), 7.26 (dd, J = 7.7, 1.5 Hz, 
1H, Harom.), 7.21 (d, J = 8.2 Hz, 1H, Harom.), 7.16 – 7.11 (m, 2H, Harom.), 7.08 (td, J = 7.5, 1.1 
Hz, 1H, Harom.), 7.06 (dd, J = 8.2, 2.1 Hz, 1H, Harom.), 4.28 (t, J = 6.2 Hz, 2H, N-CH2), 3.34 (t, 
6.0 Hz, 2H, CH2-NH3
+). 
13C-NMR (125 MHz, MeOD) : 146.2 (Carom., Cquat.), 143.8 (Carom., Cquat.), 133.3 (Carom., Cquat.), 
128.1 (Carom., CH), 127.6 (Carom., CH), 127.5 (Carom., CH), 126.1 (Carom., Cquat.), 125.1 (Carom., 
Cquat.), 123.6 (Carom., CH), 122.9 (Carom., CH), 115.7 (Carom., CH), 115.6 (Carom., CH),  43.8 (CH2), 
36.1 (CH2). 
LC-ESI-MS (m/z): 277 [M-Cl]+. 
 
3-(2-Chloro-10H-phenothiazin-10-yl)propanamine hydrochloride (53)74 
The compound was prepared from 51 (4.0 mmol) according to procedure 
5.2.5. 
Appearance: white solid. Melting point: 241 – 243 °C (lit. m.p. 233 – 
235 °C).99 Yield: 874 mg, 67 %. Purity by HPLC-UV (254 nm)-ESI-
MS: 100.0 %. 
1H-NMR (600 MHz, MeOD) : 7.32 – 7.25 (m, 1H, Harom.), 7.22 (dd, J = 7.7, 1.5 Hz, 1H, 
Harom.), 7.16 (d, J = 8.2 Hz, 1H, Harom.), 7.13 – 7.08 (m, 2H, Harom.), 7.04 (td, J = 7.5, 1.1 Hz, 
1H, Harom.), 7.02 (dd, J = 8.2, 2.1 Hz, 1H, Harom.), 4.11 (t, J = 6.4 Hz, 2H, N-CH2), 3.11 – 3.05 
(m, 2H, CH2-NH3
+), 2.21 – 2.11 (m, 2H, CH2-CH2-CH2). 
13C-NMR (125 MHz, MeOD) : 148.2 (Carom., Cquat.), 145.9 (Carom., Cquat.), 134.9 (Carom., Cquat.), 
129.5 (Carom., CH), 129.2 (Carom., CH), 128.9 (Carom., CH), 127.3 (Carom., Cquat.), 126.3 (Carom., 
Cquat.), 124.8 (Carom., CH), 124.1 (Carom., CH), 117.8 (Carom., CH), 117.6 (Carom., CH),  45.5 (CH2), 
38.8 (CH2), 26.3 (CH2). 
LC-ESI-MS (m/z): 291 [M-Cl]+. 
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N-[2-(2-Chloro-10H-phenothiazin-10-yl)ethyl]-4-(trifluoromethoxy)benzenesulfonamide 
(54)74 
The compound was prepared from 52 (1.0 mmol) according to 
procedure 5.2.6. 
Appearance: white crystalline solid. Melting point: 100 – 102 
°C. Yield: 392 mg, 78 %. Purity by HPLC-UV (254 nm)-ESI-
MS: 95.0 %. 
1H-NMR (500 MHz, DMSO-d6) : 7.98 (s (br), 1H, NH), 7.88 (dt, J = 9.0, 2.9, 2.0 Hz, 2H, 
Harom.), 7.51 – 7.46 (m, 2H, Harom.), 7.18 (td, J = 7.8, 1.6 Hz, 1H, Harom.), 7.15 – 7.11 (m, 2H, 
Harom.), 7.00 – 6.92 (m, 4H, Harom.), 3.95 (t, J = 6.6 Hz, 2H, N-CH2), 3.09 (t, J = 6.6 Hz, 2H, 
CH2-NH). 
13C-NMR (125 MHz, DMSO-d6) : 150.9 (Carom., Cquat.), 145.9 (Carom., Cquat.), 143.6 (Carom., 
Cquat.), 139.4 (Carom., Cquat.), 132.6 (Carom., Cquat.), 129.1 (Carom., 2 x CH), 128.3 (Carom., CH), 
127.9 (Carom., CH), 127.4 (Carom., CH), 123.7 (Carom., Cquat.), 123.4 (Carom., CH), 122.9 (Carom., 
Cquat.), 122.5 (Carom., CH), 121.5 (Carom., 2 x CH), 120.0 (q, J(C,F) = 256 Hz, CF3), 116.1 (Carom., 
CH), 115.7 (Carom., CH),  46.3 (CH2), 39.4 (CH2). 
LC-ESI-MS (m/z): 501 [M+H]+. 
 
N-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-4-(trifluoromethoxy)benzenesulfonamide 
(55)74 
The compound was prepared from 53 (1.0 mmol) according 
to procedure 5.2.6. 
Appearance: white crystalline solid. Melting point: 105 – 
107 °C. Yield: 382 mg, 74 %.  Purity by HPLC-UV (254 
nm)-ESI-MS: 95.7 %. 
1H-NMR (500 MHz, DMSO-d6) : 7.83 (dt, J = 9.0, 3.0, 2.2 
Hz, 2H, Harom.), 7.78 (t, J = 5.6 Hz, 1H, NH), 7.52 – 7.47 (m, 2H, Harom.), 7.19 (ddd, J = 8.2, 
7.4, 1.5 Hz, 1H, Harom.), 7.15 – 7.11 (m, 2H, Harom.), 7.02 – 6.94 (m, 4H, Harom.), 3.86 (t, J = 6.8 
Hz, 2H, N-CH2), 2.90 (td, J = 7.0, 5.5 Hz, 2H, CH2-NH), 1.75 (p, J = 6.9 Hz, 2H, N-CH2-CH2). 
13C-NMR (125 MHz, DMSO-d6) : 150.8 (Carom., Cquat.), 146.4 (Carom., Cquat.), 144.0 (Carom., 
Cquat.), 139.5 (Carom., Cquat.), 132.6 (Carom., Cquat.), 129.1 (Carom., 2 x CH), 128.2 (Carom., CH), 
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127.8 (Carom., CH), 127.4 (Carom., CH), 123.8 (Carom., Cquat.), 123.2 (Carom., CH), 123.1 (Carom., 
Cquat.), 122.4 (Carom., CH), 121.5 (Carom., 2 x CH), 120.0 (q, J(C,F) = 256 Hz, CF3), 116.5 (Carom., 
CH), 115.9 (Carom., CH),  43.9 (CH2), 40.2 (CH2), 26.5 (CH2). 
LC-ESI-MS (m/z): 515 [M+H]+. 
5.3 Procedures for the synthesis of N-acylamino acids 
 General procedure for the N-acylation of amino acids using fatty acid 
chlorides 
 
A solution of fatty acid chloride (2.2 mmol) in THF (2 mL) was added dropwise to a stirred 
solution of the corresponding α-amino acid (2.0 mmol) in 2 N NaOH (5 mL) at 0 °C. The 
resulting mixture was stirred at 0°C for additional 5 min. After subsequent stirring overnight at 
r. t., the reaction mixture was diluted with 20 mL of water, cooled to 0 °C, and the pH was 
adjusted to ≤ 2 by addition of concentrated HCl (37 %). The mixture was diluted with water 
(30 mL) and poured into a separating funnel, then extracted with ethyl acetate (3 x 30 mL). The 
combined organic layers were washed with brine (50 mL), dried over MgSO4 and concentrated 
under reduced pressure. The crude products were purified by stirring them in heptane (30 mL) 
for 30 min (or petroleum ether (b.p. 40 – 60 °C) in case of L-serine derivatives) then filtered to 
remove remaining free fatty acids. 
 General procedure for the esterification of amino acids  
 
5.3.2.1 Method 1 
Thionyl chloride (SOCl2, 2.91 mL, 40 mmol) was added dropwise to a solution of amino acid 
(20 mmol) in methanol (20 – 50 mL, depending on solubility) at 0 °C, and the resulting mixture 
was warmed to r. t. and kept stirring overnight. The resulting solution was concentrated under 
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vacuum and dissolved in fresh methanol (50 mL). The solution was neutralized to pH 7.0 by 
adding solid NaHCO3. After filtration of the precipitate, the solvent was evaporated to give the 
crude amino acid methyl ester as an oil. Dichloromethane (10 mL) was added to the resulting 
oil to precipitate salts such as NaCl and NaHCO3. The solution was filtered and concentrated 
under vacuum to afford the desired neutral amino acid methyl ester. 
5.3.2.2 Method 2 for N-acyl-L-tryptophan derivatives 
 
Thionyl chloride (SOCl2, 72 µL, 1.0 mmol) was added dropwise to a solution of N-acyl-L-
tryptophan (0.25 mmol) in alcohol (3 mL) at 0 °C, and the mixture was warmed to r. t. and kept 
stirring overnight. The resulting solution was concentrated under vacuum giving a crude solid 
mixture, which was then repeatedly dissolved in diethyl ether and concentrated under vacuum 
to afford the acylamino acid ester. 
 General procedure for amide coupling of amino acid methyl esters 
and fatty acids 
 
A solution of amino acid methyl ester (2.0 mmol) in DMF (3 mL) was added to a solution of a 
fatty acid (1.0 mmol) in DMF (2 mL) at 0 °C. Subsequently, N,N'-dicyclohexylcarbodiimide 
(DCC, 206 mg, 1.0 mmol) and 1-hydroxy-7-azabenzotriazole (HOAt, 136 mg, 1.0 mmol) were 
added consecutively to the reaction mixture and stirred for 3 days. The reaction mixture was 
then taken up in ethyl acetate (30 mL), and filtered through a sintered funnel to remove the 
formed dicyclohexylurea (DCU). The filtrate containing the product was washed with 2N HCl 
(3 × 20 ml), brine (1 × 20 ml), saturated NaHCO3 (3 × 20 ml), brine (1 × 20 ml), and finally 
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dried over MgSO4. The resulting solution was concentrated under vacuum and final purification 
was performed on a silica gel column using a mixture of petroleum ether (b.p. 40 – 60 °C) and 
ethyl acetate (1:1) as eluent. 
 General procedure for the hydrolysis of methyl esters 
 
An aqueous NaOH solution (2 mL, 2 N) was added dropwise to a solution of a previously 
prepared N-acylamino acid methyl ester (0.2 mmol) in methanol (5 mL) at r. t. The reaction 
mixture was then stirred overnight and placed in a rotary evaporator to remove the methanol. 
The remaining aqueous solution containing the sodium salt of the amphiphilic product was 
mixed with 30 mL of water followed by washing with diethyl ether (2 × 20 mL) to remove any 
unreacted ester. Then the pH value of the aqueous layer was adjusted to 2 using 1 M HCl, and 
the organic compound was further extracted with ethyl acetate (3 × 20 mL). The extract was 
dried over MgSO4 and finally concentrated under vacuum to afford the desired N-acylamino 
acid. 
 Analytical data of synthesized compounds 
5.3.5.1 L-Glutamic acid derivatives 
N-Acetyl-L-glutamic acid (65)100 
The compound was prepared according to procedure 5.3.1. 
Appearance: white solid. Melting point: 188 - 190 °C (lit. m.p. 183 – 
190 °C).101 Yield: 36 mg, 3 %. Purity by HPLC-UV (254 nm)-ESI-
MS: 96.8 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.16 (s (br), 2H, 2 x COOH), 8.06 (d, J = 7.8 Hz, 1H, NH), 
4.17 (ddd, J = 9.1, 7.8, 5.2 Hz, 1H, CαH), 2.30 – 2.21 (m, 2H, CγH2), 1.97 – 1.88 (m, 1H, CβH), 
1.79 – 1.68 (m, 1H, CβH), 1.83 (s, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.5 (C=O), 169.5 (C=O), 51.3 (CαH), 30.3 
(CH2), 26.6 (CH2), 22.5 (CH3). 
LC-ESI-MS (m/z): 190 [M+H]+. 
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N-Propionyl-L-glutamic acid (66) 
The compound was prepared from L-glutamic acid and propionyl 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 143 – 144 °C. Yield: 37 mg, 
9 %. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.29 (s (br), 2H, 2 x COOH), 7.97 (d, J = 7.8 Hz, 1H, NH), 
4.18 (ddd, J = 9.1, 7.8, 5.1 Hz, 1H, CαH), 2.33 – 2.17 (m, 2H, CγH2), 2.11 (qd, J = 7.5, 3.7 Hz, 
2H, CH2-COacyl), 1.99 – 1.88 (m, 1H, CβH), 1.80 – 1.69 (m, 1H, CβH), 0.98 (t, J = 7.6 Hz, 3H, 
CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.6 (C=O), 173.3 (C=O), 51.2 (CαH), 30.3 
(CH2), 28.3 (CH2), 26.5 (CH2), 9.9 (CH3). 
LC-ESI-MS (m/z): 204 [M+H]+. 
 
N-Butyryl-L-glutamic acid (67) 
The compound was prepared from L-glutamic acid and butyric acid 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 101 – 102 °C. Yield: 96 mg, 
18 %. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.29 (s (br), 2H, 2 x COOH), 7.99 (d, J = 7.9 Hz, 1H, NH), 
4.23 – 4.15 (m, 1H, CαH), 2.32 – 2.18 (m, 2H, CγH2), 2.08 (t, J = 7.2 Hz, 2H, CH2-COacyl), 2.00 
– 1.89 (m, 1H, CβH), 1.78 – 1.70 (m, 1H, CβH), 1.50 (sext, J = 7.4 Hz, 2H, CH2-acyl), 0.84 (t, J 
= 7.4 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.6 (C=O), 172.4 (C=O), 51.2 (CαH), 37.1 
(CH2), 30.3 (CH2), 26.5 (CH2), 18.8 (CH2), 13.6 (CH3). 
LC-ESI-MS (m/z): 218 [M+H]+. 
 
 
 
 
5 Experimental 
68 
N-Hexanoyl-L-glutamic acid (68)102 
The compound was prepared from L-glutamic acid and hexanoyl 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 92 - 93 °C. Yield: 101 
mg, 17 %. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.26 (s (br), 2H, 2 x COOH), 7.99 (d, J = 7.9 Hz, 1H, NH), 
4.21 – 4.16 (m, 1H, CαH), 2.28 – 2.21 (m, 2H, CγH2), 2.09 (td, J = 7.2, 2.5 Hz, 2H, CH2-COacyl), 
1.98 – 1.90 (m, 1H, CβH), 1.78 – 1.70 (m, 1H, CβH), 1.47 (quintet, J = 7.4 Hz, 2H, CH2-acyl), 
1.30 - 1.18 (m, 4H, 2 x CH2-acyl), 0.84 (t, J = 7.0 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.6 (C=O), 172.5 (C=O), 51.1 (CαH), 35.1 
(CH2), 30.9 (CH2), 30.2 (CH2), 26.5 (CH2), 25.0 (CH2), 21.9 (CH2), 13.9 (CH3). 
LC-ESI-MS (m/z): 246 [M+H]+. 
 
N-Octanoyl-L-glutamic acid (69)103 
The compound was prepared from L-glutamic acid and 
octanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 100 - 102 °C (lit. 
m.p. 92 - 93 °C).104 Yield: 188 mg, 29 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.28 (s (br), 2H, 2 x COOH), 7.98 (d, J = 7.9 Hz, 1H, NH), 
4.21 – 4.16 (m, 1H, CαH), 2.28 – 2.21 (m, 2H, CγH2), 2.09 (td, J = 7.2, 2.6 Hz, 2H, CH2-COacyl), 
1.97 – 1.90 (m, 1H, CβH), 1.78 – 1.70 (m, 1H, CβH), 1.47 (quintet, J = 6.9 Hz, 2H, CH2-acyl), 
1.28 - 1.19 (m, 8H, 4 x CH2-acyl), 0.85 (t, J = 7.1 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.6 (C=O), 172.5 (C=O), 51.1 (CαH), 35.2 
(CH2), 31.3 (CH2), 30.2 (CH2), 28.6 (CH2), 28.5 (CH2), 26.5 (CH2), 25.4 (CH2), 22.2 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 274 [M+H]+. 
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N-Decanoyl-L-glutamic acid (70)103 
The compound was prepared from L-glutamic acid and 
decanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 76 °C. (lit. 
m.p. 85 - 87 °C).105 Yield: 499 mg, 69 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.27 (s (br), 2H, 2 x COOH), 7.98 (d, J = 7.9 Hz, 1H, NH), 
4.20 – 4.16 (m, 1H, CαH), 2.26 – 2.23 (m, 2H, CγH2), 2.09 (td, J = 7.3, 2.7 Hz, 2H, CH2-COacyl), 
1.96 – 1.89 (m, 1H, CβH), 1.78 – 1.71 (m, 1H, CβH), 1.46 (quintet, J = 7.3 Hz, 2H, CH2-acyl), 
1.28 - 1.19 (m, 12H, 6 x CH2-acyl), 0.85 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.5 (C=O), 172.5 (C=O), 51.1 (CαH), 35.2 
(CH2), 31.4 (CH2), 30.2 (CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 26.5 (CH2), 
25.4 (CH2), 22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 302 [M+H]+. 
 
N-Dodecanoyl-L-glutamic acid (71)103 
The compound was prepared from L-glutamic 
acid and dodecanoyl chloride according to 
procedure 5.3.1. 
Appearance: white solid. Melting point: 111 
– 113 °C. (lit. m.p. 96 - 99 °C).105 Yield: 490 mg, 62 %. Purity by HPLC-UV (254 nm)-ESI-
MS: 100.0 %. [α]25D = -6.4° (c = 0.1 g/mL, in acetone). 
1H-NMR (500 MHz, DMSO-d6) : 12.27 (s (br), 2H, 2 x COOH), 7.98 (d, J = 7.9 Hz, 1H, NH), 
4.21 – 4.16 (m, 1H, CαH), 2.27 – 2.23 (m, 2H, CγH2), 2.09 (td, J = 7.3, 2.7 Hz, 2H, CH2-COacyl), 
1.98 – 1.90 (m, 1H, CβH), 1.78 – 1.70 (m, 1H, CβH), 1.47 (quintet, J = 6.8 Hz, 2H, CH2-acyl), 
1.28 - 1.19 (m, 16H, 8 x CH2-acyl), 0.85 (t, J = 6.7 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.5 (C=O), 172.5 (C=O), 51.1 (CαH), 35.2 
(CH2), 31.4 (CH2), 30.2 (CH2), 29.1 (CH2), 29.1 (CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 
28.7 (CH2), 26.5 (CH2), 25.3 (CH2), 22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 330 [M+H]+. 
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N-Tetradecanoyl-L-glutamic acid (72)103 
The compound was prepared from L-
glutamic acid and tetradecanoyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting point: 
113 – 114 °C. Yield: 258 mg, 36 %. Purity by HPLC-UV (254 nm)-ESI-MS: 95.5 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.29 (s (br), 2H, 2 x COOH), 7.99 (d, J = 7.8 Hz, 1H, NH), 
4.18 (dt, J = 8.6, 5.1 Hz, 1H, CαH), 2.26 – 2.23 (m, 2H, CγH2), 2.10 – 2.07 (m, 2H, CH2-COacyl), 
1.95 – 1.92 (m, 1H, CβH), 1.75 – 1.73 (m, 1H, CβH), 1.46 (p, J = 7.1 Hz, 2H, CH2-acyl), 1.27 – 
1.22 (m, 20H, 10 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.6 (C=O), 172.5 (C=O), 51.2 (CαH), 35.2 
(CH2), 31.3 (CH2), 30.2 (CH2), 29.2 – 29.1 (5 x CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 26.5 
(CH2), 25.4 (CH2), 22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 358 [M+H]+. 
 
N-Hexadecanoyl-L-glutamic acid (59)106 
The compound was prepared from L-
glutamic acid and hexadecanoyl 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting 
point: 114 – 117 °C. Yield: 285 mg, 37 %. Purity by HPLC-UV (254 nm)-ESI-MS: 99.7 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.29 (s (br), 2H, 2 x COOH), 7.99 (d, J = 7.7 Hz, 1H, NH), 
4.17 (dt, J = 8.6, 5.1 Hz, 1H, CαH), 2.26 – 2.23 (m, 2H, CγH2), 2.10 – 2.07 (m, 2H, CH2-COacyl), 
1.96 – 1.91 (m, 1H, CβH), 1.76 – 1.70 (m, 1H, CβH), 1.46 (p, J = 7.1 Hz, 2H, CH2-acyl), 1.27 – 
1.22 (m, 24H, 12 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.5 (C=O), 172.5 (C=O), 51.2 (CαH), 35.2 
(CH2), 31.4 (CH2), 30.2 (CH2), 29.2 – 29.1 (7 x CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 26.5 
(CH2), 25.4 (CH2), 22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 386 [M+H]+. 
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N-Octadecanoyl-L-glutamic acid (60)106 
 
The compound was prepared from L-glutamic acid and octadecanoyl chloride according to 
procedure 5.3.1. 
Appearance: white solid. Melting point: 107 – 110 °C (lit. m.p. 113 °C).107 Yield: 296 mg, 
36 %. Purity by HPLC-UV (254 nm)-ESI-MS: 97.1 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.22 (s (br), 2H, 2 x COOH), 7.99 (d, J = 7.8 Hz, 1H, NH), 
4.18 (dt, J = 8.7, 5.2 Hz, 1H, CαH), 2.27 – 2.21 (m, 2H, CγH2), 2.11 – 2.06 (m, 2H, CH2-COacyl), 
1.96 – 1.91 (m, 1H, CβH), 1.76 – 1.70 (m, 1H, CβH), 1.46 (p, J = 7.1 Hz, 2H, CH2-acyl), 1.27 – 
1.22 (m, 28H, 14 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 173.6 (C=O), 172.5 (C=O), 51.2 (CαH), 35.2 
(CH2), 31.4 (CH2), 30.2 (CH2), 29.2 – 29.1 (5 x CH2), 29.0 (CH2), 28.9 (CH2), 28.9 (CH2), 28.8 
(CH2), 28.7 (CH2), 28.7 (CH2), 26.5 (CH2), 25.4 (CH2), 24.6 (CH2), 22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 414 [M+H]+. 
 
L-Glutamic acid dimethyl ester (91)108  
The compound was prepared from L-glutamic acid according to 
procedure 5.3.2.1. 
Appearance: colorless oil. Yield: quantitative. Purity by 
HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 8.57 (s, 2H, NH2), 4.00 (t, J = 6.7 Hz, 1H, CαH), 3.72 (s, 
3H, OCH3), 3.59 (s, 3H, OCH3), 2.60 – 2.43 (m, 2H, CγH2), 2.05 (td, J = 8.5, 6.6 Hz, 2H, CβH2). 
13C-NMR (125 MHz, DMSO-d6) : 172.3 (C=O), 169.8 (C=O), 52.9 (CαH), 51.7 (CH3), 51.4 
(CH3), 29.1 (CH2), 25.4 (CH2). 
LC-ESI-MS (m/z): 176 [M+H]+. 
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N-Eicosanoyl-L-glutamic acid dimethyl ester (94) 
 
The compound was prepared from 91 and eicosanoic acid according to procedure 5.3.3. 
Appearance: white powder. Melting point: 88 – 90 °C. Yield: 52 mg, 11 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (600 MHz, CDCl3) : 6.12 (d, J = 7.6 Hz, 1H, NH), 4.61 (dt, J = 7.7, 4.8 Hz, 1H, 
CαH), 3.73 (s, 3H, OCH3), 3.66 (s, 3H, OCH3), 2.44 – 2.31 (m, 2H, CγH2), 2.19 (t, J = 7.9 Hz, 
2H, CH2-COacyl), 2.00 – 1.95 (m, 2H, CβH2), 1.61 – 1.56 (m, 4H, 2 x CH2-acyl), 1.28 – 1.23 (m, 
30H, 15 x CH2-acyl), 0.86 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 173.3 (C=O), 173.1 (C=O), 172.5 (C=O), 52.5 (CαH), 51.8 
(OCH3), 51.5 (OCH3), 36.6 (CH2), 31.9 (CH2), 30.1 (CH2), 29.7 – 29.6 (10 x CH2), 29.5 (CH2), 
29.3 (CH2), 29.3 (CH2), 29.2 (CH2), 27.4 (CH2), 25.5 (CH2), 22.7 (CH2), 14.1 (CH3-acyl). 
LC-ESI-MS (m/z): 470 [M+H] +. 
 
N-Arachidonoyl-L-glutamic acid dimethyl ester (95) 
 
The compound was prepared from 91 and arachidonic acid according to procedure 5.3.3. 
Appearance: light yellow oil. Yield: 145 mg, 56 %. Purity by HPLC-UV (254 nm)-ESI-MS: 
100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 8.17 (d, J = 7.5 Hz, 1H, NH), 5.39 – 5.26 (m, 8H, 8 x CHsp2 
(C5, C6, C8, C9, C11, C12, C14, C16)), 4.24 (ddd, J = 9.1, 7.5, 5.3 Hz, 1H, CαH), 3.59 (s, 3H, 
OCH3), 3.57 (s, 3H, OCH3), 2.79 (dt, J = 19.5, 5.6 Hz, 6H, 3 x CH2 (C7, C10, C13)), 2.40 – 
2.32 (m, 2H, CγH2), 2.11 (t, J = 7.4 Hz, 2H, CH2 (C2)), 2.01 (q, J = 7.2 Hz, 4H, 2 x CH2 (C4, 
C16)), 1.99 – 1.92 (m, 1H, CβH), 1.84 – 1.76 (m, 1H, CβH), 1.53 (p, J = 7.4 Hz, 2H, CH2 (C3)), 
1.35 – 1.19 (m, 6H, 3 x CH2 (C17, C18, C19)), 0.84 (t, J = 7.0 Hz, 3H, CH3 (C20)). 
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13C-NMR (125 MHz, DMSO-d6) : 172.6 (C=O), 172.4 (C=O), 172.3 (C=O), 130.1 (CHsp2), 
129.5 (CHsp2), 128.3 (CHsp2), 128.2 (CHsp2), 128.1 (CHsp2), 127.9 (CHsp2), 127.8 (CHsp2), 127.7 
(CHsp2), 51.9 (CαH), 51.5 (OCH3), 51.2 (OCH3), 34.5 (CH2), 31.0 (CH2), 29.8 (CH2), 28.8 
(CH2), 26.7 (CH2), 26.3 (CH2), 26.2 (CH2), 25.4 – 25.3 (4 x CH2), 22.1 (CH2), 14.1 (CH3-acyl). 
LC-ESI-MS (m/z): 462 [M+H] +. 
 
N-Eicosanoyl-L-glutamic acid (100) 
 
The compound was prepared from 94 according to procedure 5.3.4. 
Appearance: white powder. Melting point: 118 – 120 °C. Yield: 30 mg, 88 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.29 (s (br), 2H, 2 x COOH), 7.99 (d, J = 7.9 Hz, 1H, NH), 
4.18 (dt, J = 8.3, 4.2 Hz, 1H, CαH), 2.28 – 2.21 (m, 2H, CγH2), 2.08 (td, J = 7.3, 3.9 Hz, 2H, 
CH2-COacyl), 1.98 – 1.88 (m, 1H, CβH), 1.78 – 1.69 (m, 1H, CβH), 1.46 (p, J = 7.0 Hz, 2H, CH2-
acyl), 1.26 – 1.18 (m, 32H, 16 x CH2-acyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.8 (C=O), 172.6 (C=O), 172.5 (C=O), 51.2 (CαH), 35.2 
(CH2), 31.4 (CH2), 30.3 (CH2), 29.3 – 29.1 (10 x CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 
26.5 (CH2), 25.4 (CH2), 24.6 (CH2), 22.3 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 442 [M+H]+. 
 
N-Arachidonoyl-L-glutamic acid (101) 
 
The compound was prepared from 95 according to procedure 5.3.4. 
Appearance: light yellow oil. Yield: 85 mg, 89 %. Purity by HPLC-UV (254 nm)-ESI-MS: 
100.0 %. 
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1H-NMR (600 MHz, CDCl3) : 7.07 (s (br), 2H, 2 x COOH), 6.40 (d, J = 7.2 Hz, 1H, NH), 
5.40 – 5.30 (m, 8H, 8 x CHsp2 (C5, C6, C8, C9, C11, C12, C14, C16)), 4.64 (q, J = 6.6 Hz, 1H, 
CαH), 2.82 – 2.77 (m, 6H, 3 x CH2 (C7, C10, C13)), 2.53 – 2.44 (m, 2H, CγH2), 2.25 (t, J = 7.8 
Hz, 2H, CH2 (C2)), 2.22 – 2.08 (m, 4H, 2 x CH2 (C4, C16)), 2.03 (q, J = 7.2 Hz, 2H, CßH2), 
1.69 (p, J = 7.4 Hz, 2H, CH2 (C3)), 1.36 – 1.23 (m, 6H, 3 x CH2 (C17, C18, C19)), 0.86 (t, J = 
6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, CDCl3) : 178.2 (C=O), 176.1 (C=O), 173.7 (C=O), 130.5 (CHsp2), 128.9 
(CHsp2), 128.8 (CHsp2), 128.6 (CHsp2), 128.3 (CHsp2), 128.1 (CHsp2), 127.8 (CHsp2), 127.5 
(CHsp2), 51.4 (CαH), 35.7 (CH2), 31.5 (CH2), 29.6 (CH2), 29.3 (CH2), 27.2 (CH2), 26.7 (CH2), 
26.6 (CH2), 25.6 (3 x CH2), 25.3 (CH2), 22.6 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 434 [M+H]+. 
 
5.3.5.2 L-Tryptophan derivatives 
 
N-Acetyl-L-tryptophan (73)109 
The compound was prepared from L-tryptophan and acetyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting point: 189 – 190 °C (lit. m.p. 185 – 
187 °C).110 Yield: 402 mg, 82 %. Purity by HPLC-UV (254 nm)-ESI-
MS: 99.4 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.54 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 8.09 (d, 
J = 7.8 Hz, 1H, NHamide), 7.52 (d, J = 7.8 Hz, 1H, Harom.), 7.32 (dt, J = 8.2, 0.9 Hz, 1H, Harom.), 
7.12 (d, J = 2.4 Hz, 1H, Harom.), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.97 (ddd, J = 8.0, 
7.0, 1.0 Hz, 1H, Harom.), 4.45 (ddd, J = 8.6, 7.8, 5.1 Hz, 1H, CαH), 3.15 (dd, J = 14.7, 5.1 Hz, 
1H, CβH), 2.98 (dd, J = 14.6, 8.6 Hz, 1H, CβH), 1.79 (s, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 169.4 (C=O), 136.3 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 121.1 (Carom., CH), 118.5 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.1 (Carom., Cquat.), 53.1 (CαH), 27.3 (CH2), 22.6 (CH3). 
LC-ESI-MS (m/z): 247 [M+H]+. 
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N-Propionyl-L-tryptophan (74) 
The compound was prepared from L-tryptophan and propionyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting point: 178 – 179 °C (lit. m.p. 172 – 
174 °C).111 Yield: 446 mg, 86 %. Purity by HPLC-UV (254 nm)-ESI-
MS: 98.9 %. 
1H-NMR (500 MHz, DMSO-d6) : 10.78 (s, 1H, NHindole), 7.97 (d, J = 7.9 Hz, 1H, NHamide), 
7.52 (d, J = 8.0 Hz, 1H, Harom.), 7.32 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 7.11 (d, J = 2.4 Hz, 1H, 
Harom.), 7.05 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H, Harom.), 6.97 (ddd, J = 7.9, 6.9, 1.0 Hz, 1H, Harom.), 
4.46 (td, J = 8.3, 5.1 Hz, 1H, CαH), 3.15 (dd, J = 14.7, 5.0 Hz, 1H, CβH), 2.99 (dd, J = 14.6, 8.6 
Hz, 1H, CβH), 2.04 (qd, J = 7.5, 3.0 Hz, 2H, CH2-COacyl), 0.92 (t, J = 7.6 Hz, 3H, CH3), (COOH 
signal not visible). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 173.0 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 121.0 (Carom., CH), 118.5 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 53.1 (CαH), 28.4 (CH2), 27.3 (CH2), 9.8 (CH3). 
LC-ESI-MS (m/z): 261 [M+H]+. 
 
N-Butyryl-L-tryptophan (75) 
The compound was prepared from L-tryptophan and butyric acid 
chloride according to procedure 5.3.1. 
Appearance: yellow oil. Yield: 212 mg, 32 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 99.1 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.27 (s (br), 1H, COOH), 10.78 (s, 
1H, NHindole), 7.99 (d, J = 7.9 Hz, 1H, NHamide), 7.52 (d, J = 7.9 Hz, 1H, Harom.), 7.32 (d, J = 8.1 
Hz, 1H, Harom.), 7.12 (d, J = 2.5 Hz, 1H, Harom.), 7.09 – 7.01 (m, 1H, Harom.), 7.00 – 6.93 (m, 1H, 
Harom.), 4.49 – 4.45 (m, 1H, CαH), 3.16 (dd, J = 14.6, 5.1 Hz, 1H, CβH), 2.99 (dd, J = 14.6, 8.9 
Hz, 1H, CβH), 2.04 (td, J = 7.2, 3.7 Hz, 2H, CH2-COacyl), 1.44 (sext, J = 7.3 Hz, 2H, CH2-acyl), 
0.77 (t, J = 7.3 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.2 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
5 Experimental 
76 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 37.2 (CH2), 27.3 (CH2), 18.7 (CH2), 13.6 
(CH3). 
LC-ESI-MS (m/z): 275 [M+H]+. 
 
N-Hexanoyl-L-tryptophan (76)83 
The compound was prepared from L-tryptophan and hexanoyl 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 106 – 108 °C (lit. m.p. 
132 - 133 °C).112 Yield: 648 mg, 89 %. Purity by HPLC-UV (254 
nm)-ESI-MS: 98.3 %. 
1H-NMR (500 MHz, MeOD) : 7.60 (d, J = 8.0 Hz, 1H, Harom.), 7.36 (d, J = 8.1 Hz, 1H, Harom.), 
7.13 – 7.10 (m, 2H, Harom.), 7.05 – 7.02 (m, 1H, Harom.), 4.78 (dd, J = 8.5, 4.9 Hz, 1H, CαH), 
3.39 (ddd, J = 14.8, 5.0, 0.9 Hz, 1H, CβH), 3.19 (ddd, J = 14.7, 8.5, 0.7 Hz, 1H, CβH), 2.18 (td, 
J = 7.5, 1.4 Hz, 2H, CH2-COacyl), 1.55 – 1.51 (m, 2H, CH2-acyl), 1.32 – 1.25 (m, 2H, CH2-acyl), 
1.23 – 1.17 (m, 2H, CH2-acyl), 0.89 (t, J = 7.3 Hz, 3H, CH3), (OH, NH signals not visible). 
13C-NMR (125 MHz, MeOD) : 174.8 (C=O), 173.9 (C=O), 136.6 (Carom., Cquat.), 127.4 (Carom., 
Cquat.), 122.8 (Carom., CH), 120.9 (Carom., CH), 118.3 (Carom., CH), 117.8 (Carom., CH), 110.8 
(Carom., CH), 109.7 (Carom., Cquat.), 53.1 (CαH), 35.4 (CH2), 30.9 (CH2), 27.1 (CH2), 25.1 (CH2), 
21.9 (CH2), 12.8 (CH3). 
LC-ESI-MS (m/z): 303 [M+H]+. 
 
N-Octanoyl-L-tryptophan (77)83 
The compound was prepared from L-tryptophan and octanoyl 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 96 – 97 °C. Yield: 
687 mg, 87 %. Purity by HPLC-UV (254 nm)-ESI-MS: 97.7 
%. 
1H-NMR (500 MHz, DMSO-d6) : 12.37 (s (br), 1H, COOH), 10.78 (s, 1H, NHindole), 7.98 (d, 
J = 7.9 Hz, 1H, NHamide), 7.52 (d, J = 8.0 Hz, 1H, Harom.), 7.31 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 
7.11 (d, J = 2.4 Hz, 1H, Harom.), 7.05 (td, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (td, J = 8.0, 7.0, 
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1.0 Hz, 1H, Harom.), 4.46 (td, J = 8.8, 7.8, 5.0 Hz, 1H, CαH), 3.15 (dd, J = 14.7, 5.0 Hz, 1H, 
CβH), 2.98 (dd, J = 14.7, 8.9 Hz, 1H, CβH), 2.05 (td, J = 7.3, 2.4 Hz, 2H, CH2-COacyl), 1.43 – 
1.36 (m, 2H, CH2-acyl), 1.25 – 1.11 (m, 8H, 4 x CH2-acyl), 0.84 (t, J = 7.1 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.2 (CH2), 31.3 (CH2), 28.6 (CH2), 28.6 
(CH2), 27.3 (CH2), 25.3 (CH2), 22.2 (CH2), 14.0 (CH3). 
LC-ESI-MS (m/z): 331 [M+H]+. 
 
N-Decanoyl-L-tryptophan (78)83 
The compound was prepared from L-tryptophan and 
decanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 85 – 87 °C. 
Yield: 322 mg, 37 %. Purity by HPLC-UV (254 nm)-
ESI-MS: 97.3 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.47 (s (br), 1H, COOH), 10.78 (s, 1H, NHindole), 7.98 (d, 
J = 7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 
7.10 (d, J = 2.4 Hz, 1H, Harom.), 7.04 (td, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (td, J = 8.0, 6.9, 
1.1 Hz, 1H, Harom.), 4.46 (td, J = 8.4, 5.0 Hz, 1H, CαH), 3.14 (dd, J = 14.7, 5.1 Hz, 1H, CβH), 
2.98 (dd, J = 14.6, 8.8 Hz, 1H, CβH), 2.04 (td, J = 7.3, 2.2 Hz, 2H, CH2-COacyl), 1.42 – 1.36 (m, 
2H, CH2-acyl), 1.27 – 1.10 (m, 12H, 6 x CH2-acyl), 0.85 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.4 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.2 (CH2), 31.4 (CH2), 29.0 (CH2), 28.9 
(CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 359 [M+H]+. 
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N-Dodecanoyl-L-tryptophan (79)113 
The compound was prepared from L-tryptophan and 
dodecanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 113 – 115 
°C. (lit. m.p. 107 - 109 °C).114  Yield: 678 mg, 73 %. 
Purity by HPLC-UV (254 nm)-ESI-MS: 97.6 %. 
[α]25D = +14.4° (c = 0.1 g/mL, in acetone). 
1H-NMR (500 MHz, DMSO-d6) : 12.49 (s (br), 1H, COOH), 10.78 (s, 1H, NHindole), 7.98 (d, 
J = 7.9 Hz, 1H, NHamide), 7.52 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 
7.11 (d, J = 2.4 Hz, 1H, Harom.), 7.04 (td, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (td, J = 7.9, 6.9, 
1.0 Hz, 1H, Harom.), 4.46 (td, J = 8.4, 5.1 Hz, 1H, CαH), 3.15 (dd, J = 14.6, 5.0 Hz, 1H, CβH), 
2.98 (dd, J = 14.6, 8.8 Hz, 1H, CβH), 2.04 (td, J = 7.4, 1.9 Hz, 2H, CH2-COacyl), 1.39 (quintet, 
J = 7.3 Hz, 2H, CH2-acyl), 1.26 – 1.15 (m, 16H, 8 x CH2-acyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.6 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.4 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.2 (CH2), 31.4 (CH2), 29.1 (CH2), 29.1 
(CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.2 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 387 [M+H]+. 
 
N-Tetradecanoyl-L-tryptophan (80)115 
The compound was prepared from L-
tryptophan and tetradecanoyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting point: 103 
– 104 °C. Yield: 522 mg, 63 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 97.7 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.52 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 7.99 (d, 
J = 7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.11 
(d, J = 2.4 Hz, 1H, Harom.), 7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 4.46 
(td, J = 8.4, 5.0 Hz, 1H, CαH), 3.14 (dd, J = 14.7, 5.1 Hz, 1H, CβH), 2.98 (dd, J = 14.6, 8.8 Hz, 
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1H, CβH), 2.04 (td, J = 7.4, 2.4 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.2 Hz, 2H, CH2-acyl), 1.27 – 
1.12 (m, 20H, 10 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.3 (CH2), 31.5 (CH2), 29.2 (4 x CH2), 
29.1 (CH2), 29.0 (CH2), 28.9 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.3 (CH2), 14.1 
(CH3). 
LC-ESI-MS (m/z): 415 [M+H]+. 
 
N-Tetradecanoyl-L-tryptophan methyl ester (106)115 
The compound was prepared from 80 and 
methanol according to procedure 5.3.2.2. 
Appearance: off-white solid. Melting 
point: 55 – 57 °C. Yield: 110 mg, 
quantitative. Purity by HPLC-UV (254 
nm)-ESI-MS: 96.3 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 8.17 (d, J = 7.5 Hz, 1H, NHamide), 
7.47 (d, J = 7.9 Hz, 1H, Harom.), 7.32 (d, J = 8.1 Hz, 1H, Harom.), 7.12 (d, J = 2.3 Hz, 1H, Harom.), 
7.05 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 4.49 (td, J = 8.1, 5.8 Hz, 1H, 
CαH), 3.56 (s, 3H, OCH3), 3.12 (dd, J = 14.6, 5.7 Hz, 1H, CβH), 3.00 (dd, J = 14.6, 8.6 Hz, 1H, 
CβH), 2.05 (td, J = 7.2, 2.7 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.3 Hz, 2H, CH2-acyl), 1.29 – 1.10 
(m, 20H, 10 x CH2-acyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.7 (C=O), 172.4 (C=O), 136.2 (Carom., Cquat.), 127.2 
(Carom., Cquat.), 123.7 (Carom., CH), 121.1 (Carom., CH), 118.5 (Carom., CH), 118.1 (Carom., CH), 
111.6 (Carom., CH), 109.7 (Carom., Cquat.), 53.1 (CαH), 51.9 (OCH3), 35.1 (CH2), 31.5 (CH2), 29.2 
(4 x CH2), 29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.2 (CH2), 25.3 (CH2), 22.3 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 429 [M+H]+. 
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N-Tetradecanoyl-L-tryptophan ethyl ester (109) 
The compound was prepared from 80 
and ethanol according to procedure 
5.3.2.2. 
Appearance: pink-colored solid. 
Melting point: 60 – 62 °C. Yield: 115 
mg, quantitative. Purity by HPLC-UV (254 nm)-ESI-MS: 97.5 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.80 (s, 1H, NHindole), 8.13 (d, J = 7.6 Hz, 1H, NHamide), 
7.48 (d, J = 7.9 Hz, 1H, Harom.), 7.32 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 7.12 (d, J = 2.4 Hz, 1H, 
Harom.), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H, Harom.), 
4.47 (td, J = 8.1, 5.9 Hz, 1H, CαH), 4.00 (q, J = 7.1, 2H, CH2-ethyl), 3.12 (dd, J = 14.7, 5.8 Hz, 
1H, CβH), 3.01 (dd, J = 14.5, 8.5 Hz, 1H, CβH), 2.06 (td, J = 7.3, 3.8 Hz, 2H, CH2-COacyl), 1.41 
(p, J = 6.8 Hz, 2H, CH2-acyl), 1.30 – 1.11 (m, 20H, 10 x CH2-acyl), 1.07 (t, J = 7.1 Hz, 3H, CH3-
ethyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 172.2 (C=O), 136.2 (Carom., Cquat.), 127.2 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.1 (Carom., CH), 
111.5 (Carom., CH), 109.7 (Carom., Cquat.), 60.4 (CH2-ethyl), 53.2 (CαH), 35.1 (CH2), 31.4 (CH2), 
29.2 (4 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 
(CH2), 14.0 (CH3-ethyl), 14.0 (CH3-acyl). 
LC-ESI-MS (m/z): 443 [M+H]+. 
 
N-Tetradecanoyl-L-tryptophan isopropyl ester (112) 
The compound was prepared from 80 
and isopropanol according to 
procedure 5.3.2.2. 
Appearance: pink-colored sticky 
solid. Melting point: 44 – 45 °C. 
Yield: 121 mg, quantitative. Purity by HPLC-UV (254 nm)-ESI-MS: 95.9 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.80 (s, 1H, NHindole), 8.11 (d, J = 7.5 Hz, 1H, NHamide), 
7.48 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (dt, J = 8.2, 1.0 Hz, 1H, Harom.), 7.12 (d, J = 2.4 Hz, 1H, 
Harom.), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, Harom.), 
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4.80 (sept, J = 6.3 Hz, 1H, CHisopropyl), 4.43 (td, J = 8.1, 6.1 Hz, 1H, CαH), 3.10 (dd, J = 14.5, 
6.0 Hz, 1H, CβH), 2.98 (dd, J = 14.5, 8.5 Hz, 1H, CβH), 2.05 (m, 2H, CH2-COacyl), 1.47 – 1.36 
(m, 2H, CH2-acyl), 1.30 – 1.14 (m, 20H, 10 x CH2-acyl), 1.12 (d, J = 6.3 Hz, 3H, CH3-isopropyl), 1.00 
(d, J = 6.2 Hz, 3H, CH3-isopropyl), 0.84 (t, J = 7.0 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 171.7 (C=O), 136.2 (Carom., Cquat.), 127.3 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.2 (Carom., CH), 
111.5 (Carom., CH), 109.8 (Carom., Cquat.), 67.8 (CHisopropyl), 53.4 (CαH), 35.1 (CH2), 31.4 (CH2), 
29.2 (4 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 
(CH2), 21.6 (CH3-isopropyl), 21.4 (CH3-isopropyl), 14.1 (CH3-acyl). 
LC-ESI-MS (m/z): 457 [M+H]+. 
 
N-Hexadecanoyl-L-tryptophan (81)116 
The compound was prepared from L-
tryptophan and hexadecanoyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting point: 
96 – 98 °C. (lit. m.p. 95 – 97 °C).114 Yield: 
598 mg, 67 %. Purity by HPLC-UV (254 nm)-ESI-MS: 97.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.49 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 7.99 (d, 
J = 7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.11 
(d, J = 2.3 Hz, 1H, Harom.), 7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 4.46 
(td, J = 8.4, 5.0 Hz, 1H, CαH), 3.14 (dd, J = 14.7, 5.1 Hz, 1H, CβH), 2.98 (dd, J = 14.7, 8.8 Hz, 
1H, CβH), 2.04 (td, J = 7.3, 2.3 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.2 Hz, 2H, CH2-acyl), 1.27 – 
1.12 (m, 24H, 12 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.2 (CH2), 31.4 (CH2), 29.2 (6 x CH2), 
29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.2 (CH2), 14.1 
(CH3). 
LC-ESI-MS (m/z): 443 [M+H]+. 
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N-Hexadecanoyl-L-tryptophan methyl ester (107)116 
The compound was prepared from 
81 and methanol according to 
procedure 5.3.2.2. 
Appearance: off-white solid. 
Melting point: 66 – 68 °C. (lit. m.p. 
69 – 70 °C).114 Yield: 113 mg, quantitative. Purity by HPLC-UV (254 nm)-ESI-MS: 94.9 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 8.17 (d, J = 7.5 Hz, 1H, NHamide), 
7.47 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.11 (d, J = 2.3 Hz, 1H, Harom.), 
7.04 (t, J = 7.4 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 4.49 (td, J = 8.2, 5.7 Hz, 1H, 
CαH), 3.56 (s, 3H, OCH3), 3.12 (dd, J = 14.6, 5.6 Hz, 1H, CβH), 3.00 (dd, J = 14.6, 8.6 Hz, 1H, 
CβH), 2.05 (td, J = 7.3, 2.7 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.3 Hz, 2H, CH2-acyl), 1.29 – 1.10 
(m, 24H, 12 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.7 (C=O), 172.4 (C=O), 136.2 (Carom., Cquat.), 127.2 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.5 (Carom., CH), 118.1 (Carom., CH), 
111.5 (Carom., CH), 109.7 (Carom., Cquat.), 53.1 (CαH), 51.8 (OCH3), 35.1 (CH2), 31.4 (CH2), 29.2 
(6 x CH2), 29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 457 [M+H]+. 
 
N-Hexadecanoyl-L-tryptophan ethyl ester (110)117 
The compound was prepared 
from 81 and ethanol according to 
procedure 5.3.2.2. 
Appearance: pink-colored solid. 
Melting point: 67 – 69 °C. (lit. 
m.p. 56 – 58 °C).117 Yield: 123 mg, quantitative. Purity by HPLC-UV (254 nm)-ESI-MS: 
96.2%. 
1H-NMR (600 MHz, DMSO-d6) : 10.80 (s, 1H, NH(indole)), 8.13 (d, J = 7.6 Hz, 1H, 
NH(amide)), 7.48 (d, J = 8.0 Hz, 1H, Harom.), 7.32 (dt, J = 8.1, 1.0 Hz, 1H, Harom.), 7.12 (d, J = 
2.4 Hz, 1H, Harom.), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (ddd, J = 7.9, 7.0, 1.0 Hz, 
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1H, Harom.), 4.47 (td, J = 8.1, 5.9 Hz, 1H, CαH), 4.00 (q, J = 7.1, 2H, CH2-ethyl), 3.12 (dd, J = 
14.6, 5.8 Hz, 1H, CβH), 3.01 (dd, J = 14.4, 8.5 Hz, 1H, CβH), 2.05 (td, J = 7.3, 3.7 Hz, 2H, CH2-
COacyl), 1.41 (p, J = 7.3 Hz, 2H, CH2-acyl), 1.30 – 1.12 (m, 24H, 12 x CH2-acyl), 1.07 (t, J = 7.1 
Hz, 3H, CH3-ethyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 172.2 (C=O), 136.2 (Carom., Cquat.), 127.3 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.1 (Carom., CH), 
111.5 (Carom., CH), 109.8 (Carom., Cquat.), 60.4 (CH2-ethyl), 53.2 (CαH), 35.1 (CH2), 31.4 (CH2), 
29.2 (6 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 
(CH2), 14.0 (CH3-ethyl), 14.0 (CH3-acyl). 
LC-ESI-MS (m/z): 471 [M+H]+. 
 
N-Hexadecanoyl-L-tryptophan isopropyl ester (113) 
The compound was prepared 
from 81 and isopropanol 
according to procedure 5.3.2.2. 
Appearance: off-white solid. 
Melting point: 65 – 66 °C. 
Yield: 240 mg, quantitative. Purity by HPLC-UV (254 nm)-ESI-MS: 95.6 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.80 (s, 1H, NHindole), 8.11 (d, J = 7.6 Hz, 1H, NHamide), 
7.48 (d, J = 8.0 Hz, 1H, Harom.), 7.31 (dt, J = 8.2, 0.9 Hz, 1H, Harom.), 7.11 (d, J = 2.4 Hz, 1H, 
Harom.), 7.04 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H, Harom.), 6.96 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H, Harom.), 
4.80 (sept, J = 6.3 Hz, 1H, CHisopropyl), 4.42 (ddd, J = 8.4, 7.5, 6.1 Hz, 1H, CαH), 3.10 (dd, J = 
14.7, 6.2 Hz, 1H, CβH), 2.99 (dd, J = 14.8, 8.5 Hz, 1H, CβH), 2.05 (td, J = 7.3, 6.1 Hz, 2H, CH2-
COacyl), 1.45 – 1.36 (m, 2H, CH2-acyl), 1.30 – 1.17 (m, 24H, 12 x CH2-acyl), 1.12 (d, J = 6.3 Hz, 
3H, CH3-isopropyl), 1.00 (d, J = 6.3 Hz, 3H, CH3-isopropyl), 0.84 (t, J = 7.2 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 171.7 (C=O), 136.2 (Carom., Cquat.), 127.3 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.2 (Carom., CH), 
111.5 (Carom., CH), 109.8 (Carom., Cquat.), 67.8 (CHisopropyl), 53.4 (CαH), 35.1 (CH2), 31.4 (CH2), 
29.2 (6 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 
(CH2), 21.6 (CH3-isopropyl), 21.4 (CH3-isopropyl), 14.1 (CH3-acyl). 
LC-ESI-MS (m/z): 485 [M+H]+. 
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N-Octadecanoyl-L-tryptophan (82)118 
 
The compound was prepared from L-tryptophan and octadecanoyl chloride according to 
procedure 5.3.1. 
Appearance: white solid. Melting point: 93 – 95 °C. (lit. m.p. 95 – 97 °C).114 Yield: 738 mg, 
78 %. Purity by HPLC-UV (254 nm)-ESI-MS: 95.9 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.33 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 7.99 (d, 
J = 7.7 Hz, 1H, NHamide), 7.51 (d, J = 7.8 Hz, 1H, Harom.), 7.31 (d, J = 8.0 Hz, 1H, Harom.), 7.10 
(s, 1H, Harom.), 7.04 (t, J = 7.1 Hz, 1H, Harom.), 6.96 (t, J = 7.5 Hz, 1H, Harom.), 4.45 (td, J = 8.4, 
4.1 Hz, 1H, CαH), 3.13 (d, J = 4.9 Hz, 1H, CβH), 2.98 (dd, J = 14.7, 8.9 Hz, 1H, CβH), 2.04 (m, 
2H, CH2-COacyl), 1.39 (m, 2H, CH2-acyl), 1.26 – 1.14 (m, 28H, 14 x CH2-acyl), 0.84 (t, J = 7.1 Hz, 
3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 174.0 (C=O), 172.6 (C=O), 136.5 (Carom., Cquat.), 127.7 
(Carom., Cquat.), 123.9 (Carom., CH), 121.3 (Carom., CH), 118.7 (Carom., CH), 118.6 (Carom., CH), 
111.8 (Carom., CH), 110.5 (Carom., Cquat.), 53.3 (CαH), 35.6 (CH2), 31.7 (CH2), 29.5 (8 x CH2), 
29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 29.0 (CH2), 27.6 (CH2), 25.6 (CH2), 22.6 (CH2), 14.4 
(CH3). 
LC-ESI-MS (m/z): 471 [M+H]+. 
 
N-Octadecanoyl-L-tryptophan methyl ester (108)118 
 
The compound was prepared from 82 and methanol according to procedure 5.3.2.2. 
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Appearance: off-white solid. Melting point: 73 – 75 °C. (lit. m.p. 71 – 73 °C).114 Yield: 123 
mg, quantitative. Purity by HPLC-UV (254 nm)-ESI-MS: 95.8 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 8.16 (d, J = 7.6 Hz, 1H, NHamide), 
7.47 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.11 (d, J = 2.4 Hz, 1H, Harom.), 
7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.3 Hz, 1H, Harom.), 4.49 (td, J = 8.3, 5.7 Hz, 1H, 
CαH), 3.56 (s, 3H, OCH3), 3.12 (dd, J = 14.6, 5.6 Hz, 1H, CβH), 3.00 (dd, J = 14.6, 8.6 Hz, 1H, 
CβH), 2.05 (td, J = 7.3, 2.7 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.3 Hz, 2H, CH2-acyl), 1.29 – 1.08 
(m, 28H, 14 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.7 (C=O), 172.4 (C=O), 136.2 (Carom., Cquat.), 127.2 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.5 (Carom., CH), 118.1 (Carom., CH), 
111.5 (Carom., CH), 109.8 (Carom., Cquat.), 53.2 (CαH), 51.9 (OCH3), 35.1 (CH2), 31.4 (CH2), 29.2 
(8 x CH2), 29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 485 [M+H]+. 
 
N-Octadecanoyl-L-tryptophan ethyl ester (111) 
 
The compound was prepared from 82 and ethanol according to procedure 5.3.2.2. 
Appearance: pink-colored solid. Melting point: 73 – 74 °C. Yield: 126 mg, quantitative. 
Purity by HPLC-UV (254 nm)-ESI-MS: 94.9 %. 
1H-NMR (500 MHz, DMSO-d6) : 10.80 (s, 1H, NHindole), 8.13 (d, J = 7.6 Hz, 1H, NHamide), 
7.48 (d, J = 8.0 Hz, 1H, Harom.), 7.32 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 7.11 (d, J = 2.4 Hz, 1H, 
Harom.), 7.04 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, Harom.), 6.96 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H, Harom.), 
4.47 (td, J = 8.3, 6.1 Hz, 1H, CαH), 4.00 (q, J = 7.1, 2H, CH2-ethyl), 3.12 (dd, J = 14.7, 5.8 Hz, 
1H, CβH), 3.01 (dd, J = 14.6, 8.3 Hz, 1H, CβH), 2.05 (td, J = 7.3, 3.7 Hz, 2H, CH2-COacyl), 1.41 
(p, J = 7.4 Hz, 2H, CH2-acyl), 1.30 – 1.12 (m, 28H, 14 x CH2-acyl), 1.07 (t, J = 7.1 Hz, 3H, CH3-
ethyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
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13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 172.2 (C=O), 136.2 (Carom., Cquat.), 127.3 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.1 (Carom., CH), 
111.5 (Carom., CH), 109.7 (Carom., Cquat.), 60.4 (CH2-ethyl), 53.2 (CαH), 35.1 (CH2), 31.4 (CH2), 
29.2 (8 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.2 (CH2), 22.2 
(CH2), 14.0 (CH3-ethyl), 14.0 (CH3). 
LC-ESI-MS (m/z): 499 [M+H]+. 
 
N-Octadecanoyl-L-tryptophan isopropyl ester (114) 
 
The compound was prepared from 82 and isopropanol according to procedure 5.3.2.2. 
Appearance: brown solid. Melting point: 63 – 64 °C. Yield: 202 mg, quantitative. Purity by 
HPLC-UV (254 nm)-ESI-MS: 91.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.80 (s, 1H, NHindole), 8.11 (d, J = 7.5 Hz, 1H, NHamide), 
7.48 (d, J = 7.8 Hz, 1H, Harom.), 7.31 (dt, J = 8.1, 0.9 Hz, 1H, Harom.), 7.11 (d, J = 2.4 Hz, 1H, 
Harom.), 7.04 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H, Harom.), 6.96 (ddd, J = 7.9, 6.9, 1.0 Hz, 1H, Harom.), 
4.80 (sept, J = 6.3 Hz, 1H, CHisopropyl), 4.43 (td, J = 8.1, 6.2 Hz, 1H, CαH), 3.10 (dd, J = 14.6, 
6.1 Hz, 1H, CβH), 2.99 (dd, J = 14.5, 8.4 Hz, 1H, CβH), 2.11 – 2.00 (m, 2H, CH2-COacyl), 1.45 
– 1.36 (m, 2H, CH2-acyl), 1.29 – 1.17 (m, 28H, 14 x CH2-acyl), 1.12 (d, J = 6.3 Hz, 3H, CH3-
isopropyl), 1.00 (d, J = 6.2 Hz, 3H, CH3-isopropyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 171.7 (C=O), 136.2 (Carom., Cquat.), 127.3 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.2 (Carom., CH), 
111.5 (Carom., CH), 109.8 (Carom., Cquat.), 67.8 (CHisopropyl), 53.4 (CαH), 35.1 (CH2), 31.4 (CH2), 
29.2 (8 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.3 (CH2), 22.2 
(CH2), 21.6 (CH3-isopropyl), 21.4 (CH3-isopropyl), 14.1 (CH3-acyl). 
LC-ESI-MS (m/z): 513 [M+H]+. 
 
 
5 Experimental 
87 
L-Tryptophan methyl ester (92)119 
The compound was prepared from L-tryptophan according to 
procedure 5.3.2.1. 
Appearance: light yellow oil. Yield: 4.38 g, quantitative. Purity by 
HPLC-UV (254 nm)-ESI-MS: 98.9 %. 
1H-NMR (500 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 7.47 (d, J = 8.0 Hz, 1H, Harom.), 7.32 
(dt, J = 8.1, 0.9 Hz, 1H, Harom.), 7.11 (d, J = 2.3 Hz, 1H, Harom.), 7.05 (ddd, J = 8.1, 7.0, 1.2 Hz, 
1H, Harom.), 6.96 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, Harom.), 3.62 (t, J = 6.3 Hz, 1H, CαH), 3.54 (s, 
3H, OCH3), 3.01 (ddd, J = 14.2, 6.2, 0.8 Hz, 1H, CβH), 2.92 (ddd, J = 14.2, 6.6, 0.8 Hz, 1H, 
CβH), (NH2 signal not visible). 
13C-NMR (125 MHz, DMSO-d6) : 175.8 (C=O), 136.2 (Carom., Cquat.), 127.5 (Carom., Cquat.), 
123.7 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 111.5 (Carom., CH), 
110.1 (Carom., Cquat.), 55.3 (CαH), 51.4 (OCH3), 30.9 (CH2). 
LC-ESI-MS (m/z): 219 [M+H]+. 
 
N-Eicosanoyl-L-tryptophan methyl ester (96) 
 
The compound was prepared from 92 and eicosanoic acid according to procedure 5.3.3. 
Appearance: white solid. Melting point: 93 – 96 °C. Yield: 270 mg, 53 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 97.9 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.80 (s, 1H, NHindole), 8.14 (d, J = 8.3 Hz, 1H, NHamide), 
7.47 (d, J = 8.0 Hz, 1H, Harom.), 7.31 (d, J = 8.5 Hz, 1H, Harom.), 7.11 (d, J = 2.6 Hz, 1H, Harom.), 
7.05 (t, J = 7.4 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 4.61 – 4.35 (m, 1H, CαH), 3.56 
(s, 3H, OCH3), 3.14 (dd, J = 14.6, 6.0 Hz, 1H, CβH), 3.00 (dd, J = 14.7, 8.8 Hz, 1H, CβH), 2.06 
– 2.03 (m, 2H, CH2-COacyl), 1.39 (p, J = 7.2 Hz, 2H, CH2-acyl), 1.26 – 1.15 (m, 32H, 16 x CH2-
acyl), 0.84 (t, J = 7.4, 3H, CH3-acyl). 
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13C-NMR (125 MHz, DMSO-d6) : 172.7 (C=O), 172.4 (C=O), 136.2 (Carom., Cquat.), 127.2 
(Carom., Cquat.), 123.7 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.1 (Carom., CH), 
111.5 (Carom., CH), 109.7 (Carom., Cquat.), 53.1 (CαH), 51.8 (OCH3), 35.1 (CH2), 31.4 (CH2), 29.1 
(10 x CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.6 (CH2), 27.2 (CH2), 25.2 (CH2), 22.2 
(CH2), 14.0 (CH3-acyl). 
LC-ESI-MS (m/z): 513 [M+H]+. 
 
N-Arachidonoyl-L-tryptophan methyl ester (97) 
 
The compound was prepared from 92 and arachidonic acid according to procedure 5.3.3. 
Appearance: yellow oil. Yield: 370 mg, 65 %. Purity by HPLC-UV (254 nm)-ESI-MS: 99.5 
%. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 8.19 (d, J = 7.6 Hz, 1H, NHamide), 
7.47 (d, J = 7.9 Hz, 1H, Harom.), 7.32 (d, J = 8.1 Hz, 1H, Harom.), 7.11 (d, J = 2.3 Hz, 1H, Harom.), 
7.05 (t, J = 7.2 Hz, 1H, Harom.), 6.96 (t, J = 7.6 Hz, 1H, Harom.), 5.37 – 5.28 (m, 8H, 8 x CHsp2 
(C5, C6, C8, C9, C11, C12, C14, C16)), 4.49 (td, J = 8.0, 5.8 Hz, 1H, CαH), 3.55 (s, 3H, OCH3), 
3.12 (dd, J = 14.5, 5.8 Hz, 1H, CβH), 3.01 (dd, J = 14.6, 8.5 Hz, 1H, CβH), 2.82 – 2.74 (m, 6H, 
3 x CH2 (C7, C10, C13)), 2.14 – 2.03 (m, 2H, CH2 (C2)), 2.02 – 1.95 (m, 4H, 2 x CH2 (C4, 
C16)), 1.48 (p, J = 7.4 Hz, 2H, CH2 (C3)), 1.32 – 1.21 (m, 6H, 3 x CH2 (C17, C18, C19)), 0.84 
(t, J = 6.9, Hz, 3H, CH3 (C20)). 
13C-NMR (125 MHz, DMSO-d6) : 172.9 (C=O), 172.5 (C=O), 136.2 (Carom., Cquat.), 130.4 
(CHsp2), 129.9 (CHsp2), 128.6 (CHsp2), 128.5 (CHsp2), 128.4 (CHsp2), 128.2 (CHsp2), 128.1 
(CHsp2), 127.9 (CHsp2), 127.5 (Carom., Cquat.), 124.0 (Carom., CH), 121.4 (Carom., CH), 118.8 
(Carom., CH), 118.4 (Carom., CH), 111.9 (Carom., CH), 110.0 (Carom., Cquat.), 53.5 (CαH), 52.2 
(OCH3), 34.9 (CH2), 31.3 (CH2), 29.2 (CH2), 27.6 (CH2), 27.1 (CH2), 26.6 (CH2), 25.7 – 25.6 
(4 x CH2), 22.4 (CH2), 14.4 (CH3-acyl). 
LC-ESI-MS (m/z): 505 [M+H]+. 
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N-Eicosanoyl-L-tryptophan (102) 
 
The compound was prepared from 96 according to procedure 5.3.4. 
Appearance: white solid. Melting point: 95 – 98 °C. Yield: 83 mg, 83 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 96.3 %. 
1H-NMR (500 MHz, DMSO-d6) : 12.49 (s (br), 1H, COOH), 10.78 (s, 1H, NHindole), 7.97 (d, 
J = 7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.8 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.10 
(d, J = 2.3 Hz, 1H, Harom.), 7.04 (ddd, J = 8.0, 6.9, 1.1 Hz, 1H, Harom.), 6.98 – 6.92 (m, 1H, 
Harom.), 4.46 (td, J = 8.4, 5.1 Hz, 1H, CαH), 3.14 (dd, J = 14.7, 5.1 Hz, 1H, CβH), 2.98 (dd, J = 
14.6, 8.8 Hz, 1H, CβH), 2.04 (td, J = 7.3, 1.4 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.3 Hz, 2H, CH2-
acyl), 1.30 – 1.10 (m, 32H, 16 x CH2-acyl), 0.84 (t, J = 6.5, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.4 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.2 (CH2), 31.4 (CH2), 29.2 – 29.1 (10 x 
CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.3 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 499 [M+H]+. 
 
N-Arachidonoyl-L-tryptophan (103) 
 
The compound was prepared from 97 according to procedure 5.3.4. 
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Appearance: yellow oil. Yield: 77 mg, 78 %. Purity by HPLC-UV (254 nm)-ESI-MS: 99.1 
%. 
1H-NMR (600 MHz, DMSO-d6) : 12.48 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 8.02 (d, 
J = 7.8 Hz, 1H, NHamide), 7.51 (d, J = 7.8 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.10 
(d, J = 2.3 Hz, 1H, Harom.), 7.04 (t, J = 7.2 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 5.39 
– 5.25 (m, 8H, 8 x CHsp2 (C5, C6, C8, C9, C11, C12, C14, C16)), 4.46 (td, J = 8.3, 5.2 Hz, 1H, 
CαH), 3.14 (dd, J = 14.6, 5.1 Hz, 1H, CβH), 2.98 (dd, J = 14.6, 8.7 Hz, 1H, CβH), 2.83 – 2.70 
(m, 6H, 3 x CH2 (C7, C10, C13)), 2.13 – 2.03 (m, 2H, CH2 (C2)), 2.02 – 1.94 (m, 4H, 2 x CH2 
(C4, C16)), 1.47 (pd, J = 7.5, 1.9 Hz, 2H, CH2 (C3)), 1.34 – 1.18 (m, 6H, 3 x CH2 (C17, C18, 
C19)), 0.84 (t, J = 6.9, Hz, 3H, CH3 (C20)). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.1 (C=O), 136.2 (Carom., Cquat.), 130.1 
(CHsp2), 129.6 (CHsp2), 128.3 (CHsp2), 128.2 (CHsp2), 128.1 (CHsp2), 127.9 (CHsp2), 127.8 
(CHsp2), 127.7 (CHsp2), 127.4 (Carom., Cquat.), 123.6 (Carom., CH), 120.1 (Carom., CH), 118.4 
(Carom., CH), 118.3 (Carom., CH), 111.5 (Carom., CH), 110.2 (Carom., Cquat.), 53.0 (CαH), 34.8 (CH2), 
30.9 (CH2), 28.9 (CH2), 27.3 (CH2), 26.8 (CH2), 26.4 (CH2), 25.4 – 25.3 (4 x CH2), 22.1 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 491 [M+H]+. 
 
5.3.5.3 D-Tryptophan derivatives 
 
N-Decanoyl-D-tryptophan (83) 
The compound was prepared from D-tryptophan and 
decanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 92 – 95 °C. (lit. 
m.p. 93 – 95 °C).120 Yield: 134 mg, 19 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 98.1 %. 
1H-NMR (600 MHz, CDCl3) : 8.31 (s (br), 1H, NHindole), 7.54 (d, J = 7.9 Hz, 1H, Harom.), 7.32 
(d, J = 8.1 Hz, 1H, Harom.), 7.17 (t, J = 7.5 Hz, 1H, Harom.), 7.09 (t, J = 7.5 Hz, 1H, Harom.), 6.98 
(s, 1H, Harom.), 6.12 (d, J = 7.5 Hz, 1H, NHamide), 4.91 (q, J = 5.6 Hz, 1H, CαH), 3.32 (qd, J = 
14.9, 5.4 Hz, 2H, CβH2), 2.08 (t, J = 7.7 Hz, 2H, CH2-COacyl), 1.48 (p, J = 7.0 Hz, 2H, CH2-acyl), 
1.30 – 1.08 (m, 12H, 6 x CH2-acyl), 0.85 (t, J = 7.1, 3H, CH3), (OH signal not visible). 
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13C-NMR (125 MHz, CDCl3) : 175.0 (C=O), 174.3 (C=O), 136.1 (Carom., Cquat.), 127.7 (Carom., 
Cquat.), 123.2 (Carom., CH), 122.2 (Carom., CH), 119.7 (Carom., CH), 118.4 (Carom., CH), 111.4 
(Carom., CH), 109.5 (Carom., Cquat.), 53.3 (CαH), 36.4 (CH2), 31.8 (CH2), 29.4 (CH2), 29.3 (2 x 
CH2), 29.1 (CH2), 27.0 (CH2), 25.4 (CH2), 22.6 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 359 [M+H]+. 
 
N-Dodecanoyl-D-tryptophan (84) 
The compound was prepared from D-tryptophan and 
dodecanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 106 - 108 
°C. Yield: 568 mg, 74 %. Purity by HPLC-UV 
(254 nm)-ESI-MS: 97.1 %. [α]21D = -14.4° (c = 0.1 
g/mL, in acetone). 
1H-NMR (600 MHz, CDCl3) : 8.28 (s (br), 1H, NHindole), 7.54 (d, J = 7.9 Hz, 1H, Harom.), 7.33 
(d, J = 8.1 Hz, 1H, Harom.), 7.17 (t, J = 7.5 Hz, 1H, Harom.), 7.09 (t, J = 7.4 Hz, 1H, Harom.), 6.99 
(s, 1H, Harom.), 6.07 (d, J = 7.4 Hz, 1H, NHamide), 4.91 (q, J = 5.7 Hz, 1H, CαH), 3.33 (qd, J = 
15.0, 5.4 Hz, 2H, CβH2), 2.08 (t, J = 7.6 Hz, 2H, CH2-COacyl), 1.49 (p, J = 7.2 Hz, 2H, CH2-acyl), 
1.31 – 1.16 (m, 16H, 8 x CH2-acyl), 0.86 (t, J = 7.0, 3H, CH3), (OH signal not visible). 
13C-NMR (125 MHz, CDCl3) : 175.0 (C=O), 174.3 (C=O), 136.1 (Carom., Cquat.), 127.7 (Carom., 
Cquat.), 123.2 (Carom., CH), 122.2 (Carom., CH), 119.7 (Carom., CH), 118.4 (Carom., CH), 111.4 
(Carom., CH), 109.6 (Carom., Cquat.), 53.3 (CαH), 36.4 (CH2), 31.9 (CH2), 29.6 (2 x CH2), 29.5 
(CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 27.0 (CH2), 25.4 (CH2), 22.7 (CH2), 14.2 (CH3). 
LC-ESI-MS (m/z): 387 [M+H]+. 
 
N-Tetradecanoyl-D-tryptophan (85) 
The compound was prepared from D-
tryptophan and tetradecanoyl chloride 
according to procedure 5.3.1. 
Appearance: off-white solid. Melting point: 
100 - 102 °C. Yield: 523 mg, 63 %. Purity by 
HPLC-UV (254 nm)-ESI-MS: 98.8 %. 
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1H-NMR (600 MHz, CDCl3) : 8.29 (s (br), 1H, NHindole), 7.54 (d, J = 7.9 Hz, 1H, Harom.), 7.32 
(d, J = 8.2 Hz, 1H, Harom.), 7.17 (t, J = 7.5 Hz, 1H, Harom.), 7.09 (t, J = 7.5 Hz, 1H, Harom.), 6.98 
(s, 1H, Harom.), 6.08 (d, J = 7.5 Hz, 1H, NHamide), 4.92 (q, J = 5.6 Hz, 1H, CαH), 3.33 (qd, J = 
15.0, 5.3 Hz, 2H, CβH2), 2.08 (t, J = 7.8 Hz, 2H, CH2-COacyl), 1.49 (p, J = 7.2 Hz, 2H, CH2-acyl), 
1.31 – 1.13 (m, 20H, 10 x CH2-acyl), 0.85 (t, J = 6.9, 3H, CH3), (OH signal not visible). 
13C-NMR (125 MHz, CDCl3) : 175.1 (C=O), 174.2 (C=O), 136.0 (Carom., Cquat.), 127.7 (Carom., 
Cquat.), 123.1 (Carom., CH), 122.2 (Carom., CH), 119.7 (Carom., CH), 118.4 (Carom., CH), 111.4 
(Carom., CH), 109.5 (Carom., Cquat.), 53.3 (CαH), 36.4 (CH2), 31.9 (CH2), 29.7 (CH2), 29.6 (3 x 
CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 29.1 (CH2), 27.0 (CH2), 25.4 (CH2), 22.6 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 415 [M+H]+. 
 
N-Hexadecanoyl-D-tryptophan (86) 
The compound was prepared from D-
tryptophan and hexadecanoyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting point: 
95 - 97 °C. (lit. m.p. 98 – 100 °C).121 Yield: 555 mg, 63 %. Purity by HPLC-UV (254 nm)-
ESI-MS: 96.3 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.49 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 7.99 (d, 
J = 7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.10 
(d, J = 2.3 Hz, 1H, Harom.), 7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.4 Hz, 1H, Harom.), 4.46 
(td, J = 8.4, 5.0 Hz, 1H, CαH), 3.14 (dd, J = 14.6, 5.0 Hz, 1H, CβH), 2.97 (dd, J = 14.6, 8.8 Hz, 
1H, CβH), 2.04 (td, J = 7.3, 2.3 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.4 Hz, 2H, CH2-acyl), 1.29 – 
1.05 (m, 24H, 12 x CH2-acyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 52.9 (CαH), 35.3 (CH2), 31.5 (CH2), 29.2 (6 x CH2), 
29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.3 (CH2), 14.1 
(CH3). 
LC-ESI-MS (m/z): 443 [M+H]+. 
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N-Octadecanoyl-D-tryptophan (87) 
 
The compound was prepared from D-tryptophan and octadecanoyl chloride according to 
procedure 5.3.1. 
Appearance: white solid. Melting point: 97 - 99 °C. (lit. m.p. 96 – 98 °C).120 Yield: 716 mg, 
76 %. Purity by HPLC-UV (254 nm)-ESI-MS: 96.8 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.36 (s (br), 1H, OH), 10.79 (s, 1H, NHindole), 7.99 (d, J = 
7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.0 Hz, 1H, Harom.), 7.10 (d, 
J = 2.2 Hz, 1H, Harom.), 7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.5 Hz, 1H, Harom.), 4.46 (td, 
J = 8.3, 4.1 Hz, 1H, CαH), 3.14 (dd, J = 14.6, 5.0 Hz, 1H, CβH), 2.97 (dd, J = 14.6, 8.9 Hz, 1H, 
CβH), 2.04 (td, J = 7.3, 2.1 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.4 Hz, 2H, CH2-acyl), 1.28 – 1.11 
(m, 28H, 14 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 121.0 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.5 (Carom., CH), 110.2 (Carom., Cquat.), 53.0 (CαH), 35.3 (CH2), 31.5 (CH2), 29.2 (8 x CH2), 
29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.3 (CH2), 14.1 
(CH3). 
LC-ESI-MS (m/z): 471 [M+H]+. 
 
D-Tryptophan methyl ester (93)122 
The compound was prepared as hydrochloride salt from D-tryptophan 
according to procedure 5.3.2.1 without neutralization and subsequent 
work-up. 
Appearance: white solid. Melting point: 217 °C. Yield: 3.6 g, 94 %. 
Purity by HPLC-UV (254 nm)-ESI-MS: 97.2 %. 
1H-NMR (500 MHz, DMSO-d6) : 11.09 (s, 1H, NHindole), 8.60 (s, 3H, NH3+), 7.50 (d, J = 7.9 
Hz, 1H, Harom.), 7.36 (d, J = 8.1 Hz, 1H, Harom.), 7.24 (d, J = 2.4 Hz, 1H, Harom.), 7.08 (t, J = 7.3 
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Hz, 1H, Harom.), 7.00 (t, J = 7.5 Hz, 1H, Harom.), 4.20 (t, J = 6.2 Hz, 1H, CαH), 3.64 (s, 3H, 
OCH3), 3.36 – 3.25 (m, 2H, CβH2). 
13C-NMR (125 MHz, DMSO-d6) : 170.2 (C=O), 136.6 (Carom., Cquat.), 127.3 (Carom., Cquat.), 
125.4 (Carom., CH), 121.6 (Carom., CH), 119.1 (Carom., CH), 118.4 (Carom., CH), 111.2 (Carom., CH), 
106.8 (Carom., Cquat.), 53.1 (CαH), 53.1 (OCH3), 26.6 (CH2). 
LC-ESI-MS (m/z): 219 [M-Cl]+. 
 
N-Eicosanoyl-D-tryptophan methyl ester (98) 
 
The compound was prepared from 93 and eicosanoic acid according to procedure 5.3.3 with an 
additional portion of N,N-diisopropylethylamine (DIPEA, 1.1 eq.). 
Appearance: white solid. Melting point: 88 - 89 °C. Yield: 314 mg, 61 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 97.9 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 8.16 (d, J = 7.6 Hz, 1H, NHamide), 
7.47 (d, J = 7.7 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.11 (d, J = 2.3 Hz, 1H, Harom.), 
7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.5 Hz, 1H, Harom.), 4.49 (td, J = 8.3, 5.6 Hz, 1H, 
CαH), 3.56 (s, 3H, OCH3), 3.12 (dd, J = 14.6, 5.6 Hz, 1H, CβH), 3.00 (dd, J = 14.6, 8.6 Hz, 1H, 
CβH), 2.05 (td, J = 7.3, 2.7 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.6 Hz, 2H, CH2-acyl), 1.28 – 1.11 
(m, 32H, 16 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3-acyl). 
13C-NMR (125 MHz, DMSO-d6) : 173.0 (C=O), 172.7 (C=O), 136.5 (Carom., Cquat.), 127.5 
(Carom., Cquat.), 124.0 (Carom., CH), 121.3 (Carom., CH), 118.8 (Carom., CH), 118.4 (Carom., CH), 
111.8 (Carom., CH), 110.1 (Carom., Cquat.), 53.5 (CαH), 52.2 (OCH3), 35.4 (CH2), 31.7 (CH2), 29.5 
(10 x CH2), 29.4 (CH2), 29.2 (CH2), 29.1 (CH2), 28.9 (CH2), 27.5 (CH2), 25.6 (CH2), 22.5 
(CH2), 14.4 (CH3-acyl). 
LC-ESI-MS (m/z): 513 [M+H]+. 
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N-Arachidonoyl-D-tryptophan methyl ester (99) 
 
The compound was prepared from 93 and arachidonic acid according to procedure 5.3.3 with 
an additional portion of N,N-diisopropylethylamine (DIPEA, 1.1 eq.). 
Appearance: light yellow oil. Yield: 370 mg, 65 %. Purity by HPLC-UV (254 nm)-ESI-MS: 
97.6 %. 
1H-NMR (600 MHz, DMSO-d6) : 10.82 (s, 1H, NHindole), 8.20 (d, J = 7.5 Hz, 1H, NHamide), 
7.47 (d, J = 7.9 Hz, 1H, Harom.), 7.32 (d, J = 8.1 Hz, 1H, Harom.), 7.11 (d, J = 2.5 Hz, 1H, Harom.), 
7.05 (t, J = 7.5 Hz, 1H, Harom.), 6.96 (t, J = 7.5 Hz, 1H, Harom.), 5.39 – 5.26 (m, 8H, 8 x CHsp2 
(C5, C6, C8, C9, C11, C12, C14, C15)), 4.49 (td, J = 8.1, 5.9 Hz, 1H, CαH), 3.55 (s, 3H, OCH3), 
3.12 (dd, J = 14.6, 5.8 Hz, 1H, CβH), 3.01 (dd, J = 14.6, 8.5 Hz, 1H, CβH), 2.82 – 2.71 (m, 6H, 
3 x CH2 (C7, C10, C13)), 2.14 – 2.03 (m, 2H, CH2 (C2)), 2.03 – 1.93 (m, 4H, 2 x CH2 (C4, 
C16)), 1.53 – 1.43 (m, 2H, CH2 (C3)), 1.34 – 1.18 (m, 6H, 3 x CH2 (C17, C18, C19)), 0.83 (t, 
J = 6.9 Hz, 3H, CH3 (C20)). 
13C-NMR (125 MHz, DMSO-d6) : 172.7 (C=O), 172.2 (C=O), 136.2 (Carom., Cquat.), 130.1 
(CHsp2), 129.6 (CHsp2), 128.3 (CHsp2), 128.2 (CHsp2), 128.1 (CHsp2), 127.9 (CHsp2), 127.8 
(CHsp2), 127.7 (CHsp2), 127.2 (Carom., Cquat.), 123.7 (Carom., CH), 121.1 (Carom., CH), 118.5 
(Carom., CH), 118.1 (Carom., CH), 111.6 (Carom., CH), 109.7 (Carom., Cquat.), 53.2 (CαH), 51.8 
(OCH3), 34.6 (CH2), 31.0 (CH2), 28.9 (CH2), 27.3 (CH2), 26.7 (CH2), 26.3 (CH2), 25.4 – 25.3 
(4 x CH2), 22.1 (CH2), 14.1 (CH3-acyl). 
LC-ESI-MS (m/z): 505 [M+H]+. 
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N-Eicosanoyl-D-tryptophan (104) 
 
The compound was prepared from 98 according to procedure 5.3.4. 
Appearance: white solid. Melting point: 83 - 84 °C. Yield: 48 mg, 48 %. Purity by HPLC-
UV (254 nm)-ESI-MS: 98.1 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.43 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 7.99 (d, 
J = 7.9 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.10 
(d, J = 2.2 Hz, 1H, Harom.), 7.04 (t, J = 7.5 Hz, 1H, Harom.), 6.95 (t, J = 7.5 Hz, 1H, Harom.),  4.45 
(td, J = 8.3, 5.0 Hz, 1H, CαH), 3.14 (dd, J = 14.7, 5.1 Hz, 1H, CβH), 2.98 (dd, J = 14.6, 8.9 Hz, 
1H, CβH), 2.04 (td, J = 7.3, 2.1 Hz, 2H, CH2-COacyl), 1.39 (p, J = 7.3 Hz, 2H, CH2-acyl), 1.29 – 
1.08 (m, 32H, 16 x CH2-acyl), 0.84 (t, J = 6.8 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.3 (C=O), 136.2 (Carom., Cquat.), 127.4 
(Carom., Cquat.), 123.6 (Carom., CH), 120.9 (Carom., CH), 118.4 (Carom., CH), 118.3 (Carom., CH), 
111.4 (Carom., CH), 110.2 (Carom., Cquat.), 53.0 (CαH), 35.3 (CH2), 31.5 (CH2), 29.2 (10 x CH2), 
29.1 (CH2), 28.9 (CH2), 28.8 (CH2), 28.7 (CH2), 27.3 (CH2), 25.3 (CH2), 22.3 (CH2), 14.1 
(CH3). 
LC-ESI-MS (m/z): 499 [M+H]+. 
 
N-Arachidonoyl-D-tryptophan (105) 
 
The compound was prepared from 99 according to procedure 5.3.4. 
Appearance: brown oil. Yield: 79 mg, 81 %. Purity by HPLC-UV (254 nm)-ESI-MS: 97.9 
%. 
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1H-NMR (600 MHz, DMSO-d6) : 12.50 (s (br), 1H, COOH), 10.79 (s, 1H, NHindole), 8.01 (d, 
J = 7.8 Hz, 1H, NHamide), 7.51 (d, J = 7.9 Hz, 1H, Harom.), 7.31 (d, J = 8.1 Hz, 1H, Harom.), 7.10 
(d, J = 2.3 Hz, 1H, Harom.), 7.04 (t, J = 7.6 Hz, 1H, Harom.), 6.95 (t, J = 7.4 Hz, 1H, Harom.), 5.37 
– 5.26 (m, 8H, 8 x CHsp2 (C5, C6, C8, C9, C11, C12, C14, C15)), 4.46 (td, J = 8.3, 5.1 Hz, 1H, 
CαH), 3.14 (dd, J = 14.6, 5.8 Hz, 1H, CβH), 2.98 (dd, J = 14.6, 8.7 Hz, 1H, CβH), 2.82 – 2.70 
(m, 6H, 3 x CH2 (C7, C10, C13)), 2.12 – 2.03 (m, 2H, CH2 (C2)), 2.03 – 1.93 (m, 4H, 2 x CH2 
(C4, C16)), 1.47 (pd, J = 7.6, 1.9 Hz, 2H, CH2 (C3)), 1.34 – 1.18 (m, 6H, 3 x CH2 (C17, C18, 
C19)), 0.83 (t, J = 6.9 Hz, 3H, CH3 (C20)). 
13C-NMR (125 MHz, DMSO-d6) : 173.7 (C=O), 172.1 (C=O), 136.2 (Carom., Cquat.), 130.1 
(CHsp2), 129.6 (CHsp2), 128.3 (CHsp2), 128.2 (CHsp2), 128.1 (CHsp2), 127.9 (CHsp2), 127.8 
(CHsp2), 127.7 (CHsp2), 127.4 (Carom., Cquat.), 123.6 (Carom., CH), 121.0 (Carom., CH), 118.4 
(Carom., CH), 118.3 (Carom., CH), 111.4 (Carom., CH), 110.2 (Carom., Cquat.), 53.1 (CαH), 34.8 (CH2), 
31.0 (CH2), 28.9 (CH2), 27.3 (CH2), 26.8 (CH2), 26.4 (CH2), 25.4 – 25.3 (4 x CH2), 22.1 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 491 [M+H]+. 
 
5.3.5.4 L-Serine derivatives 
 
N-Decanoyl-L-serine (88)123 
The compound was prepared from L-serine and decanoyl 
chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 79 - 80 °C. 
Yield: 139 mg, 27 %. Purity by HPLC-UV (254 nm)-
ESI-MS: 100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.37 (s (br), 1H, COOH), 7.86 (d, J = 7.9 Hz, 1H, NH), 
4.25 (dt, J = 7.7, 4.7 Hz, 1H, CαH), 3.65 (dd, J = 10.9, 5.4 Hz, 1H, CβH), 3.59 (dd, J = 10.9, 4.4 
Hz, 1H, CβH), 2.12 (t, J = 7.5 Hz, 2H, CH2-COacyl), 1.49 – 1.30 (m, 2H, CH2-acyl), 1.28 – 1.18 
(m, 12H, 6 x CH2-acyl), 0.85 (t, J = 6.8 Hz, 3H, CH3), (CH2-OH signal not visible). 
13C-NMR (125 MHz, DMSO-d6) : 172.5 (C=O), 172.3 (C=O), 61.6 (CH2), 54.7 (CαH), 35.2 
(CH2), 31.5 (CH2), 29.1 (CH2), 29.0 (CH2), 28.8 (2 x CH2), 25.4 (CH2), 22.3 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 260 [M+H]+. 
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N-Dodecanoyl-L-serine (89)123 
The compound was prepared from L-serine and 
dodecanoyl chloride according to procedure 5.3.1. 
Appearance: white solid. Melting point: 83 - 85 
°C. (lit. m.p. 103 °C).124Yield: 210 mg, 37 %. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0 
%. [α]20D = +6.9° (c = 0.1 g/mL, in methanol) 
1H-NMR (600 MHz, DMSO-d6) : 12.45 (s (br), 1H, COOH), 7.86 (d, J = 7.9 Hz, 1H, NH), 
4.89 (s (br), 1H, CH2-OH), 4.25 (dt, J = 8.0, 4.9 Hz, 1H, CαH), 3.65 (dd, J = 10.9, 5.4 Hz, 1H, 
CβH), 3.59 (dd, J = 10.9, 4.4 Hz, 1H, CβH), 2.11 (t, J = 7.5 Hz, 2H, CH2-COacyl), 1.46 (p, J = 
7.0 Hz, 2H, CH2-acyl), 1.28 – 1.19 (m, 16H, 8 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.5 (C=O), 172.3 (C=O), 61.6 (CH2), 54.7 (CαH), 35.2 
(CH2), 31.5 (CH2), 29.2 (2 x CH2), 29.1 (CH2), 29.0 (CH2), 28.9 (CH2), 28.8 (CH2), 25.4 (CH2), 
22.2 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 288 [M+H]+. 
 
N-Tetradecanoyl-L-serine (90)123 
The compound was prepared from L-serine 
and tetradecanoyl chloride according to 
procedure 5.3.1. 
Appearance: white solid. Melting point: 73 - 
76 °C. Yield: 333 mg, 53 %. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.19 (s (br), 1H, COOH), 7.86 (d, J = 7.9 Hz, 1H, NH), 
4.89 (s (br), 1H, CH2-OH), 4.25 (ddd, J = 7.9, 5.4, 4.3 Hz, 1H, CαH), 3.65 (dd, J = 10.9, 5.4 Hz, 
1H, CβH), 3.59 (dd, J = 10.9, 4.4 Hz, 1H, CβH), 2.12 (t, J = 7.4 Hz, 2H, CH2-COacyl), 1.50 – 
1.42 (m, 2H, CH2-acyl), 1.29 – 1.19 (m, 20H, 10 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 172.3 (C=O), 61.6 (CH2), 54.7 (CαH), 35.2 
(CH2), 33.8 (CH2), 31.4 (CH2), 29.3 – 28.6 (6 x CH2), 25.4 (CH2), 24.6 (CH2), 22.2 (CH2), 14.1 
(CH3). 
LC-ESI-MS (m/z): 316 [M+H]+. 
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N-Hexadecanoyl-L-serine (56)123 
 
The compound was prepared from L-
serine and hexadecanoyl chloride 
according to procedure 5.3.1. 
Appearance: white solid. Melting 
point: 90 - 93 °C. (lit. m.p. 96 – 99 °C).125 Yield: 158 mg, 23 %. Purity by HPLC-UV (254 
nm)-ESI-MS: 100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 12.3 (s (br), 1H, COOH), 7.86 (d, J = 7.9 Hz, 1H, NH), 
4.89 (s (br), 1H, CH2-OH), 4.25 (dt, J = 7.9, 4.9 Hz, 1H, CαH), 3.65 (dd, J = 10.9, 5.4 Hz, 1H, 
CβH), 3.59 (dd, J = 10.9, 4.4 Hz, 1H, CβH), 2.12 (t, J = 7.5 Hz, 2H, CH2-COacyl), 1.49 – 1.43 
(m, 2H, CH2-acyl), 1.27 – 1.19 (m, 24H, 12 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3). 
13C-NMR (125 MHz, DMSO-d6) : 172.5 (C=O), 172.3 (C=O), 61.6 (CH2), 54.7 (CαH), 35.2 
(CH2), 31.4 (CH2), 29.2 – 28.7 (10 x CH2), 25.4 (CH2), 22.3 (CH2), 14.1 (CH3). 
LC-ESI-MS (m/z): 344 [M+H]+. 
 
N-Octadecanoyl-L-serine (57)126 
 
The compound was prepared from L-serine and octadecanoyl chloride according to procedure 
5.3.1. 
Appearance: white solid. Melting point: 77 - 79 °C. (lit. m.p. 103 °C).127 Yield: 394 mg, 53 
%. Purity by HPLC-UV (254 nm)-ESI-MS: 100.0 %. 
1H-NMR (600 MHz, DMSO-d6) : 11.9 (s (br), 1H, COOH), 7.85 (d, J = 7.9 Hz, 1H, NH), 
4.24 (dt, J = 7.8, 4.9 Hz, 1H, CαH), 3.65 (dd, J = 10.9, 5.4 Hz, 1H, CβH), 3.58 (dd, J = 10.9, 4.4 
Hz, 1H, CβH), 2.17 (t, J = 7.4 Hz, 2H, CH2-COacyl), 1.50 – 1.43 (m, 2H, CH2-acyl), 1.28 – 1.18 
(m, 28H, 14 x CH2-acyl), 0.84 (t, J = 6.9 Hz, 3H, CH3), (CH2-OH signal not visible). 
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13C-NMR (125 MHz, DMSO-d6) : 172.4 (C=O), 172.3 (C=O), 61.6 (CH2), 54.7 (CαH), 35.2 
(CH2), 33.8 (CH2), 31.4 (CH2), 29.2 – 28.7 (10 x CH2), 25.4 (CH2), 24.6 (CH2), 22.2 (CH2), 
14.1 (CH3). 
LC-ESI-MS (m/z): 372 [M+H]+. 
5.4 Enzymatic hydrolysis of bovine liver phosphatidylinositol 
Bovine liver PI (5 mg, average MW = 902, ~ 5.54  µmol, purchased from Avanti Lipid) was 
suspended in 2 mL of 50 mM acetate buffer (pH 5.7) containing 10 mM CaCl2 and 100 mM 
NaCl. The solution was then treated with DMSO (200 µL) and Phospholipase A1 from 
Thermomyces lanuginosus (2.31 µL, 10 kilo lipase unit per gram (KLU/g), density = 1.2 g/mL, 
5 eq., purchased from Sigma) then stirred at r. t. for 1 h. The enzymatic reaction was terminated 
by adding 0.4 mL of 200 mM EDTA and 15 mL of chloroform:methanol (1:2, v/v). After the 
addition of chloroform (5 mL) and water (5.6 mL), the methanol-water layer was taken and 
subjected to a chloroform-conditioned solid phase extraction (SPE) tube (normal phase, 
aminopropyl-modified silica, 6 mL tube volume, 500 mg bed weight, purchased from 
Macherey-Nagel, Düren). After the application of the sample (fraction 1), the tube was washed 
with a mixture of diethyl ether:acetic acid (98:2) to remove the free fatty acids (fraction 2) and 
subsequently eluted with a mixture of methanol:NH4OH (9:1) (fraction 3). All fractions were 
dried under a gentle stream of argon at r. t.  
5.5 ß-Arrestin assays on GPR18 
Recruitment of β-arrestin to GPR18 was investigated using a β-galactosidase enzyme fragment 
complementation assay (β-arrestin PathHunterTM assay, DiscoverX, Fremont, CA, U.S.). 
Chinese hamster ovary (CHO) cells stably expressing GPR18 were seeded in a volume of 90 
μL into a white-bottomed 96-well plate and incubated at a density of 40.000 cells/well in assay 
medium (Opti-MEM, 2 % fetal calf serum (FCS), 100 U/mL penicillin, 100 μg/mL 
streptomycin, 800 μg/mL geneticin and 300 μg/mL hygromycin (P/S/G/H medium)) for 24 h at 
37 °C, 5 % CO2. The medium was then changed to 0 % FCS assay medium (Opti-MEM, 100 
U/mL penicillin, 100 μg/mL streptomycin, 800 μg/mL geneticin and 300 μg/mL hygromycin 
(P/S/G/H medium)) prior to the assay. The test compounds and the agonist were separately 
diluted in phosphate-buffered saline (PBS buffer) containing 0.1 % bovine serum albumin 
(BSA) and 10 % DMSO.  
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For antagonistic activity, about 5 μL of antagonist solution were added to the cells followed by 
an incubation for 1 h at 37 °C, 5 % CO2. After this first incubation, agonist was added in a 
volume of 5 μL followed by a second incubation for 1.5 hour at 37 °C, 5 % CO2. The detection 
reagent was prepared by mixing the chemiluminescent substrate Galacton-Star®, Emerald-II™ 
and a lysis buffer A (150 mM NaCl, 5 mM K2HPO4 5 mM KH2PO4, 25 mM Mg(CH3COO)2, 
2.5 % CHAPS) in a ratio of 1:5:19. The detection reagent was added in a volume of 50 μL per 
well and the measurement plate was incubated for 1 h at r.t. Luminescence was then measured 
in a Luminometer (TopCount NXT, Packard / Perkin-Elmer). The data were analyzed using 
GraphPad PRISM Version 6.01 (San Diego, CA, USA). 
For the determination of potential agonistic properties of the test compounds, the assay was 
performed as described above for antagonist testing except that PBS buffer containing 0.1 % 
BSA and 10 % DMSO was added in place of potential antagonists and after a 60 min incubation 
the test compounds were added. 
5.6 ß-Arrestin assays on GPR55 
CHO cells stably expressing GPR55 were used (F-12 10 % FCS, 100 U/mL penicillin, 100 
μg/mL streptomycin, 800 μg/mL geneticin und 300 μg/mL hygromycin (P/S/G/H medium). For 
receptor stimulation, the GPR55 agonist lysophosphatidylinositol (LPI) was employed (1 μM) 
and the test compounds were screened were screened at 10 μM for antagonistic activity. 
The step procedures of the assay were similar to the recruitment of β-arrestin molecules on 
GPR18, except the detection reagent was varied and obtained by mixing the chemiluminescent 
substrate Galacton-Star (2 mM) with the luminescence enhancer Emerald-II and lysis buffer B 
(10 mM TRIS, 1 mM EDTA, 100 mM NaCl, 5 mM MgCl2, 1% Triton-X; pH 8) in a ratio of 
1:5:19. 
5.7 Radioligand binding assays on cannabinoid receptors 
Competition binding assays were performed versus the cannabinoid receptor agonist 
radioligand [3H](-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol ([3H]CP55,940) in concentration of 0.1 nM. As a source for 
human CB1 and CB2 receptors, membrane preparations of Chinese hamster ovary (CHO) cells 
stably expressing the respective receptor subtype were used. The test compounds were diluted 
in DMSO (final concentration of 10 μM). In case inhibition of radioligand binding was 50 % 
or more, full concentration-inhibition curves were determined to calculate Ki values. 
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The binding assays were performed at r. t. in 96-well plates. Each well contained 15 μL of test 
compound, 465 μL of assay buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.1 % BSA, pH 7.4), 60 
μL of radioligand solution and 60 μL of CB1 membrane suspension (30 μg of protein per well) 
or CB2 membrane suspension (16 μg protein per well). Total binding was determined in the 
presence of 2.5 % DMSO and nonspecific binding in the presence of 10 μM of unlabeled 
CP55,940. Three separate experiments were conducted, each in duplicates. The mixtures were 
incubated for 120 min at r. t. to reach equilibrium conditions. Incubation was terminated by 
rapid filtration using a 96-channel harvester through GF/C glass fiber filters that were 
previously presoaked in 0.3 % aqueous polyethyleneimine solution for 30 min. Filters were 
washed three times with ice-cold washing buffer (50 mM Tris-HCl 0.1 % BSA, pH 7.4). The 
glass fiber filters were then dried for 90 min at 50 °C. Radioactivity of the plates were measured 
in a Topcount Microplate Scintillation and Luminescence Counter after 10 h of pre-incubation 
with 50 μL of scintillation cocktail. 
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6 Abbreviations 
2-AG 2-arachidonoylglycerol 
2-AGPI 2-arachidonoyl-sn-glycero-3-phosphoinositol 
A2AAR A2A adenosine receptor 
abn-CBD abnormal cannabidiol 
ADP adenosine diphosphate  
AIDS acquired immunodeficiency syndrome 
anandamide N-arachidonoylethanolamine 
ATP adenosine triphosphate 
b.p. boiling point 
br broad 
BSA bovine serum albumin  
cAMP cyclic adenosine monophosphate  
CHO chinese hamster ovary 
conc. concentration 
d doublet 
DAG diacylglycerol 
DCC N,N’-dicyclohexylcarbodiimide  
DCM dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
EC50 Half maximal effective concentration 
EDTA ethylenediaminetetraacetic acid  
eq. equivalents 
ESI electrospray ionization 
FCS fetal calf serum 
GABA gamma-aminobutyric acid 
GDP guanosine diphosphate  
GPCR G protein-coupled receptor 
6 Abbreviations 
104 
GRK GPCR kinase 
GRK G protein-coupled receptor kinase 
GTP guanosine triphosphate  
h human 
HEK293 human embryonic kidney cell line 
HOAt 1-hydroxy-7-azabenzotriazole 
HPLC high-performance liquid chromatography  
IC50 half maximal inhibitory concentration  
IP3 inositol-1,4,5-trisphosphate  
KD equilibrium dissociation constant 
Ki equilibrium dissociation constant for an inhibitor 
KLU kilo lipase unit 
KOtBu potassium tert-butoxide 
LC liquid chromatography 
LPI lysophosphatidylinositol 
L-α-GPC L-α-glycerylphosphorylcholine 
m multiplet 
m.p. melting point 
MAPK mitogen-activated protein kinase 
MeOH methanol 
MHz megahertz 
MS mass spectrometry 
NAGly N-arachidonoylglycine 
NMR nuclear magnetic resonance spectroscopy 
PBS phosphate buffered saline 
PC phosphatidylcholine 
PI phosphatidylinositol 
PIP2 phosphatidylinositol-4,5-bisphosphate  
PLA1 phospholipase A1 
PLC phospholipase C  
PPAR peroxisome proliferator-activated receptor 
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ppm parts per million 
q quartet 
quat. quarternary 
r.t. room temperature 
RGS regulator of G protein signaling 
RP reversed phase  
RvD2 Resolvin D2 
s singlet 
SEM standard error of the mean 
SN2 nucleophilic aromatic substitution 
SPE solid-phase extraction 
t triplet 
TEA triethylamine 
THC Δ9-tetrahydrocannabinol  
THF tetrahydrofuran 
TLC thin layer chromatography  
TM transmembrane 
TRPV transient receptor potential cation channel vanilloid  
UDP uridine diphosphate 
UTP uridine triphosphate  
UV ultraviolet 
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